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SUMMARY 
 
Several techniques including two-dimensional electrophoresis, imaging, mass spectrometry, 
and bioinformatics are used in proteomics to identify, quantify, and characterize proteins for 
clinical applications. The main aim is to identify proteins involved in pathological processes and 
to understand how illness can lead to altered protein expression in order to develop new 
diagnostic and prognostic tests, to identify new therapeutic targets, and eventually to allow the 
design of individualized patient treatment.  
For this purpose this dissertation is divided into two main chapters. Chapter one concerns the 
development of a novel method to isolate exosomes. Normal human urine contains large 
numbers of exosomes, which are 40 to 100 nm vesicles that originate  in multivesicular bodies 
from every renal epithelial cell type facing the urinary space. Exosomes are rich in potential 
biomarkers, especially membrane proteins such as transporters and receptors that may be up- 
or downregulated during disease states. Differential centrifugation methods are commonly 
used to purify exosomes from urine. Here, we developed a new method to isolate exosomes by 
solubilizing exosomes in 1 % Sarkosyl, an anphyphilic detergent, followed by a carbon 
fractionation. We used LC-MS/MS to profile the proteome of human urinary exosomes. Overall, 
the analysis unambiguously identified 1618 proteins, showing an enrichment of 61.3% in 
exosomal proteins, after performing a Gene Ontology analysis.  Thus, our modified exosome 
precipitation method is a simple, fast, highly scalable, and effective alternative for the isolation 
of exosomes. It may facilitate either the identification of exosomal biomarkers from urine or 
the production of drug delivery devices. 
Chapter two concerns the identification of proteins in adhesive material of the capsalid 
Neobenedenia girellae by a proteomic approach based on de novo sequencing and database 
search to overcome the lack of information concerning the genome of these parasites. 
Glandular secretions were obtained by a new method, set up in our laboratory, which allowed 
collecting a small amount of secretion without any contamination from other tissues either 
from the parasites as well as from the skin of the host. The proteomic analysis reveals that the 
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adhesive is mainly composed of cytoskeletal proteins (actin, keratin and tubulin) but contains 
also ATP-synthase, 78 kDa glucose regulated protein and albumin. 
This work reports for the first time the characterization of a novel bioadhesive material used by 
capsalid parasites to adhere to fish. Such information broadens our knowledge of the molecular 
mechanisms involved in adhesiveness of parasites to hosts. Moreover, it offers new clues in 
understanding the mechanism of stickiness and adhesion of cytoskeleton components, often 
involved in both physiological and pathological processes, including neurodegenerative 
diseases. 
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1. INTRODUCTION 
1.1 VESICULATION 
 
Vesiculation is a physiological mechanism that is used in cell growth, activation and protection. 
For example, for mineral formation in cartilage, bone and predentin, calcification is initiated by 
matrix vesicles released by chondrocytes, osteoblasts and odontoblasts [1]. Vesicles released by 
activated monocytes expose tissue factor and enhance coagulation.  
In resting mammalian cells, the constitutive aminophospholipids, phosphatidylserine and 
phosphatidylethanolamine, are mainly sequestered in the inner (cytoplasmic) side of the 
plasma membrane, whereas sphingomyelin and phosphatidylcholine constitute the majority of 
the outer (exoplasmic) side [2, 3]. This asymmetric distribution is under the control of an inward 
aminophospholipid translocase (flippase), of as yet elusive nature [4]. For example, when 
subjected to procoagulant, pro-inflammatory or apoptogenic stimulation, cells of the vascular 
compartment show specific responses according to lineage and stimulus, but in most of them a 
spontaneous collapse of their membrane asymmetry happens [3, 4]. One of the resulting 
universal hallmarks is the occurrence of phosphatidylserine in the exoplasmic leaflet where it 
expresses two of its properties as a multifunctional membrane effector and the formation of 
vesicles. However, the mechanisms of packaging and vesicular emission of proteins and nucleic 
acids are poorly understood. 
 
1.2 EXTRACELLULAR VESICLES IN BODY FLUIDS 
 
Cellular microparticles (MPs), also referred to as microvesicles, are fragments shed almost 
spontaneously from the plasma membrane blebs of various eukariotyc cell types when 
submitted to a number of stress conditions, including apoptosis. Microvesicles release is an 
integral part of the membrane-remodeling process in which the asymmetric distribution of 
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constitutive phospholipids between the two leaflets is lost. After having long been considered 
‘cell dust’, microvesicles have more recently been shown to reflect in vitro cell stimulation, and 
testify to cellular activation and/or tissue degeneration occurring in vivo under a variety of 
pathophysiologic conditions [5]. 
Interestingly, this phenomenon seems conserved during evolution, as bacteria are even 
described to release microvesicles that are important components of biofilms, and is a major 
signal trafficking system [6].  
Vesicle shedding is an important defense mechanism protecting against complement attack, by 
allowing the removal of the C5b-9 attack complex from the cell surface by a calcium (Ca++)-
dependent elimination as shown for many cell types including platelets, polymorphonuclear 
leucocytes (PMN), erythrocytes and oligodendrocytes [7]. Specific vesiculation is triggered or 
enhanced in pathological conditions such as inflammation, injury, vascular dysfunction or 
cancer [8].  
A major problem in the microvesicle literature is the confusing nomenclature. Various names 
have been used, including particles, microparticles, vesicles, microvesicles, nanovesicles, 
exosomes, dexosomes, argosomes, ectosomes, etc. [3, 5]. Whereas their formation, size and 
biological function may be different, one common point between all vesicles is the fact that 
they bud from a membrane, whether this occurs at the cell surface or in a vesicular 
compartment inside the cell. Johnstone et al. [8] initially named exosomes, vesicles produced 
by intracellular budding into the late endosomal compartment. Evidently, every vesicle brings 
many of the specificities of the originating cell; however, there are some general properties 
characterizing those released directly from the cell surface which justifies a specific name, i.e. 
ectosomes [9], or ‘shedding’ microvesicles [10]. 
 
1.3. ECTOSOMES 
 
Ectosomes are also known by other names, for example, microparticles, microvesicles, and 
shedding vesicles. These names emphasize that these vesicles are discharged outside, and not 
inside the cell, and that they are similar to, but distinct from, exosomes. 
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Ectosomes are vesicles of various sizes (0.1–1mm in diameter) that bud directly from the 
plasma membrane and are shed to the extracellular space. Stein and Luzio [9] coined the term 
‘ectocytosis’ for the release of right-side-out-orientated vesicles with cytosolic content 
(ectosomes) from the surface of PMN attacked by complement. However, ectocytosis 
corresponded not only to the removal of the C5b-9 complex, but also to a specific sorting of 
membrane proteins into the shed ectosomes. Enrichment in cholesterol and diacylglycerol in 
the membrane attested to a specific sorting of lipids. 
 
 
Figure 1. Biogenesis of ectosomes 
 
Microvesicular formation is the result of dynamic interplay between phospholipid redistribution 
and cytoskeletal protein contraction. The protein and phospholipid distribution within the 
plasma membrane is far from uniform and forms micro-domains. The exposure of 
phosphatidylserine  in the outer leaflet of the membrane is also a specific characteristic [3]. 
Although ectocytosis describes the same phenomenon in all cell types, the stimuli inducing cell-
membrane budding can differ from one cell to another. Endothelial and circulating blood cells 
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release ectosomes when exposed to specific stimuli such as complement attack [7].Monocyte 
ectocytosis is induced by bacterial cell wall components including lipopolysaccharides (LPS), and 
platelets release ectosomes by activation through thrombin [5]. Fibroblasts release ectosomes 
in response to stress relaxation when cultured in a three-dimensional collagen matrix [11]. 
Many cancerous cells have an activated phenotype with highly active ectocytosis in the absence 
of any stimulus [8],[12],[13]. Background levels of microvesicles originating from circulating and 
endothelial cells are found in blood, and similarly ectosomes originating from glomerular 
epithelial cells are found in urine [14],[15]. 
Exosomes are highly heterogeneous, both in size and in composition. Ectosomes are made up 
of components (proteins, mRNAs, and miRNAs) that are typical of their cell of origin and are 
therefore distinct from those of other cell types. They can vary depending on the cellular state 
(e.g. resting, stimulated) and depending on the agent employed for stimulation.  
Generation of ectosomes is a complex but efficient process. Specific domains are assembled in 
the plane of the plasma membrane; proteins destined to appear in the ectosomes are sorted to 
these domains, and proteins destined to remain in the cell are excluded. Concomitantly, 
specific cytosolic proteins and nucleic acids (mRNAs and miRNAs) accumulate in contact with 
the plasma membrane domains. Budding of the plasma membrane domains with their 
associated protein/RNA packages requires the local disassembly of the cytoskeleton, possibly 
by activation of caspase 2. Finally, ectosome discharge occurs by an actomyosin-based 
abscission process. The mechanisms of its regulation (perhaps involving the ESCRT machinery 
and/or the small GTPase ARF6) are just beginning to emerge. 
Ectosomes are discharged even by resting cells, but the rate of release is increased considerably 
upon appropriate stimulation. Impressive responses, mimicking eruptive gun shooting from 
warships of the early 19th century, have been reported from macrophages and microglia. 
Weaker responses do occur from many cell types. The local signal that triggers the response is 
the increase of cytosolic free Ca2+([Ca2+]i) inducing the disassembly of the cytoskeleton and 
membrane abscission. The p38 MAPK, acid sphingomyelinase and the Rho–ROCK axis also 
appear to be involved. [Ca2+]i increase and MAPK activation can be induced by a variety of 
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agents, for example, ATP-mediated activation of the P2X7 receptor in macrophages and TNFa 
signalling in endothelia (figure 1). 
Their function depends on their site of discharge and on the properties of their membrane. 
Ectosomes from platelets, endothelia and leukocytes are discharged directly into the blood 
where they can release their content rapidly or persist in the circulation for quite some time. 
Ectosomes discharged to the tissue intercellular space can also release their content there, 
remain trapped locally or diffuse some distance. Effects are triggered when ectosomes (or their 
released molecules) reach their targets, often in cell types distinct from the cells of origin. 
Released molecules activate key cell-surface molecules, such as receptors and enzymes. Intact 
ectosomes can either fuse with target cells (with the ensuing incorporation of their membrane 
in the plasma membrane and release of the segregated package to the cytosol) or be taken up 
by endocytosis. The fate of the latter is variable: fusion with lysosomes; release of contents in 
the cytosol; or discharge to the extracellular space by transcytosis (Figure 2).  
 
 
Figure 2. Life cycle of ectosomes. 
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Generation of ectosomes requires the segregation of membrane domains with associated 
packages of proteins and RNAs. After their release, ectosomes can (A) diffuse into the 
extracellular space where they can release their content, (B) be endocytosed by cells, ending up 
in lysosomes or releasing their content to the cytoplasm, or (C) fuse with a target cell, with the 
release of the segregated proteins/RNAs to the cytosol. These processes can lead to changes to 
the target cell phenotype, with generation and budding of new vesicles that establish a 
horizontal transfer of their proteins/RNAs to adjacent cells (D). 
Ectosomes are specific, multi-purpose carriers that expand the borders of cells away from the 
plasma membrane, establishing communication networks by which specific properties and 
information can be shared among cells. By delivering their molecules at distance without 
dilution or degradation they reproduce effects otherwise induced by direct cell–cell contact, 
playing major roles in the integrated functioning of tissues and organs. Fusion of ectosomes at 
the surface of target cells delivers exogenous antigens, enzymes and other proteins to discrete 
sites of the plasma membrane. Concomitantly, release of the segregated protein/RNA packages 
to target cells can alter gene expression. This might explain, among other events, the functional 
and phenotypic changes taking place in stem cells without transdifferentiation, sustained by 
genetic information transferred from tissue cells via ectosomes.  
The heterogeneity of ectosomes can play different, even opposing roles. Ectosomes containing 
cytokines, in particular interleukin 1b, are pro-inflammatory; others, however, are anti-
inflammatory. Monocyte and endothelial ectosomes are often rich in tissue factor, a potent 
activator of the coagulation cascade, and can therefore trigger coagulation, thrombosis and 
also angiogenesis. Platelet ectosomes, however, contain low levels of tissue factor, and 
therefore work differently. Ectosomes derived from leukocytes and platelets have profound 
effects on innate immunity and also on the induction of adaptive immunity, reprogramming 
macrophages and dendritic cells toward immunosuppression.  
Ectosomes of specific origin are also being studied as a target of new therapies for rheumatoid 
arthritis and multiple sclerosis, where ectosomes are believed to promote inflammation and 
cell death, and for cancer, in which ectosomes play a role in invasion and metastasis. The 
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mechanisms of the effects on cancer are multiple. In addition to the above-mentioned roles in 
digestion of the intercellular matrix and immunosuppression, ectosomes can induce the 
horizontal transfer among tumor cells of critical molecules such as proteins (e.g. P-glycoprotein 
(which confers multidrug resistance to the cells), glutaminase, and fibronectin), mRNAs and 
miRNAs. This transfer is considered to be greatly important for cancer progression. 
 
1.4. APOPTOTIC BLEBS 
 
Apoptosis is a major mechanism of cell death for both normal and cancerous cells [16]. A cell 
dying by apoptosis progresses through several stages, initiating with condensation of the 
nuclear chromatin, followed by membrane blebbing, progressing to disintegration of the 
cellular content into distinct membrane enclosed vesicles termed apoptotic bodies or 
apoptosomes [16]. 
These membrane vesicles, which are condensed remnants of the shrinking apoptotic cell [17], 
are referred to as apoptotic blebs or apoptotic bodies. Apoptotic bodies are released during the 
late stages of cell death [18], they are generally larger in size (500–4,000 nm) [19], and are 
characterized by the presence of organelles within the vesicles (figure 3) [20]. 
 
 
 
Figure 3. Biogenesis and destiny of apoptotic bodies during apoptosis 
 
During normal development, most apoptotic bodies are phagocytosed by macrophages [20] 
and are cleared locally. This clearance is mediated by specific interactions between recognition 
receptors on the phagocytes and the specific changes in the composition of the apoptotic cells 
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membrane [21]. Among these changes, the best characterized involves the translocation of 
phosphatidylserine to the outer leaflet of the lipid bilayer. These translocated 
phosphatidylserines bind to Annexin V, which is recognized by phagocytes [22]. Another well-
characterized membrane alteration involves oxidation of surface molecules. These changes 
create sites for binding of thrombospondin [23] or the complement protein C3b [21]. 
Thrombospondin and C3b are, in turn, recognized by phagocyte receptors [24], [25]. Annexin V, 
thrombospondin, and C3b thus, serve as three well-accepted markers of apoptotic bodies [26]. 
The ability to transfer genetic content intercellularly does not appear to be unique to one class 
of extracellular vesicles. In mice bearing tumor xenografts, apoptotic bodies can also be 
detected in the blood of the organism [27]. Importantly, uptake of apoptosomes derived from 
H-rasV12- or human c-myc-transfected cells by murine fibroblasts resulted in loss of contact 
inhibition in vitro and a tumorigenic phenotype in vivo [28]. These results suggest that genetic 
information can also be transferred by uptake of apoptotic bodies. 
 
1.5. EXOSOMES 
1.5.1. Biogenesis 
 
Eukaryotic cells stay in contact with the environment by receiving signals such as cytokines or 
chemokines, the uptake of nutrients and the secretion of proteins into the extracellular space. 
For uptake and secretion, each cell has a complex network of membranes inside the cell. Using 
these compartments, cells not only take up macromolecules from the exterior environment 
(endocytosis) but also release newly-synthesized proteins or carbohydrates (exocytosis) (Figure 
4). Both make use of membrane vesicles for the packaging and trafficking of molecules. While 
endocytosis is the process in which the extracellular substances enter into a cell without 
directly passing  through the cell membrane, exocytosis is the primary means of cellular 
secretion. During both constitutive and regulated exocytosis the secretory-vesicles dock and/or 
fuse with the plasma membrane. Endocytic pathway, which is primarily responsible for the 
uptake, trafficking and sorting of internalized proteins has a role in vesicle secretion too [29]. In 
the endocytic pathway, transmembrane proteins are sorted into lumenal vesicles of 
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multivesicular bodies (MVBs). MVBs can have different destinies: they can fuse or mature with 
lysosomes where the degradation of their protein cargo takes place, or can fuse with the cell 
membrane to secrete the intraluminal vesicles (ILVs) into the extracellular space. These 
extracellularly released ILVs are called exosomes [30],[31]. During this process, the second 
inward budding of the endosome membrane results in a positive orientation of the ILVs lipid 
membrane. Thus when the ILVs are released to the extracellular environment, they have the 
same orientation as the cell membrane and have been shown to display many of the surface 
markers from their cell of origin [29]. The sorting process of membrane proteins during ILV 
formation is considered to be an active process and thus, exosomal surface proteins seem not 
to be a plain one-to-one presentation of the surface markers for the cell of origin. 
 
 
Figure 4. Representation of extracellular vesicles biogenesis. 
 
While the regulation of endocytic cargo sorting and its delivery to lysosomes have been 
extensively studied [32] relatively less is known about the factors which regulate the formation, 
the release and the cargo sorting into vesicles destined to be exosomes. One hypothesis is the 
possible role of the ubiquitinization (mono- or oligoubiquitinization) and ESCRT (endosomal 
sorting complex required for transport) protein complex in this process[33],[34].  ESCRT is a 
protein machinery consisting of ESCRT-0, -I, -II, and -III[11]. ESCRTs are predominantly cytosolic 
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proteins that become recruited by endosomes. It was reported that ESCRT-0, -I, and -II have 
ubiquitin binding domains and play a central role in cargo sorting. It was shown that the 
depletion of the tumor susceptibility gene-101 (TSG101), a component of the ESCRT-I complex, 
has an inhibitory effect on receptor degradation and causes different endosomal morphology 
[35]. However, some data suggest that certain molecules, such as epidermal growth factor 
receptor (EGFR) and EGF, could be involved in the ESCRT-II–independent sorting pathway [32]. 
ESCRT-III has no ubiquitin binding domains, and it is probably important in the recruitment of 
deubiquitinizing enzymes that should remove ubiquitin before cargo incorporation into ILV. 
Another important role of ESCRT-III is to activate the molecular machinery that will facilitate 
the disassembly of the ESCRTs from the endosomal membrane [32], [36]. The dissociation and 
recycling of the ESCRT complex is dependent on interaction with AAA-ATP-ase Vps4 [37]. 
The mechanisms involved in the budding of vesicles from the limiting membrane of MVB are 
also poorly understood. It is known that ESCRT-III forms a lattice-like structure on the surface of 
the endosomal membrane [33]. Activation for assembly into lattices may be the consequence 
of interaction with the membrane itself, ALIX (accessory protein of the ESCRT-II), and some 
other ESCRT-III–related proteins. The presumption is that these lattices spatially restrict 
membrane curvature–inducing factors to initiate budding away from the cytoplasm. However, 
some authors point to the crucial role of the lipids in this process, such as phosphatidylinositol-
3-phosphate (PI3,5P2) and lysobisphosphatidic acid (LBPA) [38], [39] . 
The tetraspan protein family is abundant in exosomes and may be responsible for recruitment 
of membrane proteins into ILV [37]. It is also possible that there could be differences in the 
mechanism of 
exosome secretion between the different cell types [40]. Therefore, several different 
mechanisms may be involved in the process of ILV formation.  
A ESCRT-independent mechanisms by means of ceramide-mediated budding of exosomes into 
ILVs within the MVBs have also been identified [41, 42]. Further evidence of ESCRT-
independent pathway of ILV formation has come from studying the protein Pmel17, a main 
component of the c fibrils of pre-melanosomes, which is targeted to intraluminal vesicles of 
MVBs independently of ubiquitination, ESCRT0 and ESCRTI [43].  
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Protein contents of exosomes from different cells have been mapped by proteomics and the 
most of the data obtained has been catalogued in Exocarta database [44]. 
 
1.5.2. Composition 
 
Exosomes purified from the cell culture supernatants are usually heterogeneous in size and 
contain functional mRNA translatable to proteins, mature microRNAs, lipids and proteins. 
Protein composition analysis of exosomes shows a rather limited sub-cellular localization for 
the exosomal proteins. Indeed, usually the preparations of exosomes are mostly enriched in 
cytosolic and membrane proteins and contain less proteins of nuclear, mitochondrial, 
endoplasmic-reticulum or Golgi-apparatus origin. Secondly, exosomes express a common set of 
proteins (figure 5). These are structural components and proteins with a role in exosome 
biogenesis and trafficking. Cell type specific components which presumably reflect the 
biological function of the parent cell on the other hand could also be identified in exosome 
preparations [37].  
Proteins of exosomes have been analyzed both by proteomics and targeted immunochemical 
methods, like Western-blot, FACS with immunolabeling, and immunoelectron microscopy. 
Exosomes contain a distinct set of proteins such as the Alix, TSG101, HSP70 and the 
tetraspanins CD63, CD81 and CD9. The protein content of exosomes has been extensively 
analyzed from various cell types and body fluids by mass spectrometry, Western blotting, 
fluorescence-activated cell sorting and immunoelectron microscopy. A detailed analysis of 19 
proteomic studies revealed a more generic outlook of exosomal proteins (Figure. 5). The 19 
exosomal studies used for this analysis were derived from dendritic cells [45], melanoma cells 
[46], urine [47, 48], microglia [49], mast cells [50], colorectal cancer cells [51, 52], 
mesothelioma cells [53], brain tumor [54], oligodendrocytes [55], tracheobronchial cells [56], 
hepatocytes [57], neuroglial cell [58], plasma [59], breast milk [60], breast cancer cells [61], 
saliva [62] and embryonic fibroblast cells [63]. Exosome protein composition varies depending 
on the cell type of origin and a unique tissue/cell type signature for exosomes was revealed 
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[52]. In addition, a conserved set of proteins were identified in exosomes in spite of their 
cellular origin.  
 
 
Figure 5. A graphical representation of the protein composition of exosomes categorized as per 
the function performed [64]. 
 
One class of cytosolic proteins commonly seen in exosomes includes the Rabs, the largest 
family of small GTPases, which regulate exosome docking and membrane fusion [46]. Active 
Rabs interact with proteins involved in vesicular transport and protein complexes that regulate 
vesicle fusion with acceptor membranes [65]. RAB5 localized in early endosomes mediates 
endocytosis and endosome fusion of clathrin-coated vesicles [66]. Interestingly, studies using 
green fluorescent protein-tagged endosomal GTPases showed the existence of mechanisms for 
segregating Rab GTPases into membrane domains with distinct functions [66]. Such studies 
revealed the presence of multiple combinations of RAB4, RAB5 and RAB11 membrane domains 
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in early and recycling endosomes in contrast to RAB7 and RAB9 membrane domains presence 
in late endosomes.  
In addition to Rabs, exosomes are rich in annexins (annexins I, II, IV, V, VI, VII and X1) which aid 
in membrane trafficking and fusion events [67]. Exosomes are also enriched with tetraspanins 
(CD63, CD81 and CD9) [52] and heat-shock proteins (HSP60, HSP70, HSPA5, CCT2 and HSP90), 
and contain cell-type-specific proteins such as A33 (colon epithelial-derived) [35], MHC II 
(antigen presenting cells-derived) [68] and [69], CD86 (antigen-presenting cells) [70] and [71] 
and MFG-E8/lactadherin (immature dendritic cells) [72]. Interestingly, colorectal cancer-derived 
exosomes showed a significant enrichment of coiled-coil, RAS and MIRO domain containing 
proteins [35]. Coiled coil motifs play a vital role in localization of proteins to early endosomes 
[73] and vesicular transport [74] while RAS and MIRO domains are found in small GTPases 
(Rabs) and Rho GTPases. 
Other exosomal proteins include the metabolic enzymes (GAPDH, enolase 1, aldolase 1, PKM2, 
PGK1, PDIA3, GSTP1, DPP4, AHCY, TPL1, peroxiredoxins, P4HB, LDH, cyclophilin A, FASN, MDH1 
and CNP), ribosomal proteins (RPS3), transmembrane (PIGR, LAMP1 and CD59), signal 
transduction (syntenin, 14-3-3, G proteins, ARF1, CDC42, stomatin, SLC9A3R1, RALA, PDCD6, 
rack1, mucin 1, EHD1, RAN, PEBP1, MIF, RRAS2, RAC1, NRAS and EHD4), adhesion (MFGE8 and 
integrins), ATPases (VCP, ATP1A1, DYNC1H1, ATP5B and ACLY), cytoskeletal (actins, tubulins, 
cofilin 1, ezrin, profilin 1, moesin, radixin, myosin, perlecan, THBS1, IQGAP1, keratins, gelsolin, 
fibronectin 1 and LGALS3BP) and ubiquitin molecules (ubiquitins B and C) [35].  
 
1.5.3. Biological and pathological role 
 
Despite their role in immune system modulation [75], the biological role of exosome secretion 
remained largely elusive until recent years when Lötvall’s group demonstrated that exosomes 
can transfer genetic information from one cell to another [50]. Since then several mechanisms 
have been proposed to describe exosome-cell interactions: (i) cellular binding via conventional 
receptor–ligand interactions, similar to cell–cell communication. (ii) attaching/fusing with target 
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cell membrane and (iii) internalization by recipient cells by endocytosis in a transcytotic manner 
(figure 6).  
 
 
 
 
Figure 6. Possible mechanisms of intracellular communication by exosomes [64]. 
 
Besides the physiological roles of exosomes to remove the unwanted cellular debris, recent 
findings uncover an entirely new and exciting modes of cell–cell communication and paracrine 
signalling mediated by exosomes [29, 76]. 
Many mammalian cells like dendritic, mast, epithelial, neural, stem and hematopoietic cells, 
reticulocytes, astrocytes, adipocytes, and tumor cells have been reported to release exosomes 
[37, 77] 
Emerging data shows their involvement in different diseases including inflammation, renal 
diseases, Alzheimer diseases, aging, bacterial and viral infections, allergies and cancer. Using 
different sources of tumor-derived exosomes, several groups claim that exosomes can prevent 
tumor development, induce tumor specific immunity, and provide a possible strategy for 
therapeutic tumor vaccination reviewed by van Niel et al.[37]. 
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1.5.4. Proteomic approach 
 
Compared to the techniques required for other protein enrichment for proteome-based 
analysis, the isolation of exosomes may be fairly straightforward. Their protein and lipid 
contents could be identified and characterized unaffected by isolation and purification 
procedures [40]. Currently, the most effective method for exosome isolation is 
ultracentrifugation [40], [47]. To further purify the exosomes, methods such as sedimentation 
via sucrose gradient ultracentrifugation and immunoisolation via antibody-based derivatized 
Dynabeads have proven effective [40], [48]. The purified exosomes could be verified onwards 
usually using electron microscopy techniques or western blotting using antibodies against 
known exosomal biomarkers, such as hsp70, hsp90, and annexins I, II, V, VI [40], [48]. The 
purified exosomes for proteomic analysis could be submitted to various protein or peptide 
separation approaches in combination with different types of mass spectrometry (MS) 
instruments[40]. Alternative approaches using ultrafiltration show some promise, but the main 
obstacle is a tendency to retain and concentrate soluble proteins in urine in addition to 
exosomes. These contaminating proteins are able to compete with exosomal proteins for 
identification by liquid chromatography (LC)-MS/MS and therefore may reduce the sensitivity of 
the discovery process [78]. 
 
1.5.5. Lipidomic approach  
 
Rapid technological advancements in MS and chromatographic techniques have led to 
expansion of lipidomics research. The increasing importance of this research field reflects the 
wealth of information accumulated in the past decade, which resulted in online resources such 
as Lipidomics Expertise platform (http://www.lipidomics-expertise.de), Nature Lipidomics 
Gateway (http://www.lipidmaps.org), Lipid Bank (http://lipidbank.jp), Lipid Library 
(http://www.lipidlibrary.co.uk), Lipid Data Bank (http://www.caffreylabs.ul.ie), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) http://www.genome.jp/kegg/), European 
Federation for the Science and Technology of Lipids (http://www.eurofedlipid.org). Exosomes 
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seem to be vehicles of bioactive lipids and lipolytic enzymes [79], [80]. Advent soft ionization 
technologies, such as matrix-assisted laser desorption/ionization (MALDI), electrospray 
ionization (ESI), and atmospheric pressure chemical ionization (APCI) for MS, possibly coupled 
to LC, provided powerful tools for rapid and sensitive analysis of the majority or a substantial 
fraction of lipids possible in one analysis [81]. It seems that lipids involved in exosome 
composition differ according to the cells of origin and their function. Reticulocyte-derived 
exosomes showed no increase in cholesterol/phospholipids ratio, opposite to the MHC II–
enriched exosomes derived from B cells [82], [83]. Mast cell (RBL-2H3)–and dendritic cell–
derived exosomes showed a high amount of disaturated phosphatidylcholine and 
phosphatidylethanolamine classes. This, together with a limited amount of diglycerides, 
suggests elevated membrane rigidity and an elevated transmembrane movement of lipids 
compared to the plasma membrane [82]. Most of the exosomes studied showed enrichment in 
raft lipids, such as cholesterol, sphingolipids, ceramide, and glycerophospholipids with long and 
saturated fatty-acyl chains [42, 80, 82, 84] . Exosome formation could be a way to secrete 
enzymes involved in lipid signaling [80, 82]. It was shown that cross-linking of sphingomyelin 
triggers calcium influx and ERK phosphorylation, indicating that these domains could be a 
specific signaling platform [82]. Recent studies provided evidence that the ESCRT-independent 
pathway of exosomal biogenesis requires ceramide and that release of exosomes was reduced 
after the inhibition of neutral sphingomyelinases [42, 84]. The lipidomic approach would not 
only provide insight into the roles of specific lipids in exosome biogenesis and functions, but 
also holds promise in the biomarker discovery field, shoulder to shoulder with other powerful 
“omics” technologies. 
 
1.5.6. Urinary exosomes 
 
Urinary exosomes  are delivered to the urine when the outer membranes of multivesiculat 
bodies (MVB) fuse with the apical plasma membrane of the cell. Proteomic analysis of urinary 
vesicles through nanospray LC-tandem MS identified numerous protein components of MVB, 
suggesting their similar biogenesis as in other cell types [29], [47], [48]. Approximately 75% of 
25 
 
the proteins that constitute ESCRT-0, -I, -II, -III, and ATP-ase complexes involved in the MVB 
formation are identified in urinary exosomes, as well as ALIX [48]. Urinary exosomes are 
normally secreted into the urine from all cell types that face the urinary space and account for 
3% of the total urinary protein [48], [85]. Proteomic analysis identified specific membrane 
proteins starting from podocytes through transitional epithelial cells lining the urinary drainage 
system. First, tandem mass spectrometry proteomic analysis of urinary exosomes from normal 
human subjects revealed 295 unique proteins. At least 20 of these proteins were already 
established as highly deregulated in various renal diseases and hypertension [47]. A recent 
study of urinary exosomes from normal human urine using highly sensitive LC-MS/MS based on 
an ion trap mass spectrometer (LTQ; Thermo-Finigan; ThermoElectron, San Jose, CA) identified 
1412 unique proteins. Of these proteins, 927 were not previously identified, including 14 
phosphoproteins. The identified phosphoproteins are known to be involved in serine/threonine 
and tyrosine kinase signaling pathways, as well as in some other signaling pathways that occur 
during cytokine and growth factor receptor activation and numerous other cell regulatory 
processes. Further analysis of all obtained data identified 1132 proteins unambiguously. A large 
number of identified proteins were soluble cytoplasmatic proteins and integral membrane 
proteins. Integral membrane proteins predominantly represent apical transporters present in 
every renal tubule segment. Multiple small GTP binding proteins, including proteins in the Rab, 
ARF, Rho, and Ral families, were identified, as well as cytoskeletal motor and peripheral-
membrane proteins [48]. Ubiquitin was identified throughout the molecular weight range of 
the analysis, although the published data still do not distinguish between mono- and 
polyubiquitinated proteins [48]. 
 
1.5.7. Clinical relevance  
a) Exosomes as biomarkers 
 
In the last years, the literature was overwhelmed with papers proving the role of exosomes 
(especially tumor and APC exosomes) in the transfer similar receptors to homologous and 
heterologous cells. Their specific structure probably made them a more advantageous carrier of 
26 
 
“distant” signal delivery compared to soluble molecules [79]. The lipid bilayer highly enriched 
with cholesterol, sphingomyelin, and other characteristic molecules may significantly contribute 
to the preservation of stabile conformation conditions, including post-translational modification 
of the proteins they carry, allowing their detection by powerful proteomic-based strategies. A 
number of the novel putative markers for the clinically important states were proven to be 
proteins that have undergone disease-specific post-translational modification [86].  One of the 
most important post-translational modifications is phosphorylation that regulates cellular 
signaling processes and may determine protein structure, function, and subcellular localization.  
Phosphoproteins and even the specific phosphorylation sites were identified in urinary 
exosomes [48]. Thus, urinary exosomes may become a very interesting source for biomarker 
discovery. The valuable information that could be obtained from the proteomic, lipidomic, and 
other powerful molecular analyses also could provide further insight into the biogenesis and 
function of exosomes. One of the possible applications in clinical research is large-scale 
biomarker discovery, such as those currently being pursued in blood, tissue homogenates, and 
liquor [78]. Another promising approach could be choosing a combination of proteins whose 
identification can be hypothesized to provide the required specificity (lack of false-positives) 
and sensitivity (lack of false-negatives).  Urine has evolved as one of the most attractive body 
fluids in the biomarker discovery field, with a potentially rapid application in the clinic. 
Considering their origin, urinary exosomes may provide a novel noninvasive method of 
acquiring unique information about the physiological or pathophysiological state of the renal 
cells of their origin.  For the proteomics-based approach, exosome isolation could be helpful in 
minimizing highly abundant proteins in urine. This could also provide a significant enrichment of 
low-abundance urinary proteins that have potential pathophysiological significance and 
enhance the detectability of rare proteins that may have diagnostic value.  
 
b) Exosomes as vectors for stem cell therapy 
 
Stem cell therapies exhibit great potential for the treatment of various diseases. The 
therapeutic effects of adult stem cells remain to be fully elucidated. However, exosomes 
27 
 
carrying a cargo of packaged signals in the form of RNA, miRNA, or protein, among others, may 
be a key mechanism and the vehicle of their action to reduce inflammation, alter cellular 
signaling, and result in tissue repair. Mesenchymal Stem Cells (MSC) therapy, for example, is 
being tested in animal models and in multiple clinical trials for the treatment of disorders 
including acute lung injury, myocardial infarction, diabetes, sepsis, graft-versus-host disease, 
and hepatic and acute renal failure [87]. The therapeutic effect has been recapitulated in 
several preclinical models with administration of cell-free media from MSC cultures that contain 
exosomes. Research on the effect of exosomes in vitro has focused mostly on the interaction 
with immune system [6]. Moreover, exosomes from MSCs originating from almost all sources, 
including human embryonic stem cells have been characterized and proposed as the alternative 
therapeutic vehicle is many diseases. For example, MSCs may activate kinase pathways that are 
critical for ischemic preconditionig by increasing extracellular ATP levels and decreasing 
oxidative stress and inflamation [88]. 
 
c) Exosome as vehicle of drug delivery 
 
The recognized function of exosomes as vehicles of intercellular communication has been 
further explored in the delivery of therapeutic signals such as small interfering RNAs (siRNAs) 
for drug delivery. The development of an exosome-based drug delivery system may improve 
targeting of specific cargos to treat disease. Types of therapeutic cargo include interfering 
RNAs, such as siRNAs and miRNAs [89]. Because MSCs are efficient and high producers of 
exosomes, they can be engineered to overexpress specific miRNAs that are incorporated into 
the exosomal cargo and delivered in vivo for the specific targeting of disease [90]. In addition to 
the therapeutic transfer of interfering RNAs, chemotherapeutics such as doxorubicin have been 
loaded onto exosomes and used to inhibit growth of breast and colon cancers [91]. The use of 
exosomes as drug delivery systems is just beginning to be explored. 
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1.6. Common methods for the isolation of extracellular vesicles. 
1.6.1.  differential centrifugation 
 
Differential centrifugation is considered a gold standard, and is the most common method to 
isolate extracellular vesicles and is widely used to isolate them from body fluids and 
conditioned media. Although various protocols are available, generally it consists of multiple 
steps: first, a low speed spin (300 g for 10 min), which eliminates dead cells and bulky apoptotic 
debris, followed by higher speed spins, which varies among laboratories, from 1000 g to 20 000 
g and eliminates larger vesicles and debris. A final high speed spin at 200,000 g precipitates 
exosomes (Figure 7). For more purified exosomes and eliminating contaminations, the pellet 
can be washed again in a large volume of PBS and centrifuged one last time at 200 000 g.  
 
 
Figure 7. Summary of a differential centrifugation method. 
 
One of the most important factors in the determination of sedimentation efficiency of 
exosomes in a differential centrifugation protocol is the clearing factor or k-factor of the rotor.  
The k-factor is a scale of the time taken for a particle to sediment through a particular medium. 
The value of the k-factor is determined by the maximum angular velocity (ω) of a centrifuge (in 
rad/s) and the minimum and maximum radius r of the rotor (Langer et al., 2003). It represents 
the relative sedimentation efficiency of a given centrifuge rotor at maximum rotation speed. K-
factor can be utilized to predict the time t (in hours) required for sedimentation of exosomes 
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using different rotors. The following formula represents the correlation between t, time (in 
hours), k-factor, and s, sedimentation coefficient (in Svedbergs): 
t= k/s 
Admittedly, the most efficient rotors have the lowest k-factor value and operate at a relatively 
high centrifugal force (RCF) or g, and have a low sedimentation path length.  
Another factor that should also be taken into account for increasing sedimentation stability is 
streaming, which affects both accuracy and resolution of sedimented exosomes.  
 
1.6.2. Advantages and disadvantages  
 
The main advantages of the differential centrifugation approach are the simplicity and requires 
simple laboratory equipment. However, is lengthy (4–5 h), requires an ultracentrifuge and 
results in a relatively low recovery of exosomes [92], ranging from 5% to 25% of the starting 
concentration. Another  limitation in using differential centrifugation for isolating extracellular 
vesicles is co-precipitation of protein aggregates, apoptotic bodies, or nucleosomal fragments, 
which may lead to less sample purity and less correctly bound proteins. 
Although exosome like vesicles are abundant in human urine, they are difficult to purify due to 
the presence of the most common urinary protein, Tamm–Horsfall protein (THP), also known as 
uromodulin. THP is a glycoprotein secreted by the epithelial cells lining the thick ascending limb 
of the loop of Henle, which can reach concentrations of 1.5 mg/mL, it has a role in protecting 
the urinary tract from pathogens by acting as a decoy receptor, and it may also inhibit stone 
formation in supersaturated urine. The protein has a signal peptide cleaved mass of 67.1 kDa 
and a pI of 4.9. THP contains a disulfide cross-linked zone pellucida (ZP) domain that is 
responsible for its self-associating into long, double-helical fibrils. Under high g force, THP 
precipitates, contaminating the exosome like vesicle pellet. Further, when the pellet is 
resuspended, the THP forms a hydrated three-dimensional gel that traps the vesicles. To 
recover the exosomes, dithiothreitol can be used to reduce the disulfides in the ZP domain, 
break up the fibrils, and release the vesicles [93]. However, this reduces all proteins, including 
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exosomal proteins, inactivating them and exposing their extended polypeptide backbones to 
proteolytic assault by endogenous proteases.  
 
1.6.3. Sucrose gradient centrifugation 
 
One way to address the limitations of the differential centrifugation approach and increase the 
purity of isolated exosomes is to use a sucrose gradient, which separates vesicles based on their 
different flotation densities [94] from THP. Exosomes, the finest sub-fraction of extracellular 
vesicles, have floatation densities of 1.08–1.22 g/ml on sucrose gradients [70]. In comparison, 
vesicles purified from the endoplasmic reticulum float at 1.18–1.25 g/ml, and vesicles from the 
Golgi at 1.05–1.12 g/ml [95].  
Chen Y et al.’ s protocol [96] uses the THP precipitation to sweep exosome like vesicles  from 
the chilled urine into the pellet. The resuspended pellet is then loaded onto a heavy-water 5–
30% sucrose gradient. The heavy water has a density of 1.1 g/ml, denser than normal water, 
and so is a sucrose-sparing solvent that is dense but not osmotically active. It allows the 
exosome like vesicles to band at lower sucrose concentrations than in normal water and to 
some extent prevents alterations in exosome like vesicles density. This allows the THP to 
separate from the exosome like vesicles. THP is normally secreted from the thick ascending 
loop of Henle. In contrast, exosome like vesicles are secreted from all major segments of the 
nephron [47]. As such, there are multiple populations of ELVs in urine depending on their 
origin, and these populations separate into individual bands following heavy-water 
centrifugation. The uppermost band expresses high levels of aquaporin-2, indicating that they 
derive from the collecting duct. The middle band is heavily enriched for the polycystin proteins, 
which origin from the proximal tubules. These exosome like vesicles are most likely shed from 
the proximal tubule as they are also megalin and aquaporin-1 positive. The most dense bottom 
band contains ELVs with podocin, providing evidence of glomerular origin. 
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1.6.4. Microfiltration  
Attempts to isolate exosomes using filtration-based methods, omitting ultracentrifugation, 
have shown discrepant results. This may be due to the fact that protein quickly accumulates on 
the filters blocking further flow. One example of a commercially available filter is a 
nanomembrane concentrator with 13 nm pore size, which requires only 0.5 mL of urine as 
starting volume. While some proteins, such as annexin V, podocalyxin and neuron specific 
enolase do not adhere to the membrane and are easily recovered, other proteins are more 
adherent, such as aquaporin-2 and TSG-101 [78]. Compared to other isolation methods, the 
purity of recovered protein in urinary extracellular vesicles remains low [97] and this method 
therefore seems less suitable for nephrotic urine [98] and to isolate RNA from urinary 
extracellular vesicles [97].  
Recently Merchant et al. [99] proposed a microfiltration isolation method, using low protein-
binding size exclusion filters for isolation of urinary biomarkers. They utilized hydrophilized 
polyvinylidene difluoride membrane, which have a 100 nm pore size, to easily isolate 
extracellular vesicles from fresh urine samples. Liquid chromatography-mass spectrometry 
immuno-blot analysis, and electron microscopy were used for validation and assessing the 
efficacy of the microfiltration method. They reported equivalent enrichment of extracellular 
vesicles proteomes with reduced co-purification of abundant urinary proteins in comparison 
with other standard methods of extracellular vesicles isolation, including ultracentrifugation 
and nano-filtration. Although filtration technologies are improving quickly, they face several 
challenges, such as the lack of extracellular vesicles condensation, co-purifying abundant 
proteins with extracellular vesicles isolation, contamination of isolated extracellular vesicles, 
and trapping of extracellular vesicles in nano- or micro-pores. Therefore, isolation conditions 
must be optimized for maximal recovery of extracellular vesicles and a more pure 
isolation/enrichment. Another limiting factor for high throughput application of these 
microfilters is the need for a stirred cell apparatus (a positive pressure filtration based 
concentrating device). Incorporation of the microfilter into a commercial spin filtration device 
may alleviate this limitation. 
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1.6.5. Precipitation  
 
ExoQuick™ is a commercially available precipitation kit to isolate microvesicles (System 
Biosciences, Mountain View, CA, USA). For urine, its current protocol results in a very low yield 
of both protein and RNA [97]. Modification of the sample work-up resulted in the highest 
quantities of mRNA and miRNA and an acceptable protein yield compared to the 
ultracentrifugation methods [97]. This method is relatively easy, omits the need for 
ultracentrifugation and uses less sample material (5 mL urine). However, the overnight 
incubation step limits its use for immediate diagnostic use, making it less suitable for disorders 
such as acute kidney injury. 
A standardized method to isolate exosomes doesn’t exist yet. With this work our aim was to 
develop a novel method to purify exosomes from urine. The new method is fast, easy and allow 
a high enrichment in exosomal proteins. The great advantage is that it could be used for several 
biomedical applications. 
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2. MATERIALS AND METHODS  
 
2.1. Urine collection and storage 
 
Urine samples were either taken from ongoing internal review board (IRB)-approved research 
studies, or they are discarded, de-identified urine specimens. The urine is collected as clean-
catch, midstream samples. Subsequently, the samples are stored at -20°C until further 
aliquoting and processing. Informed consent was obtained from all subjects and the research 
conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont 
Report [100]. 
In order to isolate exosomes from urine, the methods described below were used. 
 
2.2. Ultracentrifugation  
2.2.1. Single ultracentrifugation and DTT reduction 
 
Protease inhibitors were added (complete Protease Inhibitor Cocktail Tablets, Roche). 50 ml) of  
urine samples were centrifuged at 17,000 x g for 10 min at 37oC (Beckman L8-70M 
ultracentrifuge; Beckman Coulter, Fullerton, CA) . The supernatant was saved and the pellets 
were resuspended in an isolation solution (250mM sucrose, 10mM triethanolamine (pH 7.6)) 
followed by incubation with DTT (final concentration of 200 mg/ml corresponding to 1.3 M; 
Sigma-Aldrich, St Luois, MO) at 37 0C for 10 min to denature and reduce the disulfide bonds of 
zona pellucida domains in uromodulin. During the DTT incubation, samples were vortexed 
every 2 min, transferred to clean centrifuge tubes (Beckman polycarbonate) and more isolation 
solution was added to a final volume of 10 ml. The samples were centrifuged again at 17,000 x 
g for 10 min at 37 oC. The two supernatants from the 17,000 x g spins were pooled and 
ultracentrifuged at 200,000 x g for 1 h at 37 oC. Pellets were solubilized in 1% SDS and TBS (pH 
7.6) [93].  
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2.2.2. Double ultracentrifugation and DTT reduction 
 
Protease inhibitors were added (complete Protease Inhibitor Cocktail Tablets, Roche). 50 ml of 
urine were centrifuged at 17,000 x g for 10 min at 4°C. The 17,000 x g supernatant was 
ultracentrifuged at 200,000 x g for 1 h at 4°C. The abundant urinary protein uromodulin forms 
very high molecular weight complexes through disulfide linkages. These complexes sediment in 
the 200,000 x g spin unless denatured. To denature the zona pellucida domains in the Tamm-
Horsfall protein, also known as uromodulin, we mixed the resuspended pellet with 200 mg/ml 
(1.3 M) dithiothreitol (DTT) at 95°C for 2 min.The resuspended pellet was added to an 
ultracentrifuge tube, and isolation solution (10mM triethanolamine and 250 mM sucrose) was 
added to increase the volume to 10 ml. The sample was centrifuged at 200,000 x g for 1 h at 
4°C. The pellet was suspended in 1% SDS, TBS pH (7.6) [48].  
 
 
Figure 8. Single(right) and double(left) ultracentrifugation workflow. 
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2.3. Sarkosyl fractionation: rationale 
 
Sodium lauroyl sarcosinate (INCI), also known as sarkosyl, is an ionic detergent derived from 
sarcosine. This surfactant is amphiphilic due to the hydrophobic 14-carbon chain (lauroyl) and 
the hydrophilic carboxylate. Addition of an mixture of equal parts of sodium lauroyl sarcosinate 
and the non-ionic surfactant sorbitan monolaurate (S20) to water led to the formation of 
micelle-like aggregates, even though neither surfactant formed micelles when present alone. 
Such aggregates can help carry other small molecules, such as drugs, through the skin [101]. 
The Sarkosyl solubilization method facilitated separation of the inner and outer membranes, 
making the procedure amenable for effective probing of the subcellular proteome. It has been 
commonly used to fractionate bacterial proteome [102] or to solubilize overexpressed proteins 
in bacteria without denaturing them [103]. 
 
2.3.1. Sarkosyl fractionation (Method 1) 
 
Urine (50 ml) was centrifuge at 17,000 x g 15 minutes at 4oC. The Supernatant, containing free 
exosomes, was ultracentrifuged at 200,000 x g 1 hour at 4oC whereas the pellet, composed by 
exosomes trapped by uromodulin, was resuspended in 1% Sarkosyl in Tris Buffered Saline (TBS) 
pH 7.6 (Biorad Laboratories) and incubated 1 hour, under costant rotation, at 4oC. The pellet 
solubilized in Sarkosyl was ultracentrifuged at 200,000 x g 1 hour at 4oC. The supernatant was 
collected in a new vial and the pellet was resuspended in 1% SDS in TBS pH 7.6 (Biorad 
Laboratories). 
 
2.3.2.  Sarkosyl fractionation using different volumes of urine (Method 2) 
 
Different urine volumes (50 ml, 20 ml and 5 ml) from 2 different donors were used. A technical 
repeat was also performed. The samples were ultracentrifuge at 200,000 x g 1 hour at 4oC. The 
supernatant was discard and the pellet containing exosomes and uromodulin was resuspended 
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in 1% Sarkosyl in Tris Buffered Saline (TBS) pH 7.6 (Biorad Laboratories). The solution was 
incubated 1 hour at 4oC under rotation and centrifuged at 20,000 x g 1 hour at 4oC. The 
supernatant was transferred to a new tube (Sarkosyl soluble fraction), whereas the pellet was 
resuspended in 1% SDS in TBS (Sarkosyl insoluble fraction). The 2 fractions were processed 
separately using Filter Aided Sample Prepatration (FASP) and analyzed by LC-MS/MS. 
 
2.3.3.  Sarkosyl and carbon fractionation (Method 3) 
 
Urine (50 ml) of donor 1 was processed according to the protocol described in 3.1. After 
proteolitic digestion and recovery of the peptides, Sarkosyl soluble and Sarkosyl insoluble 
fractions were fractionate using Carbon packed TopTips (Glygen corporation, Columbia, MD). A 
double pre-wetting step with 200µl of 95% ACN and 0.1% TFA was performed. The carbon tips 
were equilibrated twice by adding 200µl of 0.1% TFA. The peptides were acidified using 20% 
TFA to a final concentration of 0.5% TFA. The sample was loaded to the carbon tip and wash 3 
times with 200µl of 0.1% TFA. The elution buffers (20% ACN (Acetonitrile) in 0.1% TFA 
(Trifloroacetic acid), 25% ACN in 0.1% TFA, 30% ACN in 0.1% TFA, 35% ACN in 0.1% TFA, 40% 
ACN in 0.1% TFA, 50% ACN in 0.1% TFA, 60% ACN in 0.1% TFA, 95% ACN in 0.1% TFA) were 
added and the flow through was collected in separate tubes. Each fraction was dried 
completely using a SpeedVac (Eppendorf). 
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Figure 9. Summary of Sarkosyl fractionation optimization. Exosomes were purify from 50 ml of 
urine for the method A) and from different volumes (50 ml, 20 ml, 5 ml) of urine for the method 
B).  In the last method 2 biological repeats were performed.  
 
2.4. Filter Aided Sample Preparation (FASP) 
 
Each fraction (200 µl) was reduced in 0.1M DTT for 15 minutes at 37°C, and filtered twice with 
200µL of 8M urea in 100mM Tris-Hydrochloride Solution (pH 8.5) through a 30kDa spin filter 
(Millipore, MA) for 15 minutes at 14,000g.  Samples were alkylated with 1% acrylamide solution 
for 20 minutes at room temperature.  They were then centrifuged for 10 minutes at 14,000g, 
and washed three times with 100µL of 8M urea solution followed by three washes with 100µL 
of 50mM ammonium biocarbonate solution.  The samples were digested overnight with 2µg 
trypsin (Promega, WI) at 37°C in a humidify chamber 1:50 (protein:protease).The peptides were 
eluted with 40µL of 50mM ammonium bicarbonate, followed by 50µL of 0.5 M sodium chloride 
solution.  The proteins were then acidified with TFA to a final concentration of 0.2% prior to 
desalting with C18 Silica columns (The Nest Group, Inc., MA) and then dried in a vacuum 
centrifuge before reconstitution.   
38 
 
2.5. LC-MS/MS  
 
Samples were analyzed by a nanoLC system (Eksigent) equipped with LC-chip system (cHiPLC 
nanoflex, Eksigent, trapping column: Nano cHiPLC Trap column 200 μm x 0.5 mm ChromXP C18-
CL 3 μm 120 Å, analytical column: Nano cHiPLC column 75 μm x 15 cm ChromXP C18-CL 3 μm 
120 Å) coupled online either to a Q-Exactive mass spectrometer (Thermo Scientific) or a 
TripleTOF 5600 (AB SCIEX, Concord, ON). Peptides were separated by linear 30, 60 or 120 
minutes gradients from 95 % buffer A (0.2 % FA in water)/5 % buffer B (0.2 % FA in ACN) to 65 
% buffer A/35 % buffer B.  
The mass spectrometers acquire m/z ratios of both the precursor ions (MS1) and fragment ions 
(MS2) in positive ion mode; the instruments were operated in the data dependent mode. In the 
Q-Exactive, scans were acquired in the Orbitrap mass analyzer with resolution 70,000 at 200 Th 
for MS1 and with resolution 17,500 at 200 Th for MS2. For the full scans, 3E6 ions in the mass 
range 300-1500 m/z were accumulated within a maximum injection time of 20 ms in the C trap 
and detected in the Orbitrap analyzer. The 30 most intense ions with charge states ≥ 2 were 
sequentially isolated to a target value of 2E5 with a maximum injection time of 250 ms with an 
isolation window of 2.0 m/z and fragmented in the collision by higher-energy collisional 
induced dissociation (HCD) with normalized collision energy of 27%. In the TripleTOF 5600, 
scans were acquired in the TOF and detected in the accelerator TOF mass analyzer. For TOF MS, 
the mass range 300-1300 m/z ions were accumulated within a maximum injection time of 20 
ms and detected in the accelerator TOF mass analyzer. The 35 most intense ions with charge 
states ≥ 2 were sequentially isolated with a maximum injection time of 50 ms with an isolation 
window of 2.0 m/z and fragmented in the collision by collisional induced dissociation (CID). 
 
2.6. Data processing and analysis 
 
The Thermo “.raw” files were converted into the Mascot generic format (MGF-files) using the 
proteoWizard software tool.  All MS/MS data were searched against a concatenated target-
decoy uniprot-based human protein sequence database including protein sequences of 
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common contaminants by the Protein Pilot Software (AB SCIEX, Foster City, CA), using the 
Paragon algorithm.   For the searches, trypsin was defined as the protease.  The search included 
propionamide of cysteine as a fixed modification and N-acetylation of protein and oxidation of 
methionine as variable modifications. Up to two missed cleavages were allowed for protease 
digestion and peptide had to be fully tryptic. A filter identifications of 1% False Discovery Rate 
(FDR) was used at peptide and protein level.  
The “wiff” data acquired with the TTOF 5600 were processed with the Protein Pilot Software 
(AB SCIEX) utilizing the Paragon algorith. All MS/MS data were searched against a concatenated 
target-decoy uniprot-based human protein sequence database including protein sequences of 
common contaminants. For the searches, trypsin was defined as the protease.  The search 
included propionamide of cysteine as a fixed modification and N-acetylation of protein and 
oxidation of methionine as variable modifications. Up to two missed cleavages were allowed for 
protease digestion and peptide had to be fully tryptic. A filter for identification of 1% False 
Discovery Rate (FDR) was used at peptide and protein level.  
 
3. Gene Ontology and exosomal databases.  
 
To establish a comprehensive set of functional annotations and enrichments of different 
proteins we used The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
v6.7 (National Institute of Allergy and Infectious disease (NIAID), NIH),[104] and Functional 
Enrichment Analysis Tool (FunRich) version 1.1. The total proteome was annotated. 
Annotations for biological processes were reduced to nine categories, including amino acid 
biosynthesis, cytoskeletal, development, homeostasis-related, localization, metabolism, 
neurotransmitter-related, synaptic and cell death-related.  For the cellular component analysis, 
categories included exosomes, lysosomes, extracellular region, extracellular space, extracellular 
matrix, plasma membrane, cytoskeleton. In addition, to validate the data from gene ontology 
annotations, 2 different databases containing exosomal proteins were used: Exocarta 
(http://exocarta.org/) and the Urinary Exosome Protein Database 
(http://dir.nhlbi.nih.gov/papers/lkem/exosome/Default.aspx?protein). 
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A comparison between the different approaches was performed using Venny program. 
(http://bioinfogp.cnb.csic.es/tools/venny/).  
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3. RESULTS 
 
3.1. Exosome isolation by ultracentrifugation and DTT reduction  
3.1.1. Single ultracentrifugation 
 
In this study, we carried out a proteomic profiling of a low-density membrane vesicles from 
human urine consisting mainly of exosomes, using a highly sensitive LC-MS/MS system, based 
on a TripleTOF 5600 (AB SCIEX). To purify extracellular vesicles (EV), 50 ml of urine was 
centrifuge at 17,000 x g for 10 minutes to pellet cellular debris and uromodulin. The initial 
supernatant containing suspended exosomes was kept (SN1) and the pellet was reduced with 
1.3 M DTT to free the exosomes trapped in the uromodulin aggregates. The following 
centrifugation at 17,000 x g removed any cellular debris. The supernatants (SN1 and SN2) were 
combined and ultracentrifuged at 200,000 x g 1 hour at 4oC to sediment exosomes [93]. The 
ultracentrifuged supernatant, containing exosomes, and the pellet containing debris were 
analyzed separately, separating the peptides with a linear 30 minutes gradient. 
We identified 251 proteins in the combined supernatant (SN1+SN2; exosome fraction) and 363 
proteins in the pellet (cellular debris). The majority of proteins (70.3% in the supernatant and 
64.2% in the pellet) derive from exosomes as determined by GO annotation (figure 10). Further 
GO annotation reveals significant enrichment in lysosomal (49.1% in the supernatant and 42.1% 
in the pellet) and plasma membrane proteins (49.1% in the supernatant and 41.1% in the pellet. 
Proteins deriving from extracellular region (22.6% in the supernatant and 21.7% in the pellet), 
extracellular space (19.3% in the supernatant and 20.4% in the pellet), extracellular matrix 
(7.5% in the supernatant and 9% in the pellet) and cytoskeleton (10.5% in the supernatant and 
10% in the pellet) were less abundant. 
The results suggest that proteins found in the supernatant and the pellet do not show the 
expected differences, possibly because the cellular debris still contained sizeable amounts of 
uromodulin aggregates (figure 10).  
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Figure 10. Cellular component comparison between supernatant (SN) and pellet (P) after a 
single ultracentrifugation (UC) step. 
 
3.1.2. Double ultracentrifugation 
 
To identify proteins deriving from exosomes, a second isolation protocol was followed: 50 ml of 
urine was centrifuge at 17,000 x g for 10 minutes. The supernatant, containing uromodulin and 
exosomes, was ultracentrifuge at 200,000 x g for 1 hour at 4oC and subsequently the pellet was 
reduced with 1.3 M DTT. After adding isolation buffer (250mM sucrose, 10mM triethanolamine, 
pH 7.6) to a final volume of 10 ml, the sample was ultracentrifuged for the second time to 
sediment exosomes [48]. The ultracentrifuged supernatant (containing exosomes) and the 
discarded pellet (containing cellular debris and uromodulin) were analyzed individually, 
separating the peptides with a linear 30 minutes gradient on a TripleTOF 5600. 
We identified 283 proteins in the exosome fraction (SN) and 326 proteins in the cellular debris 
pellet (P). A large number of the proteins (74.3% in SN and 69.5% in P) that were identified 
derived from exosomes.  As for the single ultracentrifugation protocol, proteins derived from 
lysosomes (49.8%, 47.4%) and plasma membrane (40.1%, 39.3%) showed similar high 
abundances in both the supernatant and the pellet. Lower percentages were seen for proteins 
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originating from extracellular region (19.4%, 19.1%), extracellular space (19.4%, 18.8%), 
extracellular matrix (8%, 9.6%) and cytoskeleton (9.7%, 10.6%) in the supernatant and pellet, 
respectively (figure 11). Similarly to what was observed in the single ultracentrifugation 
method, the supernatant (SN) and the pellet (P) did not show a significant difference in their 
proteome composition.  
 
 
Figure 11. Cellular component comparison between supernatant (SN) and pellet (P) after a 
double ultracentrifugation (UC) step.  
 
To compare the 2 different approaches, a Venn diagram was created using Venny 
(http://bioinfogp.cnb.csic.es/tools/venny/), as shown in Figure 12. The greater number of 
proteins (125) was common to both approaches and appeared both in the supernatant and in 
the pellet. This result suggests that there is not a significant difference between the single and 
double ultracentrifugation methods. 
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Figure 12. Comparison between the supernatant (SN) and pellet (P) of the single and double 
ultracentrifugation methods. 
 
3.1.3. Combination of double and single ultracentrifugation. 
 
The samples analized by the methods described in paragraph 1.1 and 1.2 of this section were 
combined and the peptides were separated using a TTOF 5600 mass spectrometer with a linear 
60 minutes gradient. 647 proteins were identified and compared with Exocarta (only proteins 
from urinary exosomes; http://exocarta.org/) (which is a database, containing exosomal 
proteins deriving from all biological fluids), and Gonzalez P.A. et al’s study [48] (figure 13 A). 
From the comparison we saw that 124 proteins were common to the 3 datasets, whereas 
Exocarta and Gonzalez et al. [48] shared 1029 proteins. while the combined ultracentrifuged 
samples shared only 135 proteins with Exocarta.  
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Figure 13. A) Comparison between our method, Gonzalez et al. [48] and exosome proteins 
deriving from uring reported in Exocarta Database. B) Comparison between Gonzalez et al. [48] 
and the Urinary Exosome Protein Database. 
 
We used the Gonzalez et al. [48] publication instead of the Urinary Exosome Protein Database 
(http://dir.nhlbi.nih.gov/papers/lkem/exosome/), which is another online resource for urinary 
exosomes, since the letter is largely based on the former as it is apparent from Figure 13B. 
 
3.2. Sarkosyl fractionation 
 
The experimental scheme is reported in Figure 8. EVs isolated from 50 ml of urine were 
fractionated using 1% Sarkosyl, which is an anphiphilic detergent. The idea is that the 
uromodulin aggregates remain insoluble in sarkosyl while the exosomes will be solubilized to 
release the exosomal proteins into the supernatant. For this purpose, urine was centrifuge at 
17,000 x g 15 minutes at 4oC. The supernatant, containing free exosomes, was ultracentrifuged 
at 200,000 x g 1 hour at 4oC whereas the pellet, composed by exosomes trapped by 
uromodulin, was resuspended in 1% Sarkosyl in Tris Buffered Saline (TBS) pH 7.6 (Biorad 
Laboratories) and incubated 1 hour, under costant rotation, at 4oC.  Protein distribution of EV 
(supernatant after 200,000 ×g centrifugation, SN) were substantially different in all fractions as 
reported in Table 1. Mass spectrometry analysis of all the fractions identified a total of 280 
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proteins in the soluble fraction and 375 proteins in the insoluble fraction after separating the 
peptides using a linear 30 minutes gradient (1% FDR both at peptide and protein level). After 
the ultracentrifugation step the pellet, containing free exosomes (not trapped by uromodulin), 
and the supernatant (depleted of exosomes) were analyzed following the same parameters: 27 
proteins were identified in the pellet containing EVs after ultracentrifugation and 84 proteins 
were identified in the supernatant (Table 1). To determine which fraction is enriched 
in/depleted of uromodulin, the main interference for the exosome isolation as it forms 
supramolecular structures in its non-reduced form, we calculated the ratio between 
uromodulin and albumin, since they are the most abundant proteins in urine (table 1). As 
expected, Sarkosyl insoluble fraction showed a 25 fold enrichment of uromodulin (URO/ALB of 
10) compared to Sarkosyl soluble fraction (URO/ALB of 0.4). 
 
SAMPLE 
Number of 
proteins 
Uromodulin/ 
Albumin 
Sarkosyl soluble (ss) 280 0.4 
Ultracentrifugation (UC) 27 9 
ss+ UC (exosomes) 256 2 
Sarkosyl insoluble (si) 375 10 
Supernatant after UC 84 2.6 
Ultracentrifugation + DTT (knepper protocol) 604 1.45 
 
Table 1. Number of proteins identified after performing the method described in paragraph 
2.1 of the Materials and Methods section. 
 
In figure 14 the number of identified proteins is summarized using a Venn diagram. Comparing 
Sarkosyl soluble (280 proteins), Sarkosyl insoluble (375 proteins) and ultracentrifugation 
combined with DTT reduction following the workflow described by Gonzales (604 proteins) [48] 
we saw that 40% of the proteins in Sarkosyl soluble fraction overlap with Sarkosyl insoluble 
fraction. The overlap between proteins identified in Sarkosyl soluble fraction and 
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ultracentrifugation followed by DTT reduction [48] was 53%, whereas the overlap was 48% for 
the comparison between Sarkosyl insoluble fraction and ultracentrifugation followed by DTT 
reduction [48]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Diagram of proteins identified in Sarkosyl soluble, Sarkosyl insoluble, 
ultracentrifugation and DTT reduction and the exosomal proteins found in urine available in 
Exocarta database (v4.1) 
 
To compare our EV dataset with other studies, we performed overlap analysis using Exocarta 
(v4.1) protein database. Results are summarized in figure 14 and show an overlap of 23% in 
Sarkosyl insoluble fraction and ultracentrifugation combined with DTT reduction, 26% in 
Sarkosyl soluble fraction compared with Exocarta database. 
We found only 67 proteins unique in Sarkosyl soluble fraction, 119 in Sarkosyl insoluble fraction 
and 308 proteins after ultracentrifugation and DTT reduction. 
 
 
 
 
Sarkosyl 
soluble Exocarta 
Sarkosyl 
insoluble UC + DTT 
48 
 
3.2.1. Optimization of the Sarkosyl-based Exosome Isolation 
 
To optimize Sarkosyl fractionation, 50 ml of urine were ultracentrifuged (200,000 x g for 1hour), 
avoiding the first centrifugation step at 17,000 x g for 10 min, and the pellet was resuspended 
in 1% Sarkosyl as represented in figure 8. After tryptic digestion the peptides were separated 
using 1 hour gradient by a TTOF 5600. 754 proteins were identified in Sarkosyl soluble fraction 
and 155 in Sarkosyl insoluble fraction. 
 
 
 
  
 
 
 
 
Table 2. Proteins identified by Protein Pilot Software. 
 
Comparing our protein list with previously published urine exosome protein list, 27% of 
proteins in Sakosyl soluble, 26% in Sarkosyl insoluble overlap with Exocarta database and 95 
proteins were common between the 2 fractions, as shown in figure 15.  
 
 
 
 
 
 
 
 
 
SAMPLE Number of proteins 
Ratio uromodulin/ 
albumin 
Sarkosyl soluble 754 1 
Sarkosyl insoluble 155 5.2 
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Figure 15. Diagram of proteins identified in Sarkosyl soluble, Sarkosyl insoluble and and the 
exosomal proteins found in urine available in Exocarta database (v4.1). 
 
Other proteomic studies that isolate and analyze exosomes fron urine [105] show very poor 
overlap with both Exocarta and Gonzales et al.’s results [48], as shown in figure 16. Protein 
overlap analysis only 93 proteins were common to the 3 studies. This indicates that urinary 
exosome preparations are not as robust and/or the exosomal compositions are not as well 
defined as many current publications make it seem. 
Sarkosyl 
insoluble 
Sarkosyl 
soluble 
Exocarta 
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Figure 16. Comparison between different exosome proteomic studies – Exocarta, Fraser et al. 
[105] and Gonzales et al. [48] 
 
To test the reproducibility of the method, 2 different biological samples were processed twice 
resulting in two biological repeats with two technical repeats each. Peptides were separated 
using a 120 minutes gradient using a QExactive mass spectrometer (Thermo Scientific); the 
resuting “.raw” files were converted to the .mgf format and analyzed using ProteinPilot 
Software (AB SCIEX). The number of proteins identified are summarized in table 3: 910 and 937 
were identified in 50 ml of urine in the first biological repeat and 581 and 459 proteins were 
identified in 50 ml in the second biological replicate.  
To identify whether lower volumes of urine can be used, 20 ml and 5 ml or urine were also 
processed and analyzed. A total of 930 and 667 proteins were identified in 20 ml and 5 ml of 
urine, respectively (table 3). 
Although quite a variation was observed for the URO/ALB ratio, a successful depletion of 
uromodulin is apparent as none of the samples had URO/ALB ratios of 5 to 10 as reported 
above (table 3). 
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SAMPLE 
Volume of 
urine 
Sarkosyl 
soluble 
Ratio 
uromodulin/ 
albumin  
1.1 50 ml 910 0.34 
1.2 50 ml 937 0.97 
2.1 50 ml 581 1.3 
2.2 50 ml 459 2.3 
1 20 ml 930 0.7 
1 5 ml 667 1.5 
 
Table 3. Number of proteins identified in urinary exosomes. 
 
To increase the number of proteins identified, Sarkosyl soluble and insoluble fractions were 
further fractionated using carbon packed TopTips: 6 fractions were analyzed with a 60 minutes 
gradient each. 1618 and 553 proteins were identified in Sarkosyl soluble and insoluble fractions, 
respectively using a 1% FDR filter.  Sarkosyl soluble fraction had an overlap of 42% with 
Exocarta and 39% with the exosomal proteome reported by Gonzalez, P.A et al. [48] 
 
 
 
 
 
 
 
 
 
 
Figure 17. Overlap betweeen Sarkosyl soluble fraction, Exocarta and the exosomal proteome 
found by Gonzalez et al [48] 
Sarkosyl soluble Exocarta 
Gonzalez,P.A. et al 
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Gene ontology analysis of the EV proteins showed a 61.3% enrichment for proteins deriving 
from exosomes (figure 18) in Sarkosyl soluble fraction compared to (per definition) 99.9% from 
Exocarta. All the other cellular components show similar percentages for the Sarkosyl soluble 
fraction and the Exocarta database. 
 
 
Figure 18. Gene ontology analysis of Sarkosyl soluble fraction and Exocarta database (v 4.1). 
 
Gene ontology analysis of the Sarkosyl insoluble fraction reveal 69% enrichment for exosomal 
proteins (figure 19), suggesting an incomplete solubilization of the exosomes by Sarkosyl. The 
sarkosyl insoluble fractions contains more mitochondrial (26.6%), centrosomal (17.7%) and 
cytosolic (22.9%) proteins than the Exocarta database (11.7%, 9.6% and 15.5% respectively), as 
shown in figure 18. 
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Figure 19. Gene ontology analysis of Sarkosyl insoluble fraction and Exocarta database (v 4.1). 
 
In figure 20 the number of identified proteins is summarized using a Venn diagram. Comparing 
Sarkosyl soluble, Sarkosyl insoluble and Exocarta database we saw that 369 out of 1618 
proteins in Sarkosyl soluble fraction overlap with Sarkosyl insoluble fraction. The overlap 
between proteins identified in Sarkosyl insoluble fraction and Exocarta was 44%. 
 
 
 
 
 
 
 
 
 
 
Sarkosyl insoluble Sarkosyl soluble 
Exocarta 
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Figure 20. Venn diagram representing the overlap between Sarkosyl soluble, Sarkosyl insoluble 
fractions and Exocarta (v4.1) 
 
To verify the isolation of exosomal proteins, the whole list of proteins was analyzed both for 
Sarkosyl soluble and insoluble fraction, looking for EVs markers. Table 4 summarized the EV 
markers found in the soluble fraction  
  
Accession Name Spectra counts 
sp|Q8WUM4|PDC6I_HUMAN Programmed cell death 6-interacting protein (Alix) 72 
sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein  51 
sp|Q5VTE0|EF1A3_HUMAN Putative elongation factor 1-alpha-like 3 36 
sp|Q99816|TS101_HUMAN Tumor susceptibility gene 101 protein 31 
sp|P50395|GDIB_HUMAN Rab GDP dissociation inhibitor beta  29 
sp|P51148|RAB5C_HUMAN Ras-related protein Rab-5C  27 
sp|P07900-2|HS90A_HUMAN Heat shock protein HSP 90-beta  24 
sp|P51149|RAB7A_HUMAN Ras-related protein Rab-7a  14 
sp|P62820|RAB1A_HUMAN Ras-related protein Rab-1A 14 
sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta  13 
sp|P21926|CD9_HUMAN CD9 antigen  13 
sp|P61026|RAB10_HUMAN Ras-related protein Rab-10 12 
sp|P61106|RAB14_HUMAN Ras-related protein Rab-14 12 
sp|P13639|EF2_HUMAN Elongation factor 2  7 
sp|P61019|RAB2A_HUMAN Ras-related protein Rab-2A 6 
sp|P08962|CD63_HUMAN CD63 antigen  5 
sp|P20339|RAB5A_HUMAN Ras-related protein Rab-5A  5 
sp|Q9HCU0|CD248_HUMAN Endosialin 5 
sp|P51153|RAB13_HUMAN Ras-related protein Rab-13  4 
sp|P14625|ENPL_HUMAN Endoplasmin  3 
sp|Q9UL26|RB22A_HUMAN Ras-related protein Rab-22A 3 
sp|P60033|CD81_HUMAN cd81 antigen 2 
sp|P05362|ICAM1_HUMAN Intercellular adhesion molecule 1  1 
 
Table 4. Exosomal markers in Sarkosyl soluble fraction. 
 
Proteins deriving from endosomal sorting complexes required for transport (ESCRT) pathway, 
key mediator for multivesicular bodies biogenesis,  are listed in table 5. 
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Accession Names Spectra 
counts 
sp|Q9UN37|VPS4A_HUMAN Vacuolar protein sorting-associated protein 4A  71 
sp|O75351|VPS4B_HUMAN Vacuolar protein sorting-associated protein 4B  31 
sp|P53990|IST1_HUMAN IST1 homolog  31 
sp|P62805|H4_HUMAN Histone H4  21 
sp|Q9UK41|VPS28_HUMAN Vacuolar protein sorting-associated protein 28 homolog  18 
sp|Q9BRG1|VPS25_HUMAN Vacuolar protein-sorting-associated protein 25  15 
sp|P55290|CAD13_HUMAN Cadherin-13  14 
sp|Q9NP79|VTA1_HUMAN Vacuolar protein sorting-associated protein VTA1 
homolog  
13 
sp|Q9H9H4|VP37B_HUMAN Vacuolar protein sorting-associated protein 37B  12 
sp|Q9NZZ3|CHMP5_HUMAN Charged multivesicular body protein 5  12 
sp|P04908|H2A1B_HUMAN Histone H2A type 1-B/E  11 
sp|Q8WV92|MITD1_HUMAN MIT domain-containing protein 1  10 
sp|Q99880|H2B1L_HUMAN Histone H2B type 1-L  7 
sp|P52758|UK114_HUMAN Ribonuclease UK114  6 
sp|Q86XT2|VP37D_HUMAN Vacuolar protein sorting-associated protein 37D  6 
sp|Q9H444|CHM4B_HUMAN Charged multivesicular body protein 4b  6 
sp|Q7LBR1|CHM1B_HUMAN Charged multivesicular body protein 1b  5 
sp|Q86VN1|VPS36_HUMAN Vacuolar protein-sorting-associated protein 36  5 
sp|O43633|CHM2A_HUMAN Charged multivesicular body protein 2a  4 
sp|Q96H20|SNF8_HUMAN Vacuolar-sorting protein SNF8  4 
sp|Q96QK1|VPS35_HUMAN Vacuolar protein sorting-associated protein 35  4 
sp|Q709C8|VP13C_HUMAN Vacuolar protein sorting-associated protein 13C  3 
sp|Q13268-2|DHRS2_HUMAN Isoform 2 of Dehydrogenase/reductase SDR family 
member 2  
2 
sp|Q96CF2|CHM4C_HUMAN Charged multivesicular body protein 4c  2 
sp|Q96FZ7|CHMP6_HUMAN Charged multivesicular body protein 6  2 
sp|Q9BY43|CHM4A_HUMAN Charged multivesicular body protein 4a  2 
sp|Q9Y3E7|CHMP3_HUMAN Charged multivesicular body protein 3  2 
sp|P16402|H13_HUMAN Histone H13  1 
sp|Q9HD42|CHM1A_HUMAN Charged multivesicular body protein 1a  1 
sp|Q9NRW7|VPS45_HUMAN Vacuolar protein sorting-associated protein 45  1 
sp|Q9UQN3|CHM2B_HUMAN Charged multivesicular body protein 2b  1 
 
Figure 5. ESCRT pathway proteins identified in Sarkosyl soluble fraction of urine exosomes. 
 
The list of exosome markers for the insoluble fraction was certainly shorter, as shown in table 6. 
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Accession Name Spectra 
counts 
sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein  45 
sp|Q5VTE0|EF1A3_HUMAN Putative elongation factor 1-alpha-like 3  33 
sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta  11 
sp|P50395|GDIB_HUMAN Rab GDP dissociation inhibitor beta  8 
sp|P07900-2|HS90A_HUMAN Isoform 2 of Heat shock protein HSP 90-alpha  7 
sp|Q8WUM4|PDC6I_HUMAN Programmed cell death 6-interacting protein  7 
sp|P13639|EF2_HUMAN Elongation factor 2  6 
sp|P62820|RAB1A_HUMAN Ras-related protein Rab-1A  4 
sp|P14625|ENPL_HUMAN Endoplasmin  2 
sp|P51149|RAB7A_HUMAN Ras-related protein Rab-7a  2 
sp|Q8WUD1|RAB2B_HUMAN Ras-related protein Rab-2B  2 
sp|P61026|RAB10_HUMAN Ras-related protein Rab-10  1 
 
Table 6. Exosomal markers in Sarkosyl insoluble fraction. 
 
Some of the proteins deriving from ESCRT pathway were found also in Sarkosyl insoluble 
fraction, as shown in table 7. However the spectra counts are lower compare to the soluble 
fraction. 
 
Accession Name Spectra 
counts 
sp|P53990|IST1_HUMAN IST1 homolog  7 
sp|O43633|CHM2A_HUMAN Charged multivesicular body protein 2a  3 
sp|Q9NP79|VTA1_HUMAN Vacuolar protein sorting-associated protein VTA1 
homolog  
3 
sp|Q9UN37|VPS4A_HUMAN Vacuolar protein sorting-associated protein 4A  3 
sp|Q709C8|VP13C_HUMAN Vacuolar protein sorting-associated protein 13C  1 
sp|Q7LBR1|CHM1B_HUMAN Charged multivesicular body protein 1b  1 
sp|Q86XT2|VP37D_HUMAN Vacuolar protein sorting-associated protein 37D  1 
sp|Q9Y3E7|CHMP3_HUMAN Charged multivesicular body protein 3  1 
 
Table 7. ESCRT pathway proteins identified in Sarkosyl insoluble fraction of urine exosomes. 
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4. DISCUSSION AND CONCLUSION 
The presence of exosomes in biological fluids has begun to be exploited as a potential source 
for disease-related biomarkers. The number of reports regarding mass spectrometry-based 
proteomic analyses of exosomes is increasing. Furthermore, it is expected that and advances in 
the field of mass spectrometry hardware and appropriate computational tools will further 
improve this trend. 
One of the objectives of this study was to develop novel approaches for the isolation of urinary 
exosomes and to expand the existing human urinary exosome database. One of the challenges 
of using urine as a biological fluid is the presence of high abundant proteins as uromodulin and 
albumin. In order to overcome this problem, standard methods require a reduction step with 
1.3 M DTT [48, 93]. 
Two exosome isolation strategies were used in this work: first, the standard ultracentrifugation 
strategy followed by a high concentration of DTT to reduce uromodulin [48, 93]; second the 
solubilization of exosomes in 1% Sarkosyl coupled with a carbon fractionation, which was a 
completely new approach. Proteins identified in the samples fractionated using the second 
method, such as all of the members of ESCRT pathway, enriched membrane-bound vesicle, and 
endosomal proteins etc., clearly indicated their multivesicular origin. The ESCRT pathway is a 
group of multisubunit protein complexes that play a central role in the processes of endosomal 
cargo sorting and MVB formation [106]. However, the function of ESCRT machinery in the 
formation and secretion of exosome is still unclear [80]. These samples contained also 
exosomal surface markers such as  Alix and TG101, indicating the successfully isolation of EVs. 
However, some of these proteins were also present in the insoluble fraction – albeit to a much 
lower extent – suggesting incomplete solubilization of the exosomes by Sarkosyl. 
Even though DTT reduction was used to reduce the amount of uromodulin in the 200,000 x g 
sediments, uromodulin was still one of the most abundant proteins in the exosome preparation 
probably; due to its sheer abundance, it probably associates with exosomal proteins or 
exosome membranes and thus is co-sedimented during the centrifugation. In an additional 
attempt to eliminate uromodulin, we also tried – without success – the modified urinary 
exosome preparation reported by Fernandez-Llama et al. [93] to recover the entrapped 
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exosomes in the low-speed pellets. After a low speed centrifugation (17,000 x g) uromodulin 
sediment, entrapping exosomes. To release exosomes from uromodulin, some papers 
described a method that uses a high concentration of DTT (1.3 M) [47, 48, 93]. We avoid  such a 
high amount of DTT by using Sarkosyl, whis is amphypathic detergent. Thus, uromodulin 
remains in the insoluble fraction and most of the remaining proteins are in the Sarkosyl soluble 
fraction. 
In addition to uromodulin, 3.4 - 5.4 grams per deciliter (g/dL). of serum albumin is also present 
in normal urine and is thus expected to be present as a common contaminant in all our samples 
and preparation independent of the attempts to remove the uromodulin and its aggregates. 
Therefore, we used the high abundance of albumin and uromodulin to estimatethe efficiency of 
Sarkosyl fractionation, calculating the ratio between these 2 proteins in the soluble and 
insoluble fraction. It is to be expected that the uromodulin and serum albumin levels in urine 
show biological variation; thus it was expected that the uromodulin and albumin levels will also 
vary in the exosome preparations from the different urine samples. However, the presence of 
these two proteins in some samples may explain as to why the total exosomal protein 
concentration is much higher in some samples than the others.  
Besides providing information to understand exosome biogenesis and function, exosome 
proteomics has brought considerable research interest in finding disease-related biomarkers. 
Analysis of urine exosomes yielded a series of proteins involved in very important biological 
processes including but not limited to protein transport, membrane trafficking, metabolic 
process and signal transduction. Proteomics analysis of urinary exosomes also identified 
proteins that play important roles in kidney function, such as proteins involved in water, drug, 
sodium, chloride, proton and glucose transport as well as some potential disease biomarkers 
currently under investigation.  
In summary, this study developed and utilized an innovative method to thoroughly analyze 
urinary exosomes obtained from normal human urine. This study provides a large set of 
proteins present in human urinary exosome proteomes and provides a valuable reference for 
future study. 
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CHAPTER 2 
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1. INTRODUCTION 
 
1.1. Monogenoidea 
 
Monogenoidea are a group of largely ectoparasitic members of the phylum Platyhelminthes. 
They are ectoparasites of fish and, less frequently, of amphibians or reptiles (turtles), that (as 
adults) range in size from a few micrometers to a couple of centimeters. The group is 
distributed worldwide and contains an estimated 25,000 species from a range of freshwater, 
brackish, and saltwater environments [106].  
Monogeneans lack respiratory, skeletal and circulatory systems and have no or weakly 
developed oral suckers. Monogenea attach to hosts using hooks, clamps and a variety of other 
specialized structures. They are often capable of dramatically elongating and shortening as they 
move. Like all ectoparasites, monogeneans have well-developed attachment structures: the 
anterior structures (prohaptor) and the posterior (opisthaptor, or simply haptor), as shown in 
figure 1. The posterior opisthaptor with its hooks, anchors, clamps etc. is typically the major 
attachment organ. 
   
Figure 1. Example of monogenean: Polyopisthocotylea polystoma 
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Like other flatworms, Monogenea have no true body cavity (coelom). They have a simple 
digestive system consisting of a mouth opening with a muscular pharynx and an intestine with 
no terminal opening (anus). Generally, they also are hermaphroditic with functional 
reproductive organs of both sexes occurring in one individual. Most species are oviparous but a 
few are viviparous. Monogenea are Platyhelminthes and therefore are among the lowest 
invertebrates to possess three embryonic germ layers—endoderm, mesoderm, and ectoderm. 
In addition, they have a head region that contains concentrated sense organs and nervous 
tissue (brain). 
 
1.1.1. Structure of adult Monogenea 
 
The body surface of adults is formed by a non-cilated neodermis which has replaced the ciliated 
epidermis of the larva. The digestive system is formed by an anterior sucker or suckers, a 
pharynx and a blind ending caecum, usually with numerous side branches extending into most 
of the body. In other words, it is a gastrovascular system, combining the functions of a digestive 
and a vascular system. The excretory/osmoregulatory system consists of numerous flame bulbs 
connected to capillaries which join to form larger ducts opening through two separate 
excretory pores in the anterior part of the body. The flame bulbs do not openly communicate 
with the surrounding tissue, i.e., the system is a protonephridial system [107]. They consist of a 
terminal cell and a proximal canal cell, whose cytoplasmic processes (ribs) interdigitate to form 
the filtration apparatus.  The structure of an adult monogenean is represented in Figure 2. 
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Figure 2. Structure of a monogenean. 
 
All monogeneans are hermaphroditic, i.e., they possess male and female reproductive systems, 
often of extraordinary complexity. The biology and morphology of species of the genus 
Polystomoides from the mouth cavity and bladder of freshwater turtles have been particularly 
well studied [108]. 
 
1.1.2. The reproductive tract 
 
In general, Monogenea are hermaphroditic, and they display a complexity of reproductive 
organs and accessory ducts that dominate the body. Typically, all parts of the male and female 
systems except the gonads are underlain by a muscular stratum of both circular and 
longitudinal fibers. The contraction and relaxation of this muscle would seem essential for the 
orderly process of egg formation, and regulation of this motility presumably resides in the 
associated nervous system [109].  
Little is known about the ultrastructure of the male reproductive system in gyrodactylids. Also, 
there is much confusion about the anatomy of the female reproductive system. There is no 
distinct germarium and the most conspicuous feature is the large oocyte located in a chamber 
situated immediately posterior to a chamber containing the developing embryos. 
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The structural organisation of the reproductive apparatus in Monogenea is rather similar to 
flatworm’s one. It consists of a male system comprising multiple testes, vas deferens, seminal 
vesicle and cirrus; and a female system comprising an ovary, oviduct, seminal receptacle, 
ootype and Mehlis' gland, and uterus, together with vitellaria, vitelline ducts and associated 
reservoir [110] (Figure 3). 
 
Figure 3. Monogenean reproductive tract  
 
Gyrodactylids are unique among monogeneans in that they are viviparous and protogynous and 
multiply rapidly by a kind of polyembryony [111]. The uterus may contain up to four embryos 
one inside each other. Gyrodactylids also have a unique reproductive strategy. Mixed 
reproductive strategy in which asexual or parthenogenetic reproduction alternates with sex in 
older, crowded populations may occur [112]. Furthermore, it is likely that viviparous 
monogeneans have evolved from oviparous ancestors. 
Some Monogenea show a genito- intestinal canal. In this respect, Kearn [113] has stated that in 
monogeneans that lack such an exit route, greater control is necessary in regulating the volume 
of vitelline cells released from the vitelline reservoir, the corollary being that the acquisition of 
a more sophisticated means of control may have led to the loss of the genito-intestinal canal.  
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1.1.3. Life cycle 
 
Monogeneans possess the simplest life cycle among the parasitic platyhelminths. They have no 
intermediate hosts and are ectoparasitic on fish (seldom in the urinary bladder and rectum of 
cold-blooded vertebrates). Although they are hermaphrodites, the male reproductive system 
becomes functional before the female part.  
Eggs often have filaments which entangle them in the gills or weed, or which increase their 
flotation ability. An operculum (egg cover) opens to allow escape of the larva (Figure 4). 
 
 
Figure 4. Original scanning electron-micrograph by Klaus Rohde. 
 
The eggs hatch releasing a heavily ciliated larval stage known as an oncomiracidium, as shown 
in figure 4. The oncomiracidium has numerous posterior hooks and is generally the life stage 
responsible for transmission from host to host [114]. The growth from oncomiracidium to adult 
is marked by the haptor increasing complexity.  
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Figure 5. General monogenian life cycle. 
 
The majority are parasites that attach to the external surface of fishes, reptiles and some 
invertebrates. Few species are internal, and they usually live in cavities that communicate with 
the external environment (i.e. the bladder). In these species, the eggs form a mass that 
meander in the water until a fish inhales the eggs during a respiratory action. 
  
1.1.4. Attachment strategies 
 
Monogeneans attach to their fish hosts by two mechanisms. Semi-permanent attachment is 
mediated by a posterior haptor comprising hooks, suckers, clamps and/or glue(s) [6]. 
Temporary attachment is controlled by secretion of an adhesive from the anterior end of the 
worm and is used when the parasites move around on host epidermis (most commonly skin 
and gills) [23]. Monopisthocotylean monogeneans loop over the host surface like a leech, 
extending and attaching the anterior end using temporary adhesive, then move the haptor 
forward and grip firmly with this organ, release the head end and stretch forward to attach 
again[12]. The secretions involved in this temporary anterior adhesion are strong enough to be 
66 
 
the only form of attachment on host surfaces subject to high shear forces from water currents 
and the adhesives act instantly and reversibly [10].  
At least 4 types of adhesion mechanisms have been observed in multicellular animals:  
1) permanent adhesion to abiotic substrate, e.g., barnacles and mussels;  
2) transitory adhesion during locomotion on abiotic surfaces, e.g., limpets;  
3) temporary adhesion to abiotic surfaces, e.g., starfish;  
4) temporary biotic or “tissue” adhesion, which is employed by many members of the 
Monogenoidea.  
The members of Monogenoidea are able to adhere securely and, in most cases, move on the 
host surface using highly specialized body organs, i.e., the posterior area of the haptor and an 
anterior adhesive region. While the posterior area of the haptor is specialized for attachment 
by physical means, due to the vast selection of hooks, anchors, clamps, and suckers, the 
anterior end usually lacks obvious physical attachment devices. While other flatworms can 
attach themselves temporarily or permanently mainly by physical means, monogenoids are 
able to adhere directly to biotic as well as to abiotic substrata using biochemical secretions 
alone. This is an important feature, considering that fish parasites must deal with physical and 
chemical properties of the water, as well as host mucus and immune responses. Nevertheless, 
monogenoids are able to achieve adhesion and move on their hosts with seemingly few 
chances of being disengaged [115]. 
In some species, the main adhesion is achieved by the posterior region of the body, and the 
majority of species attach their haptor to host tissue while moving the head for feeding, thus 
proceeding along the host surface like an inchworm. These movements are enhanced by the 
production of an adhesive material from specialized head glands, which create a firm, but 
temporary, adhesion to many substrates. This adhesive material allows these animals to adhere 
rapidly, even in the presence of strong water currents or even when the haptor is partially, if 
not completely, detached. Although the anterior end is well secured, the parasites are still able 
to disengage rapidly [106]. 
Since it has been demonstrated that these parasites are unable to swim (with some notable 
exceptions; [116]), it is clear that their separation from the host would presumably end in 
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death. The evolution of such adhesive systems has provided different solutions to several tasks, 
i.e., facilitating the search for a mating partner and allowing the movement to another host or, 
eventually, to better sites on the host surface in order to feed, grow, and reproduce [117]. 
 
1.1.5. Interaction between Monogenea and the host 
 
The selection of a certain host species by an ectoparasitic monogenean must be governed 
mainly by factors in the host surface (Figure 6). 
Buchmann et al., [118] suggested that chemical stimuli emitted from the host are necessary to 
attract the parasites and even initiate certain behavioural and physiological changes in the 
parasite. In addition, anatomical structures of certain host surfaces are likely to show higher 
compatibility with some parasite attachment mechanisms. In order to reproduce satisfactorily 
the monogenean must feed on host material which can be absorbed and used for production of 
eggs or larvae. This means that the feeding system (mouthparts and pharynx) and digestive 
apparatus (including enzyme array) of the parasite must be equipped to cope with the 
structures and molecules in the host surface [118, 119]. 
Investigations conducted up until now point to the fact that host specificity among 
monogeneans is governed by a number of dynamic interactions [118]: 
The parasite is able to recognise host molecules emitted over short distances.  
When contacting the host, substances present in parasite and host must be compatible.  
The anatomical state of the substrate must fit the attachment structures of the monogenean.  
Following attachment successful propagation of the parasite depends on appropriate host 
stimuli perceived by the parasite.  
Nutritive host material must be recovered and utilised by the monogenean and translocated for 
productive purposes. 
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Figure 6. Example of monogenean (Gyrodactylus salaris) attached to the host by opishaptor, op. 
The image shows 16 peripheral marginal hooks, mh [120].  
 To comply with all these demands for performing a satisfactory life cycle, the monogenean 
parasite needs to avoid or exploit the various immune mechanisms used by teleosts to combat 
invading organisms. 
Monogeneans comprise both oviparous and viviparous organisms which diversify the various 
types of host-seeking strategies. Thus, some oncomiracidia hatching from eggs show vivid and 
elegant movements when swimming through the water [118, 119]. These free-swimming larvae 
are able to seek the host actively over short distances. In contrast, viviparous parasites, such as 
most gyrodactylids, have to rely on more restricted transmission mechanisms: direct contact 
between fish, indirect contact mediated by the substrate or more or less random transfer of the 
parasite with water currents.  
 
1.1.6. Site selection of Monogeans 
 
Numerous studies have demonstrated that monogeneans are selective in their choice of 
attachment site [118]. This site selection can probably be influenced by both environmental and 
host-related factors and the causative mechanisms may vary between parasite types. Some 
monogeneans preferentially select either gills or skin. However, even a relatively simple 
anatomical unit such as the gill apparatus can be subdivided into numerous microhabitats. 
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Studies concerning the microhabitat selection of gill monogeneans have shown unequivocally 
that even congeneric monogeneans in many cases select different microhabitats, also in single 
species infections [121]. Some species attach primarily to the distal part of gill filaments, others 
take a proximal position. Also, the anterior versus posterior gill arches in addition to the outer 
and inner hemibranches seem to signal differently to the parasites. The exact explanation for 
this selection remains enigmatic. Environmental causes may play a role because differences in 
water currents through the gill apparatus could influence the settlement of oncomiracidia in 
various gill habitats.  
 
1.2. Neobenedenia girellae 
 
Many parasites are serious pathogens in intensive aquaculture in Japan [122]. One such 
parasite, Neobenedenia girellae (Figure 7), a capsalid monogenean, is problematic because it 
has broad host specificity and can cause high mortality in host fishes [122]. It is considered that 
N. girellae was introduced from China since imported greater amberjack fry was infected with 
this parasite (prevalence up to 70.0 %) [122].  
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Figure 7.  A stained specimen of N. girellae. 
 
Neobenedenia girellae developed rapidly on Japanese flounder reaching sexual maturity in 10-
11 days at 25℃ from oncomiracidia. Neobenedenia is unique in that they do not have a vagina 
[123].   
 
1.2.1. Structure  
 
Adult N. girellae measure up to 6 mm in length. They are oval parasites characterized at the 
anterior end by disk-shaped adhesive and feeding organs, called prophator and the posterior 
haptor, as all monogeneans. These structures assist in anchoring the parasite to the fish 
epidermis. 
The mouth and pharynx are located on the mid-ventral surface. N. girellae feeds on muvus and 
epidermal cells and displays extracorporeal digestion; the parasites deposit digestive enzymes 
released from the pharynx on the fish surface and then suck up the resulting digest into the 
intestine. 
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1.2.2. Life cycle 
The life cycle is direct: only the fish host is involved. Diamond-shaped eggs are produced by 
hermaphroditic adults on mucus strings. The eggs may detach from the adult parasite and fall 
to the bottom and hatch, or they may remain caught up in the excess mucus produced by the 
fish and hatch close to the epidermis. Likely, urea and ammonia excreted by the skin of the fish 
is a hatching stimulus for the enclosed larva [124]. In few day oncomiracidia are released, these 
resemble ciliate protozoans in size and shape. 
The free swimming life of an oncomiracidium is short (4 – 36 hours), thus it quickly searches out 
and attaches to the host’s epidermis through use of sticky cephalic glands and the developing 
haptor. Once attached, the oncomiracidium sheds its ciliated cells and develops into the adult. 
 
1.2.3. Cement structure of the Capsalidea Entobdella soleae 
 
The area available for bonding between parasite and host is greatly enlarged by the tegumental 
microvilli of the parasite's adhesive pad and by the roughly concentric arrangement of furrows 
in the flat surface of each host epidermal cell. Transmission electron microscopy sections 
through the adhesive pad of Entobdella soleae attached to the skin of its host reveal a layer of 
intervening cement, 4 or 5 μm in thickness ( Fig. 8A and 8B) [117]. The cement is in intimate 
contact with the surfaces of the parasite and the host, infiltrating between the parasite's 
tegumental microvilli and penetrating into the host's epidermal furrows ( Fig. 8C) [117]. 
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Figure 8. Transmission electron micrographs of A) and B) sections through adhesive pads of 
Entobdella soleae attached to the epidermal surface of the host (Solea solea). (top) and 
parasite (below). C) a section through the cement between parasite and host. ep, Epidermis of 
host; c, Cement. Arrows indicate surface of host [117]. 
 
The thin layer of cement matrix immediately in contact with the host's epidermal surface is 
sometimes more electron-dense than the rest of the cement (Fig. 8), indicating perhaps some 
kind of chemical interaction between the cement and exudate from the host's surface. No 
spheroidal secretory bodies were found in the cement [117]. 
 
1.2.4. Glands  
 
Adhesive is typically produced by glands located beside the pharynx or, more specifically, in the 
anterolateral and/or posterolateral regions of the animal. A maximum of 3 different types of 
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head glands may be involved in the creation of the adhesive matrix. These glands are identified 
as G1, G2, and G3, and produce secretions known as S1, S2, and S3, respectively [106].  
A single duct from each gland delivers the product to a single opening in the anteroventral 
surface of the animal. These ducts may reach the ventral surface of these animals in at least 2 
different ways. First, duct endings do not open directly to the surface of the ventral tegument 
but instead open into a sac in which different secretions may mix in a reservoir that is not 
always present (Fig. 1). The adhesive matrix is expelled via a muscular (usually circular) opening. 
This method is typical of acanthocotylids, dactylogyrids, gyrodactylids, and some monocotylids. 
The epithelium of the sacs is generally microvillous, which increases the contact surface with 
the adhesive [125]. Second, duct openings are permanently exposed, piercing through the 
tegument of pads, are more or less defined from the body shape of the animal, and are usually 
covered by microvilli, which is typical of capsalids. 
 
 
 
Figure 9. Schematic representation of a cephalic region of a Capsalidae. 
  
The more common structure of capsialids, including N. girellae, is characterized by at least 2 
glands, namely, G1 and G2. However, its structure has poorly been described. One of the most 
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intensively studied parasites with 2 secretions is the capsalid Entobdella soleae [117]. This 
parasite possesses 2 kinds of cells, G1 and G2, plus a third type of anteromedial gland, which 
are not involved in adhesion.  
In some other capsalids, like Benedenia lutjani [126] and Benedenia rohdei [111, 126, 127] are 
somewhat different, having 2 characteristic disclike pads (Fig. 9). These pads are not simple 
areas of flattened tegument like those seen in E. soleae, but they are well defined [126]. In B. 
lutjani, adhesion is achieved at 3 areas on the top edge of these discs, where the S1 and S2 
ducts terminate. The discs function like suckers and can help in securing the anterior end of the 
animal more firmly, thus supporting the secreted adhesive. The anterior adhesive organs of B. 
rohdei are microvillous, while they are free of microvilli in B. lutjani [126].This characteristic is 
well conserved among the Capsalidae. 
There are 3 different adhesive areas and nonadhesive anteromedial glands in the 
Entobdellinae. Benedenia lutjani and B. rohdei achieve very firm attachment to the substratum 
with just 1 of the 2 pads [115].The mechanism used by most capsialids to detach from the 
substratum has not been described. However, since so many features appear to be common 
among the capsalids, Whittington and Cribb [115] suggested that detachment is achieved by 
tegumental secretion from the attachment discs. Apart from the capsalids, almost all of the 
other species possessing 2 glands have variable numbers of circular openings, most of which 
are also eversible.  
 
1.3. Adhesive secretions 
 
In the marine environment, attachment mechanisms developed by animals usually rely on 
highly viscous or solid adhesive secretions, which all contain specialized proteins. Functional 
convergences are noted among marine animals, particularly in terms of the type of adhesion 
used: permanent, temporary, or instantaneous. Although marine adhesive proteins from non-
related organisms do not present any sequence homologies, molecular convergences have 
been recognized, and some adhesive motifs have been found to be shared by phylogenetically 
different animals. Also the adhesion of mussels has been thoroughly investigated and DOPA has 
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long been known as one such motif [128]. Indeed, the mussel byssus is a remarkable 
attachment structure that is formed by injection molding and rapid in situ hardening of 
concentrated solutions of proteins enriched in the catecholic amino acid 3,4-dihydroxy-L-
phenylalanine (DOPA). Fe3+, found in high concentrations in the byssus, has been speculated to 
participate in redox reactions with DOPA that lead to protein polymerization, however direct 
evidence to support this hypothesis has been lacking [128].  
After isolation of the first adhesive protein, Mepf-1, which contains DOPA (3,4-dihydroxy-L-
phenylalanine), ten further proteins have been isolated [129]. One of them is precollagen D 
which possesses a central collagen domain flanked by two fibroin-like domains with sequences 
similar to spider silk fibroin. This protein is found in spiders’ drag line [130] and also in the 
silkworm Bomyx mori [131]. A similar protein has been found in sea urchin [132]. Using 
antibodies raised against recombinant precollagen D from the mussel Mytilus galloprovincialis, 
we could identify a protein with adhesive properties in sea cucumber Cuvierian tubule extracts. 
Now, another modified amino acid, phosphoserine (pSer), is emerging as an important motif in 
biological adhesives.  
The diversity of adhesion mechanisms is therefore huge, although some common principles 
have evolved independently in different biological lineages. For instance, three types of 
adhesives may be distinguished depending on their mode of operation and their composition 
[115, 133]. Permanent adhesion involves the secretion of an adhesive that hardens with time 
and is characteristic of sessile organisms that remain in the same place throughout their life 
(such organisms have representatives among sponges, hydrozoan cnidarians, cirripede 
crustaceans, bivalve molluscs, tubicolous polychaetes, bryozoans, or tunicates). By contrast, 
nonpermanent adhesion allows simultaneous adhesion and locomotion, thus allowing adult 
organisms to graze, hunt, or locate a mate, and larval forms to explore immersed surfaces prior 
to permanent adhesion. Some organisms such as gastropod molluscs attach by a viscous film 
they produce between their body and the substratum, creeping on this film which is left behind 
them as they move (transitory adhesion). Others, such as echinoderms, attach firmly but only 
temporarily to the substratum, being able to attach and detach repetitively (temporary 
adhesion). Finally, instantaneous adhesion is characterized by an explosive release of adhesive, 
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allowing a very fast formation of adhesive bonds. Indeed, as opposed to all other adhesion 
types in which the adhesive material is secreted through exocytosis, [134, 135] the release of 
instantaneous adhesives destroys the adhesive organ which may be used only once. Two types 
of organs are known to act as instantaneous adhesive organs: the ctenophore tentilla (whose 
secretion functions in prey capture [136]) (figure 10A) and the Cuvierian tubules of sea 
cucumbers (that entangle imprudent predator [137]) (Figure 10 B). 
 
 
Figure 10. Picture of A) a ctenophore; B) a sea cucumber 
 
Also the adhesive setae of reptiles and insects have long fascinated biologists [138, 139], and 
interest in these structures has increased following recent demonstration of the adhesive 
properties of single, detached setae [139]. An understanding of the mechanism [139, 140] of 
adhesion of these structures is being developed. Proof of principle that artificial fibrillar arrays 
reminiscent of setae can, in fact, confer greater adhesive energy than unpatterned material has 
been published [141]. However, the simple polymer fibrillar arrays fabricated thus far fall far 
short of the capabilities of the biological examples. Rizzo et al., [138] have undertaken a study 
of the structural and material properties of gecko (Figure 11) setae to better understand the 
relationship between these properties and their role in reversible adhesion. 
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Figure 11. Picture of A) Tokay gecko Gekko gecko and B) its foot 
 
Reptilian setae, small bristles often mistakenly referred to as hairs, exist in two types. The most 
studied, typified by those present on the toe lamellae of the Tokay gecko Gekko gecko (figure 
12), are multibranched, hierarchical structures of 80–100 μm in length.  
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Figure 12. Scanning electron microscopy of the spatulate terminal elements of Gekko gecko 
setae. Detached setae were imaged to show (a) an array of spatule at the tip of a seta; (b) 
details of individual spatula.  (c) Setae attached to a section of toepad; and () detached setae. 
 
The second type, such as those found on the adhesive pads of anole lizards such as Anolis 
carolinensis, are smaller (ca 20 μm in length) and unbranched. In all cases, arrays of many 
millions of such setae decorate the surface of the epidermal adhesive pads of these reptiles. 
The hypothesis that setae are composed of β-keratin protein was assumed long ago, however 
only recently biochemical evidence has emerged in support of this thesis [142, 143]. β-Keratins 
are present only in avian and reptilian epidermis,. In un antiserum raised against an avian scale 
β-keratin was found to exhibit immuno cross-reactivity with gecko setae [142].  
 
1.3.1. Biochemical features of adhesive secretions in monogeneans. 
 
The adhesive secretion from monogenean, in particular from larvae, was first analyzed by 
Hamwood et al. [144], who described the presence of a substantial amount of proteins . 
Amino acid analysis of secreted adhesive material (SAM) from seven species of monogeneans 
was conducted by Hamwood [144].  Across the seven species of monogeneans, generally there 
were high levels of glycine (12-19%) and alanine (6-14%) whereas tyrosine and methionine 
were found at low levels (1-3% and 0-2% respectively), and histidine was often absent (Table 1). 
However, amino acid content varied across species. Some differences were apparent when 
species were divided along family lines. 
Only two of the 16 amino acid residue values (serine and arginine) for the capsalid, E. soleae, 
show an overlap with the range of values seen for the six monocotylid species. Also, E. soleae 
showed a noticeably lower amount of leucine and phenylalanine (Table 1) than five of the six 
monocotylid species. Within the monocotylids, Merizocotyle australensis differed from the 
other five species in having higher amounts of serine, arginine and proline, while displaying 
lower amounts of leucine and phenylalanine. If this species is excluded, the five remaining 
monocotylids show a consistent amino acid composition, except that Monocotyle helicophallus 
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has a lower level of serine (1%) than the other four monocotylid species. Both EAM and SAM 
contain significant amounts of the acidic residues Asx (asparagine or aspartate: 10%) and Glx 
(glutamine or glutamate: 14-18%) whereas these are absent in body tissue. EAM and SAM also 
contain slightly more glycine (12% vs. 8% in the body). Body tissue has a much higher content of 
alanine (43% vs. 6- 11%) and tyrosine (10% vs. < 3%) than either EAM or SAM. However, EAM 
was more similar to body composition for histidine, arginine, proline, methionine and lysine. 
 
 
Monogeneans Starfish Barnacles Limpet 
Amino acid Es Ma Mi Ms Mh Tr Nr Ar Be Mr Ll 
Asparagine or aspartate (Asx) 98 70 53 31 55 84 54 118 57 91 127 
Serine 75 149 82 84 10 80 76 76 83 99 90 
Glutamine or glutamate (Glx) 144 101 57 130 69 83 61 102 64 92 115 
Glycine 117 193 189 187 161 152 181 97 66 79 80 
Histidine 16 5 0 0 1 3 0 21 23 13 10 
Arginine 43 61 39 39 43 37 41 41 75 56 33 
Threonine 53 4 24 29 46 34 31 78 57 71 116 
Alanine 64 103 139 104 80 97 117 62 49 75 52 
Proline 45 67 54 58 53 53 56 61 86 49 79 
Tyrosine 27 14 16 11 15 14 16 27 75 42 18 
Valine 102 55 45 58 47 48 44 67 62 73 72 
Methionine 17 0 8 11 2 11 9 17 11 16 11 
Lysine 73 42 41 29 39 39 42 56 53 57 59 
Isoleucine 40 39 31 29 33 33 33 45 69 53 52 
Leucine 61 74 123 112 125 121 126 61 110 83 51 
Phenylalanine 26 31 101 112 129 111 113 38 53 37 26 
Cysteine or half-cystine ?* ?* ?* ?* ?* ?* ?* 32 6 16 20 
 
Table 1. Amino acid composition of secreted adhesives from different marine organisms. 
Organisms included are the monogenean flatworms Entobdella soleae (Es), Merizocotyle 
australensis (Ma), M. icopae (Mi), Monocotyle spiremae (Ms), M. helicophallus (Mh), 
Troglocephalus rhinobatidis (Tr) and Neoheterocotyle rhinobatidis (Nr), the starfish echinoderm 
Asterias rubens (Ar), the barnacles Balanus eburneus (Be) and Megabalanus rosa (Mr) and the 
limpet Lottia limatula (Ll)  [144].  
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SAM of Entobdella soleae does not contain polysaccharides, including acid mucins, or lipids. It is 
also highly insoluble. The SAM has a soft consistency. Some of these features, such as 
insolubility, softness and protein content, are similar to the temporary adhesive used by the 
starfish Asterias rubens, but carbohydrate and lipid are also present in the adhesive of this 
echinoderm [145]. 
SAM from the monogenean adhesive is a porous material comprising a network of strands; the 
starfish “print” has a similar, spongy appearance but this results from raised ridges of 
homogeneous material.  
Consequently, the biochemical characterization of this temporary adhesive material is 
important also to develop new pharmacological strategies for the eradication of these parasites 
from aquaculture. Moreover, monogenoidean adhesive properties suggest the existence of 
new biochemical features, namely protein based molecular mechanisms leading to very rapid, 
strong but fully reversible protein-based adhesiveness in a water environment, which make 
well worth to investigate their structure. 
 
1.3.2.  Adhesive secretion of Neobedenia girellae 
 
There has been only very few studies on the temporary adhesive materials from platyhelminth, 
mainly Capsalidae, which present very similar highly insoluble adhesive secretions [146]. The 
only partial characterization at the molecular level, up to now, was carried out by Hamwood et 
al. [144] on the monogenean capsalid parasite Entobdella soleae, which shares several 
morphological and functional features with N. girellae, including using hooks, ventosae and 
adhesive secretions to attach/detach from hosts [106]. Compared to sea star adhesive, which is 
the other temporary glue chemically characterized, the adhesive material presents a different 
amino acid composition and lacks carbohydrates and lipids. I suggested the presence of keratin 
and neurophysin as identified via an amino acid content search of data bases but no further 
attempt was undertaken so far to disclose the protein composition of the glue [144]. 
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1.3.3. De-adhesion 
 
In monogenean parasites, there is some evidence that the tegument of the worm may be 
involved in de-adhesion [117]. As starfish display a somewhat similar adhesive system, the 
models for de-adhesion proposed for these echinoderms may be applicable. Thomas and 
Hermans suggested in 1985 that de-adhesion occurs via secreted glycosaminoglycans that 
competitively displace the glue secreted by the tube-feet of starfish. Heparin, a 
glycosaminoglycan (highly acidic polysaccharide), prevents adhesion by the starfish Leptasterias 
hexactis [144]. Adhesion was not completely inhibited by heparin in the two monogenean 
species tested here, but some lessening of adhesion occurred. Perhaps lectin probes may clarify 
the presence or absence of glycosaminoglycans on newly detached specialized tegument of the 
anterior adhesive areas of monogeneans. 
Flammang et al. present immunocytochemical data that support a second model for de-
adhesion in starfish [145]. Here, an enzyme releases the fuzzy coat from the surface of the tube 
foot, leaving the fuzzy coat on the glue [145]. It is possible that the anterior adhesive area 
tegument of monogeneans may secrete an enzyme which is responsible for de-adhesion or 
perhaps the second, granular secretory bodies are involved, although Kearn et al., found 
evidence to dismiss the latter possibility, supporting a role for the tegument [117]. Certainly the 
anterior adhesive area tegument contains different inclusions from the general body tegument 
[115, 119]. To fully understand the de-adhesion process in monogenean flatworms, it will be 
necessary to pursue further electron microscopic studies of the anterior adhesive areas before 
and after release of the glue as has been done for E. soleae by Kearn et al., [117].  
 
1.3.4. Biomedical relevance  
 
Substantial impetus behind understanding these adhesive secretions are the potential 
technological applications that can be derived from their knowledge. These applications cover 
two broad fields of applied research: design of water-resistant adhesives and development of 
new antifouling strategies. In this context, echinoderm adhesives could offer novel features or 
82 
 
performance characteristics for biotechnological applications. For example, the rapidly 
attaching adhesive of Cuvierian tubules, the releasable adhesive of tube feet or the powerful 
adhesive of asteroid larvae could each be useful to address particular bioadhesion problems 
[133]. 
 
1.4. De novo sequencing 
 
De novo is Latin for, "over again", or "a new".  A popular definition for "de novo peptide 
sequencing" is, peptide sequencing performed without prior knowledge of the amino acid 
sequence.  
The introduction of chemical protein sequencing by Edman degradation [147] in the 1950s was 
a milestone in the development of protein research. For identification of Edman degradation 
products, mainly LC was used. Intermittently, MS was introduced as alternative method to LC 
with optical detection. This was achieved in combination with the early soft ionization 
techniques chemical ionization [148], field desorption [149], and fast atom bombardment [150, 
151]. Later, the gradual refinement of MS/MS techniques created the basis for peptide 
sequencing by MS, which finally gave fast access to multiple internal protein sequences by the 
analysis of proteolytic peptides. Within the last two decades, protein sequence determination 
by MS/MS 
became more and more powerful, a development driven mainly by the improvements of LC 
techniques in combination with ESI [152]. The advantages of MS/MS techniques with respect to 
speed, sensitivity, and applicability to complex peptide mixtures gradually led to the 
replacement of Edman techniques by LC-MS/MS. For these reasons, tandem mass spectrometry 
(MS/MS) is emerging as the most reliable tool to identify proteins. There are now several 
configurations of mass spectrometers that provide MS/MS data with sufficient mass accuracy 
to deduce peptide sequences of enzymatically digested proteins from either low-energy 
collisionally induced (CID) or high collisional dissociation (HCD) MS/MS spectra. However, 
deducing peptide sequences from raw MS/MS data is slow and tedious when performed 
manually. Instead, the most popular approach is to search databases of known genomes with 
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the uninterpreted experimental MS/MS data. A number of such approaches have been 
described, the most popular being Mascot [153] and Sequest [154]. These methods are 
effective but often give false positives or incorrect identifications. Searching databases with 
masses and partial sequences (sequence tags) derived from MS/MS data give more reliable 
eesults [155]. For unknown genomes, de novo sequencing must be carried out in order to 
obtain sequences or partial sequences. Full sequences can then be obtained by cloning the 
gene of interest. 
The deduction of amino acid sequences from MS/MS spectra is dependent on the quality of the 
data and further complicated by poor fragmentation and inaccuracies due to mass shifts caused 
by drifts in temperature and other instrumental parameters. To aid the assignment of 
sequences a number of chemical techniques have been developed to favor the formation of 
more stable ‘y’ or ‘b’ ions [156, 157]. A number of algorithms and software packages have been 
reported for the deduction of protein sequences from MS/MS data [158-164]. One software 
package developed independently, Lutefisk, has gained a lot of attention [161, 162]. Most of 
these software packages, including Lutefisk, use a graph theory approach. The spectrum is first 
translated into a ‘spectrum graph’ where nodes in the graph correspond to peaks in the 
spectrum and two nodes are connected by an edge if the mass difference between the two 
corresponding peaks is equal to the mass of an amino acid. The software then attempts to find 
a path that connects the N and C termini, and to connect all the nodes corresponding to the y 
ions (or b ions), as shown in Figure 13.  
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Figure 13. Example of (A) unannotated and (B) annotated MS/MS spectrum [165]. 
 
For this study, we used a software called PEAKS, for de novo sequencing of peptides from 
MS/MS data. PEAKS performs de novo sequencing directly from the MS/MS data and therefore 
does not rely on a protein database. It computes the best possible sequence among all possible 
amino acid combinations. Analogous approaches have been described, but were 
computationally inefficient and abandoned [163, 164]. Instead, PEAKS relies on a sophisticated 
dynamic programming algorithm and mathematical model to perform the computation 
efficiently. Indeed, PEAKS computes peptides whose ions correspond to as many high 
abundance peaks in the spectrum as possible.  
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The approach taken in PEAKS can be summarized into four steps, as described by Ma et al. 
[166]:  
1) Preprocessing,  
(2) Candidate computation,  
(3) Refined scoring, 
(4) Global and positional confidence scoring.  
The first step consists of preprocessing of the raw MS/MS data. This involves a new method for 
noise filtering and peak centering, as well as deconvolution of the doubly and triply charged 
species to singly charged ions. This step is very important for the interpretation of MS/MS data 
by PEAKS because optimal preprocessing of data is a crucial step for de novo sequencing by 
MS/MS. 
The second step, candidate computation, is the critical step in which the 10 000 best sequences 
of all possible combinations of amino acids for a given precursor ion mass are computed. For 
this computation, the a, b, c, x, y and b/yions are considered. The basic assumption of this 
model is that the greater number of high abundance peaks that are matched by those ions of a 
sequence, the more likely the predicted sequence is the correct sequence.  
In the third step, each of the 10 000 candidates is reevaluated by a more stringent scoring 
scheme, and the best candidates (the number can be specified by users) under the new scoring 
scheme will be outputted. In this refined rescoring step, ion mass error tolerance is stricter. 
Finally, a recalibration of the data is performed to account for minor deviations in the MS/MS 
data. This recalibration method is similar to that described by Taylor et al. [162] 
In the last step, PEAKS computes a confidence score for each of the top-scoring peptide 
sequences. The refined scores can be seen as non-normalized measures of the likelihood of 
correctness for each peptide, and the distribution of scores gives a measure of the overall 
probability of successful sequencing. Finally, the positional confidences for each residue are 
derived from consensus among the globally top-scoring sequences. 
 
The purpose of this study was to identify the proteins present in the adhesive material of the 
capsalid N. girellae by a proteomic approach based on de novo sequencing and data base 
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search to overcome the lack of information concerning the genome of these parasites. 
Glandular secretions were obtained by a new method, set up in our laboratory, based on the 
electrical stimulation of the parasites. 
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2. MATERIALS AND METHODS 
 
2.1. Parasites 
 
N. girellae parasites were collected from fish belonging to the Pomacanthidae family. Parasites 
were removed using a buffer solution with a lower ionic strength (20 g/L NaCl) and maintained 
in a 35 g/L saline solution. Secreted material was collected using electrostimulation of parasites. 
Electrostimulation was carried out in our laboratory in an Ionoptix, by subjecting N. girellae 
parasites in a 50% PBS solution to a 40 V electric field with a 2 Hz frequency, stimulating the 
release of adhesive material. Secreted material was collected in test-tubes. This collection 
procedure, which does not involve mechanical actions to detach parasites from host and test-
tube surface, allows excluding the presence, in the secretion, of contaminating material from 
the fish and the parasite surfaces. The idea of using electrostimulation to obtain head gland 
secretion was drawn from works carried out on scorpion poison [167] and the method has been 
adapted to be applied to Monogenoidea. 
 
2.2. Collection of salivary extracts, solubilization and separation of samples by 2-DE 
 
The secretion of 30 parasites was collected in a test tube and the SDS soluble (SDS-S) and 
insoluble (SDS-I) components were separated by centrifugation at 13,000 ×g following addition 
of 80 μL 2% SDS, 5 mM beta-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.8 and sonication for 5 
min at room temperature. The supernatant (SDS-S) was mixed with 80 μL urea buffer (7 M urea, 
2 M tiourea, 4% CHAPS, 40 mM Tris). SDS-I was solubilized in 100 μL of the same urea buffer by 
sonication; complete solubilization was verified by the absence of visible pellet following 
centrifugation for 5 min at 13,000 rpm. Total protein content, determined by the Bradford 
method, was equal to 8 and 32 μg in SDS-S and SDS-I, respectively. 
Proteins were reduced and alkylated as described in [168]. Following precipitation in anhydrous 
acetone/methanol (8:1, v/v) at - 20 °C, pellets (SDS-I and SDS-S) were suspended in the 2-DE 
sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% Resolyte 3.5–10 NL, Bromophenol 
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Blue), sonicated for 1 min and centrifuged. No visible pellet was detected in the samples. 2-DE 
was performed as follows: for the first dimension, the material was loaded by sample cups onto 
rehydrated IPG-strips with a non linear 3-10 pH gradient (110 mm, Amersham Biosciences, 
Cologno Monzese, Italy). IEF was carried out at 14 °C, 19,667 V total voltage, for 6 h and 10 min. 
Before the second dimension, the strips were rinsed with buffer (6 M urea in 0.375 M Tris–HCl 
pH 8.8, 2% SDS, 20% glycerol, Bromophenol Blue). The second dimension was performed on a 
homemade 11% SDS-polyacrylamide gel (8.5 × 6.5 × 0.15 cm) at 20 mA/gel constant current. 
After running, the gel was submitted to a silver staining protocol compatible with trypsin in-gel 
digestion followed by mass spectrometry analysis. Silver-stained gels were scanned using an 
ImageScanner (EPSON 1660 densitometer, Bruker Daltonics, Milano, Italy). Analysis of 2-D gel 
images was accomplished using PDQuestTM Advanced 2-D Gel Analysis Software version 8.0.1 
(BioRad Laboratories, Hercules, California, USA). 
 
2.3. Protein identification by tandem mass spectrometry and de novo sequencing 
 
For protein identification, each 2-DE spot was excised, dried, soaked with ammonium 
bicarbonate 0.1 M and digested overnight with trypsin (sequence grade, Sigma-Aldrich) at 37 °C 
using a protease: protein ratio (1:10). Tryptic digests were extracted with 50% ACN in 0.1% TFA, 
desalted/concentrated on a μZipTipC18 (Millipore) using 50% ACN in 0.1% formic acid as 
eluent, concentrated using Savant Speed Vac (Thermo Fisher Scientific, Bremen, Germany) and 
submitted to mass spectrometry. LC-ESI-MS/MS analysis was performed on a Dionex UltiMate 
3000 HPLC System with a Hypersil Gold column (150 mm, internal diameter of 180 μm) filled 
with 3 μm Reprosil-Pur C18-AQ resin. Gradient: 5-15% ACN in 0.1% formic acid for 10 min, 15-
40% ACN in 0.1% formic acid for 52 min and 40-95% ACN in 0.1% formic for 68 min at a flow 
rate of 1.2 μl/min. The eluate was electrosprayed into an LTQ Orbitrap Velos (Thermo Fisher 
Scientific, Bremen, Germany) through a Proxeon nanoelectrospray ion source (Thermo Fisher 
Scientific). Data acquisition was controlled by Xcalibur 2.0 and Tune 2.4 software (Thermo 
Fisher Scientific). 
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The full scans (400-1800 m/z) were acquired at resolution 30,000, AGC target 500,000, 
maximum injection time of 500 ms; data-dependent MS/MS fragmentation was performed 
either with HCD or CID activation; in the case of HCD activation (0.1 ms), MS/MS scans were 
acquired in the Orbitrap at resolution 7500; in the case of CID activation (normalized collision 
energy of 35%, 10 ms activation), MS/MS scans were acquired in the linear trap. Isolation 
window: 3 Da, unassigned charge states: rejected, charge state 1: rejected, charge states 2 +, 3 
+, and 4 +: not rejected; dynamic exclusion enabled (60 s, exclusion list size: 200). 
 
2.4. Database searching 
 
Protein identification in the case of the SDS insoluble material was performed by a three-step 
approach involving a combination of automatic and manual inspections. In the case of the SDS 
soluble sample only the first analysis step was performed. In detail: in the first step the MS/MS 
data were analyzed with Peak Studio (version 5.3, Bioinformatic Solutions Inc., Waterloo, 
Canada) [169] according to the filtration parameters reported in Table S1 and using release 
2013_06 of UniProtKB/Swiss-Prot database (all organisms). Data processing, including peak 
centroiding, charge deconvolution, and deisotope, were conducted for data refinement. 
Only proteins identified by at least 4 different peptides in at least one spot using both HCD and 
CID fragmentation were considered as positively identified. 
The de novo peptides that were unassigned in the first step were manually selected and those 
with ALC% ≥ 80 were subjected to the second step of the analysis. Sequences were manually 
submitted to protein-BLAST searches (Basic Local Alignment Search Tool) 
(http://blast.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/Blast.cgi?PAGE=Proteins) searching 
non-redundant protein sequence database (nr, all organisms). Peptides were assigned to a 
certain protein when the query sequence was identical to the database peptide sequence 
except for the first and the last amino acid. In the third step, the residual peptides unassigned 
in the second step were again manually inspected and only sequence stretches of at least 10 
consecutive amino acids with local confidence ≥ 80 were analyzed by BLAST and identified 
based on a less strict sequence similarity (accepted conservative substitutions: D/E, K/R, T/S). 
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The presence of post-translational modifications (PTM) was evaluated by additional database 
search analyses of the mass spectrometric data; the initial analysis was conducted using Peaks 
Studio 5.3 in order to detect selected PTM (hydroxylation at Tyr, Arg and Lys, phosphorylation 
at Tyr, Ser and Thr and nitration at Tyr) which could be potentially present based on the 
properties of adhesive materials from other organisms. Additional investigations on the 
presence of unspecified PTM were performed using the “485 built-in modifications” option of 
the PTM module of Peaks Studio 7.0. 
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3. RESULTS 
 
3.1. Sample preparation and fractionation 
  
The novel method based on electrical stimulation of the parasites detailed above allowed 
collecting about 40 μg proteins from 30 parasites. According to Hamwood et al. the glue 
produced by capsalids is insoluble in many buffers and solvents including SDS [144]. Preliminary 
experiments confirmed such observation; however, to detect the potential presence of low-
abundant SDS-soluble components, an SDS extraction step was performed upon collection of 
the secretion and the SDS soluble (SDS-S) and insoluble (SDS-I) proteins were separated by 
centrifugation. 
Both fractions were separated using 2-DE (Fig. 14 and Fig. 15). As expected considering the 
properties of the glue, electrophoresis achieves only a very partial separation of the various 
components and SDS-I contains most of the starting material. However, the pre-fractionation 
step allowed a more reliable characterization of the samples and the detection of additional 
components besides the very abundant keratin and actin (see below). 
 
 
Figure 14.  2-DE of the SDS insoluble fraction of the adhesive material (SDS-I). First dimension: 
pH 3-10 NL 11 cm IPG; second dimension: 11% SDS PAGE. Gels were stained with mass 
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compatible silver. Numbers refer to spots listed in Tables 2, 3, and 4. Table 4, listing the 
peptides, can be found at pag 107. 
 
Figure. 15. 2-DE of the SDS soluble fraction of the adhesive material (SDS-S). First dimension: 
pH 3–10 NL 11 cm IPG; second dimension: 11% SDS PAGE. Gels were stained with mass 
compatible silver. Numbers refer to spots listed in Tables 2, 5 and 6. Table 6, listing the 
peptides, can be found at pag 145. 
 
Proteins SDS-I SDS-S 
 Spot n.a Spot n.b 
 
Actin 2-6, 8. 10—12,  16-25, 27 
 
4-8, 10 
Albumin 3, 9, 14. 15, 18, 27 
 
 
ATP-synthase 13, 24, 25 
 
1 
78 kDa glucose regulated 
protein/Hsp 70/Dna/K 
 
1, 3, 8, 14, 29  
Keratin 1-8, 11, 13-15, 18, 19, 21-27, 29, 30 
 
1, 3, 9 
-Tubulin 11, 12, 13. 24. 25, 26, 28 1, 2, 9  
 
a numbers refer to Fig. 14 
b numbers refer to Fig. 15 
Table 2. List of proteins identified in SDS-I and SDS-S fractions of the adhesive material. 
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Spot n. Accession -10lgP Cov % # 
Peptides 
Mass Description 
1 P25691|K2M3_SHEEP 309.03 15 7 55255 Keratin, type II microfibrillar  
 P11021|GRP78_HUMAN 274.37 17 7 72333 78 kDa glucose-regulated 
protein  
 A5A6M6|K2C1_PANTR 260.03 35 20 65489 Keratin, type II cytoskeletal 1  
 P08418|HSP70_SCHMA 163.92 8 4 69875 Heat shock 70 kDa protein 
homolog  
2 P53470|ACT1_SCHMA 265.99 29 11 41731 Actin-1  
 P13645|K1C10_HUMAN 342.52 54 43 58827 Keratin, type I cytoskeletal 
10  
 Q00214|ACTM_STYPL 140.95 18 4 42354 Actin, muscle  
3 P08779|K1C16_HUMAN 311.01 28 9 51267 Keratin, type I cytoskeletal 
16  
 P53470|ACT1_SCHMA 238.55 18 4 41731 Actin-1  
 A7ZHA4|DNAK_ECO24 218.86 13 5 69115 Chaperone protein DnaK  
 P13645|K1C10_HUMAN 279.16 28 18 58827 Keratin, type I cytoskeletal 
10  
 Q5R1X3|ACTB_PANTR 224.74 39 9 41737 Actin, cytoplasmic 1  
 P02769|ALBU_BOVIN 199.15 20 9 69294 Serum albumin  
 P11142|HSP7C_HUMAN 154.15 15 5 70898 Heat shock cognate 71 kDa 
protein  
4 P53470|ACT1_SCHMA 126.99 7 2 41731 Actin-1  
 Q6IFZ9|K2C74_MOUSE 46.50 2 1 54746 Keratin, type II cytoskeletal 
74  
 A5A6M6|K2C1_PANTR 235.91 18 7 65489 Keratin, type II cytoskeletal 1  
 Q00214|ACTM_STYPL 194.06 17 5 42354 Actin, muscle  
5 P08779|K1C16_HUMAN 274.51 50 19 51267 Keratin, type I cytoskeletal 
16  
 Q93129|ACTC_BRABE 103.73 7 2 41704 Actin, cytoplasmic  
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 P04264|K2C1_HUMAN 243.79 29 17 66039 Keratin, type II cytoskeletal 1  
 Q5JAK2|ACTG_RANLE 169.15 26 7 41779 Actin, cytoplasmic 2  
6 P20399|ACT2_XENTR 146.60 4 27 42033 Actin, alpha cardiac muscle 2  
 P04264|K2C1_HUMAN 251.49 25 10 66039 Keratin, type II cytoskeletal 1  
 Q26065|ACT_PLAMG 167.81 15 3 41762 Actin, adductor muscle  
7 A5A6M6|K2C1_PANTR 236.52 27 16 65489 Keratin, type II cytoskeletal 1  
 P04264|K2C1_HUMAN 251,61 23 12 66039 Keratin, type II cytoskeletal 1  
8 P63261|ACTG_HUMAN 223.96 15 4 41792 Actin, cytoplasmic 2  
 P11021|GRP78_HUMAN 153.22 10 4 72333 78 kDa glucose-regulated 
protein  
 P04264|K2C1_HUMAN 248.92 18 12 66039 Keratin, type II cytoskeletal 1  
 P08418|HSP70_SCHMA 111.73 5 2 69875 Heat shock 70 kDa protein 
homolog  
 P63270|ACTH_CHICK 95.02 7 2 41877 Actin, gamma-enteric 
smooth muscle  
9 P02769|ALBU_BOVIN 334.45 30 15 69293 Serum albumin  
10 P53470|ACT1_SCHMA 227.77 37 12 41731 Actin-1  
11 P68365|TBA1C_CRIGR 282.81 51 14 49909 Tubulin alpha-1C chain  
 P20399|ACT2_XENTR 229.25 39 6 42033 Actin, alpha cardiac muscle 2  
 P13645|K1C10_HUMAN 175.51 16 7 58827 Keratin, type I cytoskeletal 
10  
 P69003|ACT1_HELTB 169.63 26 7 41788 Actin CyI, cytoplasmic  
 P06604|TBA2_DROME 89.45 10 3 49967 Tubulin alpha-2 chain  
12 P20399|ACT2_XENTR 200.92 32 6 42033 Actin, alpha 2  
 P68365|TBA1C_CRIGR 146.82 15 4 49909 Tubulin alpha-1C chain  
13 P13645|K1C10_HUMAN 217.94 28 13 58827 Keratin, type I cytoskeletal 
10  
 Q3MHM5|TBB4B_BOVIN 175.16 31 10 49831 Tubulin beta-4B chain  
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 P46561|ATPB_CAEEL 117.26 12 4 57527 ATP synthase subunit beta, 
mitochondrial  
14 P13645|K1C10_HUMAN 218.20 13 4 58827 Keratin, type I cytoskeletal 
10  
 P02769|ALBU_BOVIN 273.21 15 7 69293 Serum albumin  
 A7ZHA4|DNAK_ECO24 223.70 14 5 69115 Chaperone protein DnaK  
 P04264|K2C1_HUMAN 257.28 25 15 66039 Keratin, type II cytoskeletal 1  
 Q9W6Y1|HSP7C_ORYLA 185.60 9 8 76169 Heat shock cognate 71 kDa 
protein  
15 P02769|ALBU_BOVIN 368.32 46 23 69293 Serum albumin  
 P13645|K1C10_HUMAN 183.77 9 3 58827 Keratin, type I cytoskeletal 
10  
 P13645|K1C10_HUMAN 326.38 29 32 58827 Keratin, type I cytoskeletal 
10  
16 O17502|ACTM_BRALA 174.73 13 4 42187 Actin, muscle  
17 P68556|ACT1_DIPDE 228.13 32 8 41744 Actin-1/4  
18 Q90X97|ACTS_ATRMM 198.83 27 4 42061 Actin, alpha skeletal muscle  
 P02769|ALBU_BOVIN 262.13 19 9 69294 Serum albumin  
 Q91ZK5|ACTB_SIGHI 204.29 23 5 41719 Actin, cytoplasmic 1  
 P02769|ALBU_BOVIN 195.08 14 6 69294 Serum albumin  
 A5A6M6|K2C1_PANTR 177.21 13 6 65489 Keratin, type II cytoskeletal 1  
19 P53470|ACT1_SCHMA 213.24 27 9 41731 Actin-1  
 P53464|ACTM_HELTB 215.58 27 10 41762 Actin, cytoskeletal  
 P04264|K2C1_HUMAN 164.22 12 6 66039 Keratin, type II cytoskeletal 1  
20 Q90X97|ACTS_ATRMM 337.45 64 16 42061 Actin, alpha skeletal muscle  
21 P68556|ACT1_DIPDE 233.60 31 8 41744 Actin-1/4  
 A5A6M6|K2C1_PANTR 196.18 15 7 65489 Keratin, type II cytoskeletal 1  
 P04264|K2C1_HUMAN 197.27 25 13 66039 Keratin, type II cytoskeletal 1  
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 Q5R1X3|ACTB_PANTR 122.44 21 4 41737 Actin, cytoplasmic 1  
22 A5A6M6|K2C1_PANTR 252.18 16 10 65489 Keratin, type II cytoskeletal 1  
 P63261|ACTG_HUMAN 212.04 15 4 41792 Actin, cytoplasmic 2  
 P08779|K1C16_HUMAN 207.96 29 11 51268 Keratin, type I cytoskeletal 
16  
 P53480|ACTC_TAKRU 89.85 7 2 41975 Actin, alpha cardiac  
23 Q9UVX4|ACT_COPC7 119.78 9 2 41612 Actin  
 P04264|K2C1_HUMAN 179.64 19 8 66039 Keratin, type II cytoskeletal 1  
 P84185|ACT5C_ANOGA 167.88 21 6 41721 Actin, cytoplasmic  
24 P86221|TBB2C_MESAU 94.72 9 2 31916 Tubulin beta-2C chain 
(Fragments)  
 P13645|K1C10_HUMAN 238.09 32 16 58827 Keratin, type I cytoskeletal 
10  
 Q9YHC3|TBB1_GADMO 181.31 21 8 49749 Tubulin beta-1 chain  
 Q05825|ATPB_DROME 178,15 19 7 54108 ATP synthase subunit beta, 
mitochondrial  
 Q5R1X3|ACTB_PANTR 125.38 16 3 41737 Actin, cytoplasmic 1  
25 Q9YHC3|TBB1_GADMO 249.37 34 12 49748 Tubulin beta-1 chain  
 P13645|K1C10_HUMAN 199.00 18 9 58827 Keratin, type I cytoskeletal 
10  
 Q05825|ATPB_DROME 188.17 15 6 54108 ATP syn-beta, mitochondrial  
 P13645|K1C10_HUMAN 246.95 31 19 58827 Keratin, type I cytoskeletal 
10  
 P68556|ACT1_DIPDE 203.76 41 12 41773 Actin-2  
 P30883|TBB4_XENLA 134.29 11 4 49816 Tubulin beta-4 chain  
 P46561|ATPB_CAEEL 118.77 11 4 50537 ATP synthase subunit beta  
26 P08779|K1C16_HUMAN 220.57 27 9 51267 Keratin, type I cytoskeletal 
16  
 Q3ZBU7|TBB4_BOVIN 133.00 8 3 49585 Tubulin beta-4 chain  
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 P13645|K1C10_HUMAN 296.00 23 11 58827 Keratin, type I cytoskeletal 
10  
 P30883|TBB4_XENLA 192.94 14 5 49816 Tubulin beta-4 chain  
27 P08779|K1C16_HUMAN 158.62 17 5 51267 Keratin, type I cytoskeletal 
16  
 P13645|K1C10_HUMAN 239.28 15 10 58827 Keratin, type I cytoskeletal 
10  
 Q5R1X3|ACTB_PANTR 226.40 35 8 41373 Actin, cytoplasmic 1  
 P02769|ALBU_BOVIN 223.94 26 12 69294 Serum albumin  
28 Q2KJD0|TBB5_BOVIN 200.32 20 6 49670 Tubulin beta-5 chain  
29 P08418|HSP70_SCHMA 171.54 10 6 69875 Heat shock 70 kDa protein 
homolog  
 P35527|K1C9_HUMAN 141.98 9 3 62064 Keratin, type I cytoskeletal 9  
 Q9W6Y1|HSP7C_ORYLA 219.09 12 7 76169 Heat shock cognate 71 kDa 
protein  
 A5A6M6|K2C1_PANTR 211.53 15 8 65489 Keratin, type II cytoskeletal 1  
30 P02538|K2C6A_HUMAN 71.72 5 2 60045 Keratin, type II cytoskeletal 
6A  
 P13645|K1C10_HUMAN 181.26 25 13 58827 Keratin, type I cytoskeletal 
10  
Table 3. Proteins identified by MS/MS analysis of SDS-I. Spot numbers refer to Fig. 14 
 
Spot n. Accession -10lgP Number of 
Peptides 
1 P46561|ATPB_CAEEL 174.72 5 
 Q3MHM5|TBB2C_BOVIN 138.02 3 
 Q6EIY9|K2C1_CANFA 119.13 3 
2 Q3ZBU7|TBB4_BOVIN 103.35 2 
3 A5A6M6|K2C1_PANTR 137.79 3 
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4 P86700|ACT_CHIOP 129.48 3 
5 P86700|ACT_CHIOP 137.88 3 
6 P91754|ACT_LUMRU 181.67 6 
7 A5DQP9|ACT_PICGU 113.69 2 
8 P86700|ACT_CHIOP 129.93 3 
9 P13645|K1C10_HUMAN 99.13 3 
 P06604|TBA2_DROME 81.74 2 
10 A5DQP9|ACT_PICGU 107.66 2 
 
Table 5. Proteins identified by MS/MS analysis of SDS-S. Spot numbers refer to Fig. 15 
 
3.2. Characterization of SDS-I 
 
SDS-I was analyzed in duplicate using two different fragmentation techniques (HCD and CID) in 
order to assess overall reproducibility of the de novo mass spectrometric identification of the 
protein content of each spot. Since no genome is available for any monogenean parasite, 
protein identification was achieved by a strategy based on de novo sequencing using nano LC-
ESI MS/MS with LTQ-Orbitrap Velos followed by analysis with Peaks Studio 5.3 software. Tables 
1 and 2 report the proteins identified in SDS-I. Only proteins identified by at least 4 different 
peptides in at least one spot using both HCD and CID-based MS/MS analyses were considered 
as positively identified components of the adhesive material. Peptides supporting identification 
are reported in Table 4.  
Representative MS/MS spectra of one peptide for each protein are shown in Fig. 16 A-F. 
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Figure 16A. Representative MS/MS spectra of human actin G. 
 
 
Figure 16B. Representative MS/MS spectra of bovin albumin. 
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Figure 16C. Representative MS/MS spectra of Drosophila melanogaster ATP synthase subunit 
beta, mitochondrial. 
 
 
Figure 16D. Representative MS/MS spectra of human 78 kDa glucose-regulated protein. 
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Figure 16E. Representative MS/MS spectra of atlantic cod tubulin beta-1 chain 
 
 
Figure 16F. Representative MS/MS spectra of human Keratin, type I cytoskeletal 16 
 
Due to the absence of genome information for these organisms, several peptides fulfilling the 
required parameters for confident sequence determination by Peaks Studio could not be 
assigned to any protein. In order to identify further possible undetected protein components, 
manual BLAST searches using the unassigned peptides were performed. However, as can be 
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inferred from Table 4, no additional SDS-I proteins fulfilling the 4-peptide criterion detailed 
above were detected. 
 
3.3. Characterization of SDS-S 
 
Results concerning the characterization of SDS-S material are summarized in Tables 1, Table 5 
and Table 6. Altogether, the data clearly confirm that the adhesive material is insoluble in SDS 
and that SDS-S contains low amounts of the same proteins found in SDS-I, partially solubilized 
by SDS; in conclusion, the adhesive material is composed only of few proteins: keratin, actin, 
tubulin, ATP-synthase, 78 kDa glucose regulated protein (GRP78/HSP 70/DnaK) and albumin. 
 
3.4. Lack of some expected post-translational modifications in proteins from the bioadhesive 
material 
 
As emphasized by many Authors [170] and [171], most aquatic organisms exploit modified 
amino acid side chains, like phosphorylated Ser and hydroxylated Tyr (3, 4 
dihydroxyphenilalanine, DOPA) to gain high-surface affinity and strong adhesiveness. Barnacles 
are an exception and adhere with unmodified amino acids [170] and [172]. We investigated the 
presence of post-translational modifications (PTM) by various additional database search 
analyses of the mass spectrometric data, either using the “458-built-in modifications” option of 
the PTM module of Peaks Studio 7.0 to search for unspecified modifications or setting only 
specific modifications, selected on the basis of known features of adhesive materials from other 
organisms (i.e. hydroxylation at Tyr, Arg and Lys, phosphorylation at Tyr, Ser and Thr and 
nitration at Tyr as variable modifications). No significant PTM other than Cys-
carbamidomethylation, Met oxidation, N-terminal acetylation and formylation, dehydration 
and deamidation, which are well known PTM which can be present following the usual 
protocols for proteomic studies, were detected. Based on these findings, and on the 
characterization carried out by Hamwood et al. [4] on the secretion of the monogenea E. soleae 
that excludes the presence of lipids, glycans and DOPA upon analyses by colorimetric assays, it 
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is possible to speculate that Capsalidae rely for adhesion on a mechanism different from that 
described in mussels. 
As pointed out above, the lack of PTM in an adhesive material is quite unusual. Up to now, the 
only bioadhesive material from aquatic organisms which does not rely on post translationally 
modified residues for adhesion is the cement of barnacle, where the nanofibrillar network of 
proteins plays a very important role in the formation of the glue [172]. Six cement proteins 
have been identified so far. All of them, except for the enzymatic one, are novel, without 
significant homology with other proteins in databases currently available. They contain 
amyloid-like sequences that form a beta-sheet structure and homogenously interact with each 
other to form an insoluble self-assembly [172]. None of the peptides characterized in the 
present report shows significant similarities with barnacle cement proteins. 
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4. DISCUSSION AND CONCLUSION 
 
Our data demonstrate that the composition of the glue in N. girellae is completely different 
from the cement of barnacle and more similar to the adhesive material described in certain 
reptilians, like gecko, whose ability to adhere to vertical surfaces relies on the presence of 
specialized adhesive setae on their feet [138]. In gecko, the characterization of these structures 
demonstrated that the main components of the adhesive material are α-keratins (45-60 kDa) 
and associated-β keratins (sKAβPs) (8-22 kDa) present in different isoforms [138]. The similarity 
among the gecko and the N. girellae keratins was specifically analyzed carrying out a multi 
alignment analysis for all the peptides ascribed to N. girellae keratin and the gecko keratins 
described in [138]. No significant similarity was found except for the C-terminal region of gecko 
keratins rich in Gly and Ser residues whose role in gecko remains, at present, still unknown. 
Interestingly, few studies indicate that adhesion of setae increases with increasing 
environmental humidity due to the modification of the contact geometry of the hydrophobic 
surfaces. On the other hand, a fundamental difference between the adhesive mechanisms of 
terrestrial animals, such as geckos, and of fish parasites, like N. girellae, is that the latter must 
displace water to initiate contact with a surface. It is unknown whether water displacement 
occurs due to the surface properties of the adhesive organ or the nature of their secretion. 
Interestingly, a “keratin-like fibrous component” was discovered in ligament of the bivalve Silica 
radiata [173]. Characterization of the protein by MS/MS analysis revealed that it matches the 
sequence (27% coverage) of human K2C1/KRT1, which is one of the keratin forms matching the 
peptides identified in the present study ( Table 2, Table 3, Table 4, Table 5 and Table 6), 
confirming that keratins with considerable degree of identity with a human form can be present 
in phylogenetically very distant organisms. 
Beside keratin, another component of the N. girellae adhesive is actin, a highly conserved 
protein of the cytoskeleton of all eukaryotic cells. Among its different functions in a variety of 
cellular events such as motion, chromosome segregation, transport of macromolecules and 
endo- and esocytosis, this protein has been described as one of the components of the glue-like 
substances secreted by silkworm Bombyx mori L colleterial glands [174]. Although its role is not 
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understood until now, it is suggested that it might participate or regulate the secretion of these 
glands important for gliding motility [174]. In Monogenea the secretion is also used during 
locomotion for temporary adhesion to living host tissue. Therefore, actin present in the salivary 
extracts may play a role similar to the one described in apicomplexan parasites. 
Albumin is the third protein of the N. girellae proteome already described as a glue component, 
being used with glutaraldehyde as a new surgical adhesive and suture support [175]. Since at 
the moment it is not possible to suggest any mechanism or a plausible substitute for the 
crosslinking agent glutaraldehyde, its role as an active component of the adhesive material 
cannot be established. However possible expression of an albumin-like protein in these 
organisms is reinforced by the observation that a protein with about 70% identity with bovine 
serum albumin has been sequenced from the platyhelmint Schistosoma mansoni (Uniprot 
accession number Q95VB7_SCHMA). As far as the other components of the secretion in N. 
girellae are concerned (tubulin, ATP-synthase, and 78 kDa glucose regulated protein), these 
proteins have never been described in secreted adhesive materials until now. However, 78 kDa 
glucose regulated protein/HSP70/DnaK plays a role in facilitating the assembly of multimeric 
protein complexes inside the ER and may have a role in the post-translational modification, 
assembly or packaging of proteins prior to secretion [176], while ATP-synthase has been shown 
to be involved in the cellular secretory mechanism [177]. Thus, both macromolecules are 
involved at different levels in the mechanism of eukaryotic secretions and in the modulation of 
the membrane plasticity, but the specific role played in the secreted adhesive material of the 
fish parasite is presently unknown. 
In conclusion, the composition of a new bioadhesive material from the fish parasite N. girellae 
has been determined by a proteomic approach based on mass spectrometric de novo 
sequencing to overcome the absence of genomic information. The secretion of N. girellae is 
constituted mainly by cytoskeletal proteins. Such composition, together with the possible 
absence of post-translationally modified proteins, suggests that these organisms rely for 
adhesion on a mechanism completely different from the one described in other fish parasites or 
in mussels. 
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The results presented in this dissertation complement previous investigations concerning the 
role of glycoproteins produced by fish epithelium in the initial steps leading to N. girellae 
recognition of the host [178, 179]. Characterization at the molecular level of all processes 
involved control of this important pathogen in marine cultured fish. 
The results reported in this PhD thesis has been published in a paper entitled “A new 
bioadhesive material from fish parasite Neobenedenia girellae” [180]. 
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SUPPLEMENTARY TABLES 
 
Table 4 
 
Spot 
n. 
Protein Accession Peptide -10lgP m/z z 
1 P25691|K2M3_SHEEP R.KSDLEANVEALVEESNFLKR.L 131.57 764.3967 3 
  R.TKLEAAVAEAEQQGEAALNDAR.
S 
122.58 762.3792 3 
  R.KSDLEANVEALVEESNFLK.R 111.96 1068.0411 2 
  K.SDLEANVEALVEESNFLKR.L 108.62 721.6978 3 
  R.LYDEEIQILNAHISDTSVIVK.M 107.53 800.7551 3 
  K.SDLEANVEALVEESNFLK.R 105.77 669.6641 3 
  K.LGLDIEIATYR.R 87.96 632.3477 2 
 P11021|GRP78_HUMAN K.DNHLLGTFDLTGIPPAPR.G 130.94 967.5046 2 
  K.TFAPEEISAMVLTK.M 110.61 768.8978 2 
  R.GVPQIEVTFEIDVNGILR.V 99.36 1000.0416 2 
  R.IEIESFYEGEDFSETLTR.A 93.04 1082.9930 2 
  K.TFAPEEISAM(+15.99)VLTK.M 83.56 776.8955 2 
  R.IINEPTAAAIAYGLDKR.E 76.03 908.4957 2 
  R.LTPEEIER.M 58.09 493.7583 2 
  K.SQIFSTASDNQPTVTIK.V 47.99 918.9650 2 
 A5A6M6|K2C1_PANTR R.SGGGFSSGSAGIINYQR.R 79.59 829.3984 2 
  K.WELLQQVDTSTR.T 72.93 738.3770 2 
  R.FLEQQNQVLQTK.W 71.25 738.3959 2 
  K.YEELQITAGR.H 70.26 590.3033 2 
  K.SLNNQFASFIDK.V 70.04 692.3469 2 
  K.QISNLQQSISDAEQR.G 69.96 858.9270 2 
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  R.TNAENEFVTIK.K 69.29 633.3219 2 
  K.SKAEAESLYQSK.Y 68.57 670.8377 2 
  R.DYQELMNTK.L 63.17 571.2623 2 
  K.LNDLEDALQQAK.E 57.23 679.3500 2 
  R.GSYGSGGSSYGSGGGSYGSGGG
GGGHGSY.G 
54.63 1208.9661 2 
  R.TNAENEFVTIKK.D 53.87 465.2481 3 
  R.GGGGGGYGSGGSSYGSGGGSYG
SGGGGGGGR.G 
52.73 1192.4795 2 
  R.SGGGFSSGSAGII.N 51.91 548.7664 2 
  R.SLDLDSIIAEVK.A 49.78 651.8616 2 
  K.IEISELNR.V 49.65 487.2681 2 
  K.AQYEDIAQK.S 44.50 533.2637 2 
  R.SLVNLGGSK.S 43.48 437.7519 2 
  W.ELLQQVDTSTR.T 42.65 645.3368 2 
  R.SGGGFSSGSAGI.I 40.14 492.2247 2 
 P08418|HSP70_SCHMA R.IINEPTAAAIAYGLDK.K 66.40 830.4509 2 
  K.NQVAMNPTNTVFDAK.R 57.59 825.3978 2 
  K.SINPDEAVAYGAAVQA.A 52.13 788.3850 2 
  K.SINPDEAVAYGAAVQAA.I 40.63 823.9027 2 
2 P53470|ACT1_SCHMA K.SYELPDGQVITIGNER.F 120.77 895.9473 2 
  R.AVFPSIVGRPR.H 102.84 599.8553 2 
  R.VAPEEHPVLLTEAPLNPKANR.E 95.83 765.7512 3 
  R.VAPEEHPVLLTEAPLNPK.A 90.56 652.0239 3 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
86.56 784.3576 3 
  K.AGFAGDDAPR.A 85.12 488.7275 2 
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  K.DSYVGDEAQSK.R 82.28 599.7626 2 
  R.HQGVMVGMGQK.D 79.05 586.2862 2 
  K.EISALAPSTMK.I 72.61 574.3040 2 
  M.AEEDVAALVIDNGSGMC(+57.0
2)K.A 
70.43 939.9096 2 
  M.AEEDVAALVIDNGSGMC(+57.0
2)KAGFAGDDAPR.A 
45.95 946.0854 3 
 P13645|K1C10_HUMAN K.SKELTTEIDNNIEQISSYK.S 89.02 1106.5425 2 
  K.GSLGGGFSSGGFSGGSFSR.G 86.39 854.3824 2 
  R.GSSGGGC(+57.02)FGGSSGGYG
GLGGFGGGSFR.G 
83.84 1171.9850 2 
  G.SSGGGC(+57.02)FGGSSGGYGG
LGGFGGGSFR.G 
80.76 1143.4729 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
80.40 1041.9767 2 
  R.YC(+57.02)VQLSQIQAQISALEE
QLQQIR.A 
78.98 1373.7164 2 
  R.NVSTGDVNVEMNAAPGVDLTQ
LLNNMR.S 
77.47 1436.6879 2 
  R.ISSSKGSLGGGFSSGGFSGGSFSR.
G 
77.29 737.3465 3 
  R.ALEESNYELEGK.I 74.84 691.3207 2 
  K.QSLEASLAETEGR.Y 73.60 695.8381 2 
  K.ELTTEIDNNIEQISSYK.S 73.22 998.9799 2 
  F.GGSSGGYGGLGGFGGGSFR.G 68.26 817.3649 2 
  R.SQYEQLAEQNR.K 67.54 683.3168 2 
  R.NVQALEIELQSQLALK.Q 66.93 899.0007 2 
  S.SKGSLGGGFSSGGFSGGSFSR.G 64.57 641.6312 3 
  K.IRLENEIQTYR.S 63.09 717.8811 2 
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  S.SGGYGGLGGFGGGSFR.G 61.59 716.8284 2 
  G.SLGGGFSSGGFSGGSFSR.G 61.52 825.8706 2 
  R.LENEIQTYR.S 61.26 583.2907 2 
  R.VLDELTLTK.A 60.66 516.2977 2 
  R.LKYENEVALR.Q 59.72 617.8371 2 
  R.QSVEADINGLR.R 59.35 601.3059 2 
  K.VTMQNLNDR.L 58.89 545.7637 2 
  R.SQYEQLAEQNRK.D 56.44 747.3631 2 
  L.GGGFSSGGFSGGSFSR.G 56.25 725.8134 2 
  Q.ISALEEQLQQIR.A 55.58 714.3879 2 
  N.LTTDNANILLQIDNAR.L 55.33 892.9708 2 
  K.NQILNLTTDNANILLQIDNAR.L 54.72 789.7501 3 
  R.SLLEGEGSSGGGGR.G 54.53 631.7972 2 
  I.SSSKGSLGGGFSSGGFSGGSFSR.
G 
54.19 699.6525 3 
  S.GGYGGLGGFGGGSFR.G 53.54 673.3113 2 
  K.GSLGGGFSSGGFSGGSFS.R 48.86 776.3321 2 
  F.GGGGFGGGFGGGFGGDGGLLS
GNEK.V 
47.55 1057.9764 2 
  K.TIDDLKNQILNLTTDNANILLQID
NAR.L 
46.97 1018.2128 3 
  R.LAADDFR.L 45.67 404.1996 2 
  K.YENEVALR.Q 45.37 497.2484 2 
  F.GGGFGGDGGLLSGNEK.V 45.16 711.3291 2 
  L.RQSVEADINGLR.R 45.03 453.2398 3 
  K.SKELTTEIDNNIEQISSY.K 44.35 1042.4968 2 
  R.RVLDELTLTK.A 43.39 594.3469 2 
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  G.GYGGLGGFGGGSFR.G 43.27 644.8013 2 
  N.TEYQQLLDIK.I 43.06 625.8302 2 
  K.IRLENEIQTY.R 40.21 639.8320 2 
 Q00214|ACTM_STYPL K.SYELPDGQVITIGNER.F 73.09 895.9420 2 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
55.28 1275.5864 2 
  R.VAPEEHPVLLTEAPLNPK.A 53.70 977.5286 2 
  R.GYSFVTTAER.E 51.60 565.7724 2 
3 P08779|K1C16_HUMAN R.RVLQGLEIELQSQLSM(+15.99)K
.A 
120.87 663.3627 3 
  R.TDLEMQIEGLKEELAYLR.K 117.45 717.7017 3 
  R.LLEGEDAHLSSQQASGQSYSSR.E 115.81 784.0320 3 
  R.VLQGLEIELQSQLSMK.A 115.44 605.9995 3 
  R.VLQGLEIELQSQLSM(+15.99)K.
A 
103.46 916.4915 2 
  R.GQTGGDVNVEM(+15.99)DAAP
GVDLSR.I 
98.70 1052.4791 2 
  R.NKIIAATIENAQPILQIDNAR.L 95.93 769.4311 3 
  R.ALEEANADLEVK.I 88.03 651.3301 2 
  R.TDLEM(+15.99)QIEGLKEELAYL
R.K 
82.06 723.0335 3 
  K.EVASNSELVQSSR.S 80.06 703.3466 2 
  R.LASYLDK.V 50.70 405.2224 2 
 P53470|ACT1_SCHMA R.AVFPSIVGRPR.H 107.60 400.2383 3 
  K.AGFAGDDAPR.A 106.87 488.7261 2 
  R.HQGVMVGMGQK.D 74.37 586.2877 2 
  M.AEEDVAALVIDNGSGMC(+57.0
2)K.A 
69.49 939.9116 2 
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 A7ZHA4|DNAK_ECO24 K.IELSSAQQTDVNLPYITADATGPK
.H 
112.71 844.7629 3 
  K.TAIESALTALETALK.G 91.48 766.4296 2 
  R.KDVNPDEAVAIGAAVQGGVLTG
DVK.D 
84.24 808.4277 3 
  R.GM(+15.99)PQIEVTFDIDADGIL
HVSAK.D 
80.74 791.3943 3 
  K.DVNPDEAVAIGAAVQGGVLTGD
VK.D 
60.76 765.7276 3 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 95.19 854.3823 2 
  K.QSLEASLAETEGR.Y 83.99 695.8384 2 
  R.ALEESNYELEGK.I 83.02 691.3212 2 
  R.SQYEQLAEQNR.K 75.96 683.3172 2 
  K.SKELTTEIDNNIEQISSYK.S 74.29 738.0300 3 
  R.SLLEGEGSSGGGGR.G 66.89 631.7972 2 
  R.VLDELTLTK.A 61.98 516.2969 2 
  R.QSVEADINGLR.R 60.99 601.3066 2 
  R.LENEIQTYR.S 59.02 583.2905 2 
  R.LKYENEVALR.Q 55.14 617.8378 2 
  L.GGGFSSGGFSGGSFSR.G 52.17 725.8148 2 
  R.SQYEQLAEQNRK.D 51.72 747.3648 2 
  K.YENEVALR.Q 50.37 497.2484 2 
  K.VTMQNLNDR.L 47.78 545.7645 2 
  K.IRLENEIQTYR.S 43.22 478.9230 3 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
42.28 1041.9799 2 
  K.DAEAWFNEK.S 41.59 555.2435 2 
  K.ELTTEIDNNIEQISSYK.S 40.82 998.9791 2 
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 Q5R1X3|ACTB_PANTR K.SYELPDGQVITIGNER.F 90.94 895.9414 2 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
77.51 1275.5778 2 
  R.VAPEEHPVLLTEAPLNPK.A 75.69 977.5281 2 
  F.NTPAMYVAIQAVLSLYASGR.T 65.68 709.0358 3 
  K.YSVWIGGSILASLSTFQQMWISK.
Q 
60.60 1301.6658 2 
  R.GYSFTTTAER.E 59.67 566.7614 2 
  K.DLYANTVLSGGTTMYPGIADR.M 57.87 1108.0305 2 
  R.DLTDYLMK.I 54.90 499.7413 2 
  R.AVFPSIVGR.P 41.75 473.2750 2 
 P02769|ALBU_BOVIN K.DAFLGSFLYEYSR.R 76.00 784.3676 2 
  K.LGEYGFQNALIVR.Y 69.88 740.3931 2 
  K.GLVLIAFSQYLQQC(+57.02)PFD
EHVK.L 
59.19 1246.6290 2 
  R.RHPYFYAPELLYYANK.Y 55.33 682.3407 3 
  K.LVVSTQTALA 52.12 501.7898 2 
  K.EYEATLEEC(+57.02)C(+57.02)A
K.D 
50.91 751.8031 2 
  R.MPC(+57.02)TEDYLSLILNR.L 50.21 862.9115 2 
  K.LVNELTEFAK.T 48.68 582.3137 2 
  K.VPQVSTPTLVEVSR.S 40.49 756.4183 2 
 P11142|HSP7C_HUMAN R.GVPQIEVTFDIDANGILNVSAVD
K.S 
71.01 838.7689 3 
  K.NQVAMNPTNTVFDAK.R 64.62 825.3937 2 
  Y.GAAVQAAILSGDK.S 59.70 600.8257 2 
  R.IINEPTAAAIAYGLDK.K 53.73 830.4423 2 
  R.TLSSSTQASIEIDSLYEGIDFYTSIT 48.56 999.8168 3 
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R.A 
4 P53470|ACT1_SCHMA K.SYELPDGQVITIGNER.F 99.94 895.9508 2 
  K.EISALAPSTMK.I 54.10 574.3060 2 
 Q6IFZ9|K2C74_MOUSE R.FLEQQNQVLQTK.W 46.50 738.3968 2 
 A5A6M6|K2C1_PANTR R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
107.03 883.3621 2 
  R.SGGGFSSGSAGIINYQR.R 90.37 829.3917 2 
  K.QISNLQQSISDAEQR.G 86.61 858.9211 2 
  K.YEELQITAGR.H 75.81 590.2965 2 
  R.FLEQQNQVLQTK.W 74.72 738.3881 2 
  R.TNAENEFVTIK.K 51.56 633.3146 2 
  R.GSYGSGGSSYGSGGGSYGSGGG
GGGHGSY.G 
40.87 1208.9606 2 
 Q00214|ACTM_STYPL K.SYELPDGQVITIGNER.F 102.30 895.9417 2 
  R.GYSFVTTAER.E 74.94 565.7715 2 
  R.VAPEEHPVLLTEAPLNPK.A 65.64 977.5274 2 
  Y.ELPDGQVITIGNER.F 51.32 770.8942 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
45.90 588.5187 4 
5 Q93129|ACTC_BRABE K.SYELPDGQVITIGNER.F 71.77 895.9470 2 
  R.AVFPSIVGRPR.H 63.92 400.2390 3 
 P08779|K1C16_HUMAN K.TEELNKEVASNSELVQSSR.S 92.61 707.3518 3 
  R.VLQGLEIELQSQLSMK.A 84.74 605.9984 3 
  R.ISSVLAGGSC(+57.02)RAPSTYG
GGLSVSSR.F 
83.16 809.4067 3 
  R.LLEGEDAHLSSQQASGQSYSSR.E 81.03 784.0325 3 
  K.IIAATIENAQPILQIDNAR.L 76.39 1032.5730 2 
  R.NKIIAATIENAQPILQIDNAR.L 70.23 769.4300 3 
115 
 
  R.QTVEADVNGLR.R 67.60 601.3101 2 
  K.ASLENSLEETK.G 67.43 610.8023 2 
  R.QFTSSSSMKGSC(+57.02)GIGG
GIGGGSSR.I 
66.31 754.6765 3 
  R.ALEEANADLEVKIRDWYQR.Q 63.78 773.7273 3 
  R.EVFTSSSSSSSR.Q 63.52 630.7876 2 
  R.QFTSSSSM(+15.99)KGSC(+57.0
2)GIGGGIGGGSSR.I 
61.40 760.0085 3 
  K.DYSPYFKTIEDLR.N 59.41 823.9019 2 
  R.QRPSEIKDYSPYFK.T 59.08 586.6311 3 
  K.VTMQNLNDRLASYLDKVR.A 56.69 712.7100 3 
  K.EVASNSELVQSSR.S 53.57 703.3481 2 
  K.VTMQNLNDRLASYLDK.V 50.20 627.6541 3 
  R.QTVEADVNGLRR.V 45.92 679.3596 2 
  R.DQYEQMAEK.N 40.88 571.2431 2 
 P04264|K2C1_HUMAN K.QISNLQQSISDAEQR.G 72.65 858.9209 2 
  R.SGGGFSSGSAGIINYQR.R 71.50 829.3922 2 
  R.FLEQQNQVLQTK.W 66.25 738.3889 2 
  R.TNAENEFVTIK.K 65.07 633.3152 2 
  R.SLDLDSIIAEVK.A 64.36 651.8544 2 
  K.SLNNQFASFIDK.V 63.41 692.3422 2 
  R.TNAENEFVTIKK.D 62.73 697.3619 2 
  K.YEELQITAGR.H 62.07 590.2975 2 
  K.WELLQQVDTSTR.T 61.95 738.3707 2 
  K.NKLNDLEDALQQAK.E 56.59 533.9437 3 
  R.DYQELMNTK.L 55.73 571.2567 2 
  K.LNDLEDALQQAK.E 55.26 679.3450 2 
116 
 
  K.KQISNLQQSISDAEQR.G 49.20 615.6467 3 
  K.SLNNQFASFIDKVR.F 48.67 819.9242 2 
  K.NMQDMVEDYR.N 47.46 650.7608 2 
  K.IEISELNR.V 44.37 487.2635 2 
  R.GSYGSGGSSYGSGGGSYGSGGG
GGGHGSYGSGSSSGGYR.G 
40.47 1104.7621 3 
 Q5JAK2|ACTG_RANLE K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
64.65 850.7204 3 
  K.SYELPDGQVITIGNER.F 64.00 895.9409 2 
  R.VAPEEHPVLLTEAPLNPK.A 62.81 977.5270 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
51.21 588.5181 4 
  K.SYELPDGQVITIGN.E 49.77 753.3698 2 
  R.AVFPSIVGRPR.H 49.14 599.8499 2 
  R.DLTDYLMK.I 45.61 499.7416 2 
6 A7E3Q8|PLST_BOVIN K.ISFDEFVYIFQEVK.S 71.30 882.4435 2 
  K.IGLFADIELSR.N 71.24 617.3400 2 
  K.LNLAFVANLFNK.Y 69.10 682.3864 2 
  K.MVMTVFAC(+57.02)LMGR.G 56.99 708.3340 2 
  K.TISSSLAVVDLIDAIQPGC(+57.02
)INYDLVK.S 
20.88 935.4946 3 
 P04264|K2C1_HUMAN R.SGGGFSSGSAGIINYQR.R 103.48 829.3904 2 
  K.YEELQITAGR.H 89.61 590.2976 2 
  R.FLEQQNQVLQTK.W 78.96 738.3889 2 
  R.GGGGGGYGSGGSSYGSGGGSYG
SGGGGGGGR.G 
73.21 1192.4720 2 
  R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
70.36 883.3622 2 
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  K.QISNLQQSISDAEQR.G 63.70 858.9195 2 
  L.LQPLNVEIDPEIQK.V 54.14 818.4437 2 
  R.TNAENEFVTIK.K 49.27 633.3142 2 
  R.TNAENEFVTIKK.D 43.08 697.3632 2 
  R.GSYGSGGSSYGSGGGSYGSGGG
GGGHGSY.G 
40.11 1208.9606 2 
 Q26065|ACT_PLAMG K.SYELPDGQVITIGNER.F 84.95 895.9429 2 
  R.VAPEEHPVLLTEAPLNPK.A 84.82 977.5280 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
42.88 588.5182 4 
7 A5A6M6|K2C1_PANTR R.SLVNLGGSKSISISVAR.G 79.79 844.4842 2 
  R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
69.33 883.3671 2 
  R.SGGGGGRFSSC(+57.02)GGGG
GSFGAGGGFGSR.S 
67.56 765.3257 3 
  R.FLEQQNQVLQTK.W 67.20 738.3937 2 
  R.SLDLDSIIAEVK.A 66.73 651.8579 2 
  R.TNAENEFVTIKK.D 66.08 465.2470 3 
  K.YEELQITAGR.H 65.38 590.3003 2 
  R.SGYRSGGGFSSGSAGIINYQR.R 65.28 707.6719 3 
  R.SGGGFSSGSAGIINYQRR.T 65.09 605.3004 3 
  K.AEAESLYQSKYEELQITAGR.H 58.53 762.7106 3 
  R.TNAENEFVTIK.K 57.96 633.3190 2 
  R.SGGGFSSGSAGIINYQR.R 56.80 829.3943 2 
  K.SLNNQFASFIDKVR.F 54.99 546.9553 3 
  K.LALDLEIATYR.T 52.24 639.3559 2 
  K.SLNNQFASFIDK.V 50.94 692.3447 2 
  K.AEAESLYQSK.Y 46.91 563.2722 2 
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  K.SISISVAR.G 30.86 416.7462 2 
  R.GSGGGSSGGSIGGRGSSSGGVK.
S 
30.44 584.6111 3 
 P04264|K2C1_HUMAN R.SGGGFSSGSAGIINYQR.R 88.64 829.3939 2 
  K.WELLQQVDTSTR.T 77.47 738.3712 2 
  K.YEELQITAGR.H 77.20 590.2980 2 
  R.FLEQQNQVLQTK.W 75.99 738.3910 2 
  R.TNAENEFVTIK.K 75.78 633.3171 2 
  R.GGGGGGYGSGGSSYGSGGGSYG
SGGGGGGGR.G 
75.17 1192.4706 2 
  K.SLNNQFASFIDK.V 64.60 692.3420 2 
  K.QISNLQQSISDAEQR.G 62.91 858.9222 2 
  K.IEISELNR.V 48.90 487.2648 2 
  R.TNAENEFVTIKK.D 48.60 697.3663 2 
  L.NVEIDPEIQK.V 41.47 592.8064 2 
  K.LNDLEDALQQAK.E 40.98 679.3463 2 
8 P63261|ACTG_HUMAN R.VAPEEHPVLLTEAPLNPK.A 114.98 652.0230 3 
  K.SYELPDGQVITIGNER.F 110.08 895.9458 2 
  R.AVFPSIVGRPR.H 97.56 400.2378 3 
  K.AGFAGDDAPR.A 85.68 488.7256 2 
 P11021|GRP78_HUMAN K.DNHLLGTFDLTGIPPAPR.G 82.06 967.5056 2 
  R.AKFEELNM(+15.99)DLFR.S 73.20 764.8740 2 
  R.IEIESFYEGEDFSETLTR.A 69.93 1082.9946 2 
  R.GVPQIEVTFEIDVNGILR.V 44.97 1000.0419 2 
 P04264|K2C1_HUMAN R.SGGGFSSGSAGIINYQR.R 86.55 829.4000 2 
  K.LNDLEDALQQAK.E 82.45 679.3514 2 
  K.SLNNQFASFIDK.V 78.86 692.3474 2 
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  K.QISNLQQSISDAEQR.G 78.65 858.9296 2 
  K.YEELQITAGR.H 78.28 590.3024 2 
  R.FLEQQNQVLQTK.W 76.88 738.3953 2 
  R.TNAENEFVTIK.K 76.13 633.3217 2 
  K.WELLQQVDTSTR.T 70.76 738.3780 2 
  R.DYQELMNTK.L 54.76 571.2627 2 
  K.IEISELNR.V 50.74 487.2685 2 
  R.TNAENEFVTIKK.D 48.15 697.3691 2 
  Q.FASFIDK.V 42.46 414.2179 2 
 P08418|HSP70_SCHMA K.NQVAMNPTNTVFDAK.R 87.75 825.4045 2 
  R.TVSDAVITVPAYFNDSQR.Q 47.94 991.9959 2 
 P63270|ACTH_CHICK K.SYELPDGQVITIGNER.F 70.78 895.9498 2 
  R.GYSFVTTAER.E 48.48 565.7770 2 
9 P02769|ALBU_BOVIN K.VPQVSTPTLVEVSR.S 127.05 756.4209 2 
  K.LFTFHADIC(+57.02)TLPDTEK.Q 107.86 954.4592 2 
  K.DAIPENLPPLTADFAEDK.D 98.00 978.4794 2 
  K.DAFLGSFLYEYSR.R 97.60 784.3710 2 
  K.HLVDEPQNLIK.Q 96.45 653.3578 2 
  K.TVMENFVAFVDK.C 87.34 700.3465 2 
  K.TVM(+15.99)ENFVAFVDK.C 85.36 708.3448 2 
  K.DAIPENLPPLTADFAEDKDVC(+5
7.02)K.N 
82.60 820.0610 3 
  K.LGEY(+15.99)GFQNALIVR.Y 78.73 748.3943 2 
  R.HPEYAVSVLLR.L 76.50 642.3566 2 
  K.EYEATLEEC(+57.02)C(+57.02)A
K.D 
76.03 751.8063 2 
  K.EAC(+57.02)FAVEGPK.L 75.03 554.2581 2 
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  R.M(+15.99)PC(+57.02)TEDYLSLI
LNR.L 
67.40 870.9170 2 
  K.LVNELTEFAK.T 64.60 582.3159 2 
  K.YIC(+57.02)DNQDTISSK.L 54.82 722.3220 2 
  K.LVVSTQTALA 52.19 501.7929 2 
  K.DAFLGSFLYEY(+15.99)SR.R 15.97 792.3687 2 
10 P53470|ACT1_SCHMA K.QEYDESGPGIVHR.K 82.41 496.2355 3 
  R.VAPEEHPVLLTEAPLNPK.A 77.44 977.5363 2 
  K.SYELPDGQVITIGNER.F 77.12 895.9500 2 
  K.AGFAGDDAPR.A 71.09 488.7278 2 
  R.AVFPSIVGRPR.H 69.18 400.2403 3 
  R.HQGVMVGMGQK.D 67.08 586.2893 2 
  K.EISALAPSTM(+15.99)K.I 53.37 582.3024 2 
  K.DSYVGDEAQSK.R 51.97 599.7653 2 
  K.QEYDESGPGIVHRK.C 51.69 807.8992 2 
  K.EISALAPSTMK.I 50.95 574.3049 2 
  R.GYSFTTTAER.E 49.63 566.7667 2 
  K.DSYVGDEAQSKR.G 46.19 677.8162 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
42.67 784.3629 3 
  K.IKIVAPPER.K 39.64 511.8219 2 
  M.AEEDVAALVIDNGSGMC(+57.0
2)K.A 
35.29 939.9144 2 
11 P68365|TBA1C_CRIGR R.FDGALNVDLTEFQTNLVPYPR.I 100.83 1205.1023 2 
  R.QLFHPEQLITGK.E 90.61 705.8873 2 
  R.NLDIERPTYTNLNR.L 90.52 573.6296 3 
  K.TIGGGDDSFNTFFSETGAGK.H 87.93 1004.4474 2 
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  R.IHFPLATYAPVISAEK.A 85.34 586.3235 3 
  K.VGINYQPPTVVPGGDLAK.V 80.17 912.9924 2 
  R.LISQIVSSITASLR.F 75.67 744.4378 2 
  R.AVFVDLEPTVIDEVR.T 75.24 567.9711 3 
  R.LDHKFDLMYAK.R 72.07 690.8498 2 
  K.LADQC(+57.02)TGLQGFLVFHSF
GGGTGSGFTSLLMER.L 
69.88 1130.8711 3 
  K.DVNAAIATIK.T 65.07 508.2901 2 
  K.EIIDLVLDR.I 61.49 543.3116 2 
  K.AYHEQLTVAEITNAC(+57.02)FE
PANQMVK.C 
54.59 922.1061 3 
  R.TIQFVDWC(+57.02)PTGFK.V 51.03 799.8851 2 
 P20399|ACT2_XENTR K.MTQIMFETFNVPAMYVAIQAVL
SLYASGR.T 
98.07 1084.5416 3 
  K.LC(+57.02)YVALDFENEMATAA
SSSSLEK.S 
97.07 846.0535 3 
  K.DSYVGDEAQSK.R 90.27 599.7622 2 
  R.VAPEEHPTLLTEAPLNPK.A 83.13 652.6838 3 
  K.SYELPDGQVITIGNER.F 74.29 895.9459 2 
  K.YSVWIGGSILASLSTFQQMWITK.
Q 
72.82 872.7856 3 
  R.C(+57.02)PETLFQPSFIGMESAGI
HETTYNSIMK.C 
33.48 1063.4855 3 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 62.85 854.3828 2 
  K.ELTTEIDNNIEQISSYK.S 62.21 998.9811 2 
  G.SSGGGC(+57.02)FGGSSGGYGG
LGGFGGGSFR.G 
54.79 1143.4698 2 
  R.ALEESNYELEGK.I 49.99 691.3215 2 
  K.QSLEASLAETEGR.Y 46.65 695.8367 2 
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  G.SLGGGFSSGGFSGGSFSR.G 41.58 825.8706 2 
  K.DAEAWFNEK.S 40.61 555.2431 2 
 P69003|ACT1_HELTB R.VAPEEHPVLLTEAPLNPK.A 54.43 977.5280 2 
  K.SYELPDGQVITIGNER.F 54.17 895.9420 2 
  K.DLYANTVLSGGSTMFPGIADR.M 49.52 1093.0254 2 
  Y.VALDFEQEMSTAASSSSLEK.S 46.66 1065.4879 2 
  K.LC(+57.02)YVALDFEQEMSTAAS
SSSLEK.S 
46.64 1283.5781 2 
  K.AGFAGDDAPR.A 42.77 488.7233 2 
  R.AVFPSIVGR.P 40.30 473.2743 2 
 P06604|TBA2_DROME K.VGINYQPPTVVPGGDLAK.V 50.27 912.9879 2 
  R.AVFVDLEPTVVDEVR.T 48.48 844.4402 2 
  K.DVNAAIATIK.T 44.83 508.2889 2 
12 P20399|ACT2_XENTR K.MTQIMFETFNVPAMYVAIQAVL
SLYASGR.T 
101.17 1084.5411 3 
  K.SYELPDGQVITIGNER.F 81.12 895.9448 2 
  K.LC(+57.02)YVALDFENEMATAA
SSSSLEK.S 
66.39 846.0524 3 
  K.YSVWIGGSILASLSTFQQMWITK.
Q 
64.70 872.7861 3 
  R.KYSVWIGGSILASLSTFQQMWIT
K.Q 
61.60 915.4791 3 
  R.C(+57.02)PETLFQPSFIGMESAGI
HETTYNSIMK.C 
51.42 1063.4855 3 
 P68365|TBA1C_CRIGR R.FDGALNVDLTEFQTNLVPYPR.I 76.77 1205.1008 2 
  R.LISQIVSSITASLR.F 71.07 744.4412 2 
  R.AVFVDLEPTVIDEVR.T 61.35 851.4545 2 
  R.IHFPLATYAPVISAEK.A 56.29 586.3224 3 
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13 P13645|K1C10_HUMAN K.SKELTTEIDNNIEQISSYK.S 59.38 1106.5439 2 
  K.GSLGGGFSSGGFSGGSFSR.G 53.23 854.3836 2 
  K.ELTTEIDNNIEQISSYK.S 52.92 998.9813 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
52.69 1041.9785 2 
  R.GSSGGGC(+57.02)FGGSSGGYG
GLGGFGGGSFR.G 
49.27 1171.9880 2 
  R.ALEESNYELEGK.I 47.72 691.3226 2 
  K.QSLEASLAETEGR.Y 46.51 695.8379 2 
  K.IRLENEIQTYR.S 46.18 717.8823 2 
  L.GGGFSSGGFSGGSFSR.G 45.18 725.8151 2 
  R.SQYEQLAEQNR.K 44.39 683.3173 2 
  R.SLLEGEGSSGGGGR.G 42.60 631.7969 2 
  R.QSVEADINGLR.R 41.46 601.3071 2 
  R.LKYENEVALR.Q 40.90 617.8383 2 
 Q3MHM5|TBB4B_BOVIN R.IMNTFSVVPSPK.V 47.93 660.3493 2 
  R.AVLVDLEPGTMDSVR.S 47.15 801.4078 2 
  K.GHYTEGAELVDSVLDVVR.K 45.69 979.9834 2 
  K.MSATFIGNSTAIQELFK.R 44.66 929.4661 2 
  R.ISEQFTAMFR.R 42.71 615.2978 2 
  R.INVYYNEATGGK.Y 42.63 664.8225 2 
  R.MSMKEVDEQMLNVQNK.N 42.16 641.9656 3 
  H.SLGGGTGSGMGTLLISK.I 42.05 768.4023 2 
  K.LAVNMVPFPR.L 41.97 572.3162 2 
  R.FPGQLNADLR.K 40.13 565.7961 2 
 P46561|ATPB_CAEEL R.FTQAGSEVSALLGR.I 46.13 718.3746 2 
  R.IPSAVGYQPTLATDMGSMQER.I 46.08 751.3554 3 
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  K.AHGGYSVFAGVGER.T 44.71 703.8378 2 
  K.VSLVYGQMNEPPGAR.A 44.28 809.3998 2 
14 P13645|K1C10_HUMAN K.NQILNLTTDNANILLQIDNAR.L 121.63 789.7539 3 
  R.NVQALEIELQSQLALK.Q 100.99 899.0049 2 
  K.ADLEMQIESLTEELAYLK.K 96.09 1048.5219 2 
  K.ADLEM(+15.99)QIESLTEELAYLK
.K 
88.28 1056.5209 2 
  K.GSLGGGFSSGGFSGGSFSR.G 56.17 854.3835 2 
 P02769|ALBU_BOVIN K.LFTFHADIC(+57.02)TLPDTEK.Q 121.77 954.4591 2 
  K.DAFLGSFLYEYSR.R 114.07 784.3707 2 
  K.LGEY(+15.99)GFQNALIVR.Y 98.00 748.3927 2 
  K.TVMENFVAFVDK.C 96.78 700.3458 2 
  K.TVM(+15.99)ENFVAFVDK.C 91.59 708.3441 2 
  R.HPEYAVSVLLR.L 84.17 642.3554 2 
  K.DAIPENLPPLTADFAEDK.D 82.04 978.4789 2 
  R.HPEY(+15.99)AVSVLLR.L 77.82 650.3536 2 
  K.QTALVELLK.H 49.23 507.8102 2 
 A7ZHA4|DNAK_ECO24 K.IELSSAQQTDVNLPYITADATGPK
.H 
110.23 844.7629 3 
  K.VALQDAGLSVSDIDDVILVGGQT
R.M 
92.02 1221.1411 2 
  K.TAIESALTALETALK.G 91.10 766.4282 2 
  R.KDVNPDEAVAIGAAVQGGVLTG
DVK.D 
84.94 808.4265 3 
  K.DVNPDEAVAIGAAVQGGVLTGD
VK.D 
79.29 765.7277 3 
 P04264|K2C1_HUMAN R.SGGGFSSGSAGIINYQR.R 83.62 829.3984 2 
  K.WELLQQVDTSTR.T 78.96 738.3770 2 
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  K.YEELQITAGR.H 78.21 590.3029 2 
  R.FLEQQNQVLQTK.W 73.21 738.3960 2 
  R.TNAENEFVTIK.K 73.06 633.3212 2 
  K.SLNNQFASFIDK.V 71.62 692.3484 2 
  R.DYQELMNTK.L 70.97 571.2628 2 
  K.LNDLEDALQQAK.E 70.40 679.3514 2 
  K.QISNLQQSISDAEQR.G 66.97 858.9263 2 
  R.SLDLDSIIAEVK.A 63.27 651.8597 2 
  K.NKLNDLEDALQQAK.E 56.61 800.4199 2 
  K.NMQDMVEDYR.N 49.99 650.7678 2 
  K.IEISELNR.V 47.81 487.2675 2 
  K.AEAESLYQSKYEELQITAGR.H 46.08 762.7122 3 
  L.NVEIDPEIQK.V 43.11 592.8107 2 
 Q9W6Y1|HSP7C_ORYLA R.IINEPTAAAIAYGLDK.K 81.89 830.4507 2 
  K.DAGTISGLNVLR.I 66.90 608.3370 2 
  K.NQVAMNPTNTVFDAK.R 63.99 825.4003 2 
  R.IINEPTAAAIAYGLDKK.V 53.57 596.6672 3 
  K.SINPDEAVAYGAAVQA.A 49.40 788.3844 2 
  K.SINPDEAVAYGAAVQAA.I 43.28 823.9020 2 
  K.SINPDEAVAYGAAVQAAIL.S 42.12 936.9874 2 
  K.SINPDEAVAYGAAVQ.A 40.24 752.8674 2 
15 P13645|K1C10_HUMAN K.TIDDLKNQILNLTTDNANILLQID
NAR.L 
103.89 1018.2082 3 
  R.NVSTGDVNVEMNAAPGVDLTQ
LLNNMR.S 
90.17 958.1332 3 
  R.NVQALEIELQSQLALK.Q 89.86 899.0048 2 
  K.NQILNLTTDNANILLQIDNAR.L 89.47 789.7552 3 
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  K.ADLEMQIESLTEELAYLK.K 73.78 1048.5214 2 
 P02769|ALBU_BOVIN K.AEFVEVTKLVTDLTK.V 108.29 846.9686 2 
  K.LKPDPNTLC(+57.02)DEFK.A 105.51 526.2585 3 
  K.C(+57.02)C(+57.02)AADDKEAC
(+57.02)FAVEGPK.L 
104.16 643.2679 3 
  K.DAFLGSFLYEYSR.R 101.47 523.2494 3 
  R.M(+15.99)PC(+57.02)TEDYLSLI
LNR.L 
99.73 870.9145 2 
  K.LFTFHADIC(+57.02)TLPDTEK.Q 97.27 954.4578 2 
  K.EYEATLEEC(+57.02)C(+57.02)A
K.D 
96.58 751.8069 2 
  K.DAIPENLPPLTADFAEDKDVC(+5
7.02)K.N 
93.44 820.0610 3 
  K.DAIPENLPPLTADFAEDK.D 92.80 978.4775 2 
  R.KVPQVSTPTLVEVSR.S 92.63 820.4683 2 
  K.VPQVSTPTLVEVSR.S 91.09 756.4215 2 
  K.DAFLGSFLYEY(+15.99)SR.R 89.93 792.3692 2 
  K.EAC(+57.02)FAVEGPK.L 88.54 554.2581 2 
  K.HLVDEPQNLIK.Q 88.10 653.3582 2 
  K.TVMENFVAFVDK.C 86.91 700.3466 2 
  K.TVM(+15.99)ENFVAFVDK.C 86.23 708.3431 2 
  R.HPEYAVSVLLR.L 86.22 428.5729 3 
  K.EC(+57.02)C(+57.02)HGDLLEC(
+57.02)ADDR.A 
86.08 583.8899 3 
  K.GLVLIAFSQYLQQC(+57.02)PFD
EHVK.L 
85.13 831.4206 3 
  R.HPEY(+15.99)AVSVLLR.L 82.03 433.9044 3 
  K.DDPHAC(+57.02)YSTVFDK.L 80.48 777.8263 2 
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  K.YNGVFQEC(+57.02)C(+57.02)Q
AEDK.G 
75.27 874.3519 2 
  R.RPC(+57.02)FSALTPDETYVPK.A 73.79 940.9597 2 
  K.YIC(+57.02)DNQDTISSK.L 72.73 722.3215 2 
  K.LVNELTEFAK.T 65.75 582.3162 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 103.53 854.3891 2 
  K.ELTTEIDNNIEQISSYK.S 91.49 998.9890 2 
  R.SQYEQLAEQNR.K 82.78 683.3214 2 
  R.ALEESNYELEGK.I 82.75 691.3257 2 
  R.ISSSKGSLGGGFSSGGFSGGSFSR.
G 
75.98 737.3527 3 
  L.GGGFSSGGFSGGSFSR.G 69.35 725.8202 2 
  R.VLDELTLTK.A 66.04 516.3018 2 
  K.SKELTTEIDNNIEQISSYK.S 63.72 1106.5593 2 
  F.GGSSGGYGGLGGFGGGSFR.G 61.01 817.3705 2 
  K.SKELTTEIDNNIEQISS.Y 60.63 960.9712 2 
  K.GSLGGGFSSGGFSGGSF.S 59.46 732.8218 2 
  G.SLGGGFSSGGFSGGSFSR.G 57.27 825.8782 2 
  R.QSVEADINGLR.R 55.67 601.3098 2 
  I.SSSKGSLGGGFSSGGFSGGSFSR.
G 
55.58 699.6583 3 
  K.QSLEASLAETEGR.Y 53.04 695.8424 2 
  L.TTEIDNNIEQISSYK.S 51.91 877.9235 2 
  R.LENEIQTYR.S 51.20 583.2949 2 
  K.GSLGGGFSSGGF.S 50.95 515.2343 2 
  K.GSLGGGFSSGGFSGGS.F 50.08 659.2883 2 
  K.DAEAWFNEK.S 49.88 555.2476 2 
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  R.KDAEAWFNEK.S 48.78 619.2962 2 
  E.IDNNIEQISSYK.S 47.82 712.3557 2 
  S.SKGSLGGGFSSGGFSGGSFSR.G 47.70 641.6356 3 
  G.FSSGGFSGGSFSR.G 44.34 640.2863 2 
  K.GSLGGGFSSGGFSGGSFS.R 43.16 776.3391 2 
  K.VTMQNLNDR.L 42.84 545.7679 2 
  K.DAEAWFNEKSK.E 42.60 662.8128 2 
  L.EIELQSQLALK.Q 42.59 636.3633 2 
  K.SKELTTEIDNNIEQ.I 42.47 817.4003 2 
  G.GFSSGGFSGGSFSR.G 41.69 668.7985 2 
  D.NNIEQISSYK.S 41.65 598.3003 2 
  R.SLLEGEGSSGGGGR.G 40.70 631.8019 2 
16 O17502|ACTM_BRALA K.SYELPDGQVITIGNER.F 97.21 895.9510 2 
  K.AGFAGDDAPR.A 78.49 488.7282 2 
  R.GYSFVTTAER.E 70.94 565.7782 2 
  K.DAYVGDEAQSKR.G 58.53 669.8179 2 
  R.FLEQQNQVLQTK.W 64.05 738.3962 2 
17 P68556|ACT1_DIPDE K.SYELPDGQVITIGNER.F 96.62 895.9556 2 
  R.VAPEEHPVLLTEAPLNPK.A 75.96 652.0303 3 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
75.70 850.7382 3 
  K.QEYDESGPGIVHR.K 74.22 496.2382 3 
  R.AVFPSIVGRPR.H 73.17 599.8603 2 
  R.HQGVMVGMGQK.D 71.43 586.2906 2 
  K.DSYVGDEAQSK.R 70.30 599.7672 2 
  K.AGFAGDDAPR.A 68.93 488.7289 2 
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  K.IKIVAPPER.K 40.82 511.8244 2 
18 Q90X97|ACTS_ATRMM K.SYELPDGQVITIGNER.F 97.72 895.9466 2 
  R.VAPEEHPTLLTEAPLNPK.A 96.48 652.6829 3 
  K.YSVWIGGSILASLSTFQQMWITK.
Q 
95.34 872.7842 3 
  K.LC(+57.02)YVALDFENEMATAA
SSSSLEK.S 
84.36 1268.5775 2 
  K.LC(+57.02)YVALDFENEM(+15.9
9)ATAASSSSLEK.S 
54.89 1276.5742 2 
  K.YSVWIGGSILASLSTFQQM(+15.
99)WITK.Q 
16.68 1316.6689 2 
  K.DLYANNVMSGGTTMYPGIADR.
M 
11.84 1123.5105 2 
 P02769|ALBU_BOVIN K.LGEYGFQNALIVR.Y 103.16 740.3992 2 
  K.DAFLGSFLYEYSR.R 102.92 784.3708 2 
  R.M(+15.99)PC(+57.02)TEDYLSLI
LNR.L 
95.58 870.9139 2 
  K.TVMENFVAFVDK.C 87.61 700.3467 2 
  K.SLHTLFGDELC(+57.02)K.V 86.45 710.3480 2 
  R.HPEYAVSVLLR.L 78.60 642.3566 2 
  R.MPC(+57.02)TEDYLSLILNR.L 77.67 862.9158 2 
  K.LVNELTEFAK.T 67.62 582.3171 2 
  K.EYEATLEEC(+57.02)C(+57.02)A
K.D 
58.56 751.8066 2 
  K.LFTFHADIC(+57.02)TLPDTEK.Q 57.36 954.4592 2 
 Q91ZK5|ACTB_SIGHI K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
106.31 1275.5778 2 
  R.VAPEEHPVLLTEAPLNPK.A 80.36 977.5281 2 
  K.SYELPDGQVITIGNER.F 79.65 895.9401 2 
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  R.TTGIVMDSGDGVTHTVPIYEGYA
LPHAILR.L 
77.34 1061.8661 3 
  R.VAPEEHPVLLTEAPLN.P 40.06 864.9536 2 
 P02769|ALBU_BOVIN K.LGEYGFQNALIVR.Y 89.71 740.3955 2 
  K.LVNELTEFAK.T 74.73 582.3140 2 
  R.RHPEYAVSVLLR.L 65.63 480.6046 3 
  K.HLVDEPQNLIK.Q 64.53 653.3553 2 
  K.LVVSTQTALA 47.88 501.7900 2 
  K.SHC(+57.02)IAEVEKDAIPENLPP
LTADFAEDKDVC(+57.02)K.N 
40.46 878.6646 4 
 A5A6M6|K2C1_PANTR K.YEELQITAGR.H 79.14 590.2976 2 
  R.SGGGFSSGSAGIINYQR.R 76.86 829.3912 2 
  K.SLNNQFASFIDK.V 65.02 692.3413 2 
  R.SGYRSGGGFSSGSAGIINY.Q 59.96 918.9222 2 
  R.TNAENEFVTIK.K 54.23 633.3152 2 
  R.GGGGGGYGSGGSSYGSGGGSYG
SGGGGGGGR.G 
40.20 1192.4698 2 
19 P53470|ACT1_SCHMA K.SYELPDGQVITIGNER.F 82.44 895.9576 2 
  R.AVFPSIVGRPR.H 80.60 400.2426 3 
  K.QEYDESGPGIVHR.K 79.21 496.2365 3 
  R.VAPEEHPVLLTEAPLNPK.A 76.14 977.5430 2 
  K.AGFAGDDAPR.A 71.47 488.7286 2 
  R.HQGVMVGMGQK.D 67.72 586.2924 2 
  K.EISALAPSTMK.I 53.47 574.3082 2 
  K.QEYDESGPGIVHRK.C 51.61 807.9025 2 
  K.DSYVGDEAQSK.R 48.52 599.7650 2 
 P53464|ACTM_HELTB K.DLYANTVLSGGTSMYPGIADR.M 81.48 1101.0237 2 
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  K.SYELPDGQVITIGNER.F 79.01 895.9410 2 
  R.VAPEEHPVLLTEAPLNPK.A 66.68 977.5290 2 
  H.PVLLTEAPLNPK.A 61.95 646.3804 2 
  R.GYSFTTTAER.E 56.39 566.7623 2 
  R.AVFPSIVGRPR.H 53.40 599.8505 2 
  R.VAPEEHPVLLTEAPLNPKANR.E 51.67 765.7463 3 
  Y.ELPDGQVITIGNER.F 50.67 770.8947 2 
  R.VAPEEHPVLLTEAPLN.P 42.65 864.9548 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
40.27 588.5208 4 
 P04264|K2C1_HUMAN R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
71.79 883.3640 2 
  K.YEELQITAGR.H 67.08 590.2986 2 
  R.TNAENEFVTIK.K 64.43 633.3169 2 
  K.QISNLQQSISDAEQR.G 62.58 858.9219 2 
  R.SGGGFSSGSAGIINYQR.R 51.40 829.3940 2 
  R.SGYRSGGGFSSGSAGIIN.Y 48.03 837.3890 2 
20 Q90X97|ACTS_ATRMM K.DLYANNVM(+15.99)SGGTTM(+
15.99)YPGIADR.M 
124.10 1139.5037 2 
  R.KDLYANNVMSGGTTMYPGIADR
.M 
98.08 1187.5520 2 
  R.TTGIVLDSGDGVTHNVPIYEGYAL
PHAIMR.L 
95.68 1066.2029 3 
  K.SYELPDGQVITIGNER.F 94.32 895.9491 2 
  R.VAPEEHPTLLTEAPLNPK.A 94.25 978.5168 2 
  K.DLYANNVMSGGTTMYPGIADR.
M 
86.98 1123.5054 2 
  K.AGFAGDDAPR.A 86.64 488.7253 2 
132 
 
  R.AVFPSIVGRPR.H 85.33 400.2383 3 
  K.QEYDEAGPSIVHR.K 82.62 750.8542 2 
  K.EITALAPSTMK.I 80.73 581.3096 2 
  R.HQGVMVGMGQK.D 80.44 586.2862 2 
  K.DLYANNVM(+15.99)SGGTTMY
PGIADR.M 
77.38 1131.5059 2 
  R.DLTDYLMKILTER.G 75.90 805.9221 2 
  K.DLYANNVMSGGTTM(+15.99)Y
PGIADR.M 
74.73 1131.5059 2 
  K.YSVWIGGSILASLSTFQQM(+15.
99)WITK.Q 
74.70 1316.6703 2 
  R.GYSFVTTAER.E 73.62 565.7748 2 
  K.EITALAPSTM(+15.99)K.I 72.22 589.3070 2 
  R.HQGVM(+15.99)VGM(+15.99)
GQK.D 
68.93 401.8564 3 
  K.LC(+57.02)YVALDFENEMATAA
SSSSLEK.S 
68.35 1268.5806 2 
  K.LC(+57.02)YVALDFENEM(+15.9
9)ATAASSSSLEK.S 
66.76 1276.5736 2 
  R.DLTDYLM(+15.99)KILTER.G 65.28 813.9210 2 
  K.IWHHTFYNELR.V 63.22 758.3728 2 
  K.LC(+57.02)Y(+15.99)VALDFENE
MATAASSSSLEK.S 
59.77 1276.5741 2 
  R.DLTDYLMK.I 55.93 499.7433 2 
  R.DLTDYLM(+15.99)K.I 53.86 507.7414 2 
  K.DSYVGDEAQSK.R 52.67 599.7617 2 
21 P68556|ACT1_DIPDE R.VAPEEHPVLLTEAPLNPK.A 106.56 652.0280 3 
  K.SYELPDGQVITIGNER.F 86.99 895.9539 2 
  K.QEYDESGPGIVHR.K 83.16 496.2359 3 
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  K.QEYDESGPGIVHRK.C 76.68 807.8989 2 
  K.DSYVGDEAQSK.R 65.35 599.7668 2 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
57.51 850.7329 3 
  K.DSYVGDEAQSKR.G 48.02 677.8156 2 
  R.TTGIVLDSGDGVTHSVPIYEGYAL
PHAILR.L 
40.29 788.6683 4 
 A5A6M6|K2C1_PANTR K.WELLQQVDTSTR.T 82.73 738.3777 2 
  R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
79.73 883.3718 2 
  R.FLEQQNQVLQTK.W 77.26 738.3964 2 
  R.SLDLDSIIAEVK.A 66.83 651.8622 2 
  R.TNAENEFVTIKK.D 64.77 697.3642 2 
  K.SLNNQFASFIDK.V 63.52 692.3506 2 
  R.SGGGFSSGSAGIINYQR.R 53.05 829.4178 2 
 P04264|K2C1_HUMAN K.QISNLQQSISDAEQR.G 57.83 858.9217 2 
  K.WELLQQVDTSTR.T 55.33 738.3708 2 
  R.FLEQQNQVLQTK.W 53.31 738.3895 2 
  K.YEELQITAGR.H 52.11 590.2986 2 
  R.TNAENEFVTIK.K 51.11 633.3156 2 
  K.SLNNQFASFIDK.V 50.15 692.3417 2 
  R.DYQELMNTK.L 47.34 571.2575 2 
  R.SGGGFSSGSAGIINYQR.R 46.27 829.3926 2 
  K.AEAESLYQSKYEELQITAGR.H 44.21 1143.5537 2 
  K.NMQDMVEDYR.N 42.39 650.7622 2 
  K.LNDLEDALQQAK.E 42.18 679.3447 2 
  K.IEISELNR.V 40.18 487.2643 2 
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  R.FSSC(+57.02)GGGGGSFGAGGG
FGSR.S 
40.05 883.3635 2 
 Q5R1X3|ACTB_PANTR K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
54.18 1275.5759 2 
  K.SYELPDGQVITIGNER.F 53.91 895.9414 2 
  R.VAPEEHPVLLTEAPLNPK.A 44.62 652.0198 3 
  K.DLYANTVLSGGTTMYPGIADR.M 42.22 1108.0287 2 
22 A5A6M6|K2C1_PANTR K.WELLQQVDTSTR.T 97.25 738.3749 2 
  K.YEELQITAGR.H 86.38 590.3011 2 
  R.FLEQQNQVLQTK.W 85.77 738.3931 2 
  R.THNLEPYFESFINNLR.R 82.50 665.3277 3 
  R.SLDLDSIIAEVK.A 79.30 651.8582 2 
  K.LALDLEIATYR.T 78.47 639.3550 2 
  K.SLNNQFASFIDKVR.F 74.35 546.9559 3 
  R.TNAENEFVTIKK.D 73.55 697.3665 2 
  K.SLNNQFASFIDK.V 68.92 692.3448 2 
  R.TNAENEFVTIK.K 61.14 633.3180 2 
 P63261|ACTG_HUMAN K.SYELPDGQVITIGNER.F 112.85 895.9460 2 
  R.VAPEEHPVLLTEAPLNPK.A 98.51 652.0233 3 
  R.AVFPSIVGRPR.H 93.26 400.2378 3 
  K.AGFAGDDAPR.A 75.38 488.7257 2 
 P08779|K1C16_HUMAN R.LLEGEDAHLSSQQASGQS.Y 66.34 928.9247 2 
  K.IIAATIENAQPILQIDNAR.L 59.22 1032.5648 2 
  R.ALEEANADLEVK.I 59.01 651.3271 2 
  R.APSTYGGGLSVSSR.F 58.24 669.8305 2 
  K.TEELNKEVASNSELVQSSR.S 54.51 707.3472 3 
  R.VLDELTLAR.T 50.22 515.2963 2 
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  R.ISSVLAGGSC(+57.02)R.A 46.50 553.7800 2 
  R.QTVEADVNGLR.R 45.88 601.3064 2 
  R.LLEGEDAHLSSQQASGQSYSSR.E 45.55 1175.5400 2 
  R.LLEGEDAHLSSQQASGQSY.S 41.62 1010.4570 2 
  R.GQTGGDVNVEMDAAPGVDLSR.
I 
41.06 1044.4794 2 
 P53480|ACTC_TAKRU R.GYSFVTTAER.E 51.88 565.7720 2 
  K.SYELPDGQVITIGNER.F 48.89 895.9406 2 
23 Q9UVX4|ACT_COPC7 K.SYELPDGQVITIGNER.F 87.91 895.9506 2 
  R.VAPEEHPVLLTEAPLNPK.A 63.74 977.5371 2 
 A5A6M6|K2C1_PANTR R.SLDLDSIIAEVK.A 63.67 651.8625 2 
  K.SLNNQFASFIDK.V 59.70 692.3502 2 
 P04264|K2C1_HUMAN R.FLEQQNQVLQTK.W 59.43 738.3892 2 
  K.YEELQITAGR.H 57.20 590.2975 2 
  K.WELLQQVDTSTR.T 55.95 738.3710 2 
  K.QISNLQQSISDAEQR.G 53.62 858.9202 2 
  R.TNAENEFVTIK.K 53.49 633.3154 2 
  R.SGGGFSSGSAGIINYQR.R 51.79 829.3881 2 
  K.SLNNQFASFIDK.V 48.34 692.3406 2 
  R.GGGGGGYGSGGSSYGSGGGSYG
SGGGGGGGR.G 
41.90 1192.4718 2 
 P84185|ACT5C_ANOGA R.VAPEEHPVLLTEAPLNPK.A 61.21 977.5255 2 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
60.66 1275.5774 2 
  K.SYELPDGQVITIGNER.F 56.06 895.9387 2 
  K.AGFAGDDAPR.A 47.29 488.7224 2 
  R.GYSFTTTAER.E 46.98 566.7609 2 
136 
 
  K.DLYANTVLSGGTTMYPGIADR.M 44.73 1108.0267 2 
  K.SYELPDGQVITIGN.E 41.42 753.3693 2 
24 P86221|TBB2C_MESAU K.LAVNMVPFPR.L 65.50 572.3218 2 
  R.AVLVDLEPGTMDSVR.S 58.44 801.4161 2 
  K.LAVNM(+15.99)VPFPR.L 49.66 580.3181 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 76.68 854.3823 2 
  K.QSLEASLAETEGR.Y 71.43 695.8372 2 
  R.ALEESNYELEGK.I 69.72 691.3212 2 
  R.GSSGGGC(+57.02)FGGSSGGYG
GLGGFGGGSFR.G 
63.82 1171.9835 2 
  K.ELTTEIDNNIEQISSYK.S 62.64 998.9788 2 
  R.SLLEGEGSSGGGGR.G 59.56 631.7955 2 
  R.VLDELTLTK.A 59.23 516.2977 2 
  R.QSVEADINGLR.R 58.18 601.3059 2 
  R.LENEIQTYR.S 56.14 583.2897 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
54.73 1041.9766 2 
  K.VTMQNLNDR.L 52.85 545.7639 2 
  K.DAEAWFNEK.S 52.65 555.2431 2 
  R.LKYENEVALR.Q 50.96 617.8370 2 
  K.SKELTTEIDNNIEQISSYK.S 44.96 738.0306 3 
  L.GGGFSSGGFSGGSFSR.G 43.11 725.8136 2 
  R.LAADDFR.L 40.05 404.1987 2 
 Q9YHC3|TBB1_GADMO R.IMNTFSVVPSPK.V 71.85 660.3483 2 
  R.AVLVDLEPGTMDSVR.S 64.17 801.4061 2 
  R.INVYYNEASGGK.Y 59.12 657.8135 2 
  K.LAVNMVPFPR.L 59.07 572.3145 2 
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  R.FPGQLNADLR.K 57.78 565.7958 2 
  K.NSSYFVEWIPNNVK.T 56.09 848.9114 2 
  K.TAVC(+57.02)DIPPR.G 49.14 514.7585 2 
  K.EVDEQMLNVQNK.N 47.34 723.8420 2 
 Q05825|ATPB_DROME R.FTQAGSEVSALLGR.I 72.01 718.3731 2 
  R.IPSAVGYQPTLATDMGSMQER.I 68.51 751.3527 3 
  R.TIAMDGTEGLVR.G 66.66 631.8178 2 
  K.AHGGYSVFAGVGER.T 61.50 703.8376 2 
  K.VVDLLAPYAK.G 58.28 544.8149 2 
  K.IGLFGGAGVGK.T 55.03 488.2797 2 
  R.VALTGLTVAEYFR.D 45.11 720.3911 2 
 Q5R1X3|ACTB_PANTR K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
62.58 1275.5751 2 
  K.SYELPDGQVITIGNER.F 59.92 895.9416 2 
  K.DLYANTVLSGGTTMYPGIADR.M 50.34 1108.0262 2 
25 Q9YHC3|TBB1_GADMO K.NSSYFVEWIPNNVK.T 89.33 848.9203 2 
  R.IMNTFSVVPSPK.V 89.14 660.3566 2 
  R.ISEQFTAMFR.R 80.41 615.3033 2 
  R.AVLVDLEPGTM(+15.99)DSVR.S 78.72 809.4127 2 
  K.LAVNMVPFPR.L 74.75 572.3217 2 
  K.GHYTEGAELVDSVLDVVR.K 73.60 653.6667 3 
  R.INVYYNEASGGK.Y 68.48 657.8196 2 
  R.AVLVDLEPGTMDSVR.S 67.72 801.4149 2 
  R.LHFFM(+15.99)PGFAPLTSR.G 66.85 546.2808 3 
  R.YLTVAAIFR.G 65.66 527.3104 2 
  K.EVDEQMLNVQNK.N 63.45 723.8488 2 
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  R.LHFFMPGFAPLTSR.G 63.35 810.9218 2 
  K.TAVC(+57.02)DIPPR.G 57.79 514.7632 2 
  R.EIVHLQAGQC(+57.02)GNQIGA
K.F 
56.86 911.9662 2 
 P13645|K1C10_HUMAN R.NVQALEIELQSQLALK.Q 82.14 899.0120 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
77.10 1041.9874 2 
  K.IRLENEIQTYR.S 66.83 717.8892 2 
  R.QSVEADINGLRR.V 66.55 679.3636 2 
  K.VTM(+15.99)QNLNDR.L 57.47 553.7661 2 
  R.LENEIQTYR.S 54.56 583.2952 2 
  K.VRALEESNYELEGK.I 52.58 818.9135 2 
  K.ADLEMQIESLTEELAYLK.K 50.58 1048.5312 2 
  R.LASYLDK.V 44.72 405.2234 2 
 Q05825|ATPB_DROME R.FTQAGSEVSALLGR.I 86.14 718.3812 2 
  R.DQEGQDVLLFIDNIFR.F 80.08 961.4869 2 
  K.VVDLLAPYAK.G 75.91 544.8224 2 
  K.IGLFGGAGVGK.T 62.80 488.2861 2 
  R.VALTGLTVAEYFR.D 62.51 720.4012 2 
  R.TIAM(+15.99)DGTEGLVR.G 50.96 639.8212 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 76.35 854.3817 2 
  K.SKELTTEIDNNIEQISSYK.S 70.62 738.0312 3 
  K.ELTTEIDNNIEQISSYK.S 69.72 998.9785 2 
  K.QSLEASLAETEGR.Y 64.67 695.8366 2 
  R.SQYEQLAEQNR.K 64.49 683.3167 2 
  R.ALEESNYELEGK.I 63.90 691.3192 2 
  R.QSVEADINGLR.R 61.76 601.3065 2 
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  R.VLDELTLTK.A 61.51 516.2972 2 
  K.IRLENEIQTYR.S 59.85 717.8814 2 
  R.LKYENEVALR.Q 59.16 617.8367 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
58.56 1041.9772 2 
  L.GGGFSSGGFSGGSFSR.G 52.85 725.8140 2 
  K.DAEAWFNEK.S 48.55 555.2428 2 
  R.LENEIQTYR.S 47.31 583.2896 2 
  N.AAPGVDLTQLLNNMR.S 46.57 806.9175 2 
  R.NVSTGDVNVEMN.A 41.86 639.7795 2 
  R.LAADDFR.L 41.09 404.1990 2 
  I.SSSKGSLGGGFSSGGFSGGSFSR.
G 
40.38 699.6532 3 
  R.RVLDELTLTK.A 40.10 396.5666 3 
 P68556|ACT1_DIPDE K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
71.62 1275.5778 2 
  K.SYELPDGQVITIGNER.F 69.82 895.9412 2 
  R.VAPEEHPVLLTEAPLNPK.A 68.62 977.5269 2 
  R.HQGVMVGMGQKDSYVGDEAQ
SK.R 
56.18 784.3561 3 
  K.YSVWIGGSILASLSTFQQMWISK.
Q 
54.62 1301.6680 2 
  R.AVFPSIVGRPR.H 54.50 599.8505 2 
  R.GYSFTTTAER.E 54.25 566.7605 2 
  R.DLTDYLMK.I 53.85 499.7412 2 
  K.SYELPDGQVITIGN.E 52.24 753.3689 2 
  R.AVFPSIVGR.P 47.10 473.2750 2 
  R.HQGVMVGMGQKDSYVGDEAQ 43.26 627.5428 4 
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SKR.G 
  K.DLYANTVLSGGTTMYPGIADR.M 42.59 1108.0271 2 
 P30883|TBB4_XENLA R.AVLVDLEPGTMDSVR.S 68.74 801.4056 2 
  R.IMNTFSVVPSPK.V 61.74 660.3475 2 
  R.FPGQLNADLR.K 46.04 565.7949 2 
  K.LAVNMVPFPR.L 45.64 572.3135 2 
 P46561|ATPB_CAEEL R.FTQAGSEVSALLGR.I 70.98 718.3729 2 
  K.VSLVYGQMNEPPGAR.A 62.88 809.3976 2 
  K.AHGGYSVFAGVGER.T 43.84 469.5605 3 
  K.VVDLLAPYAK.G 43.20 544.8156 2 
26 P08779|K1C16_HUMAN K.IIAATIENAQPILQIDNAR.L 88.95 1032.5770 2 
  R.VLQGLEIELQSQLSM(+15.99)K.
A 
76.77 916.4974 2 
  R.NKIIAATIENAQPILQIDNAR.L 72.70 769.4329 3 
  R.ALEEANADLEVK.I 69.90 651.3327 2 
  R.GQTGGDVNVEM(+15.99)DAAP
GVDLSR.I 
68.06 1052.4857 2 
  R.TDLEMQIEGLK.E 65.41 638.8270 2 
  R.QTVEADVNGLRR.V 61.64 679.3629 2 
  K.VTM(+15.99)QNLNDR.L 56.70 553.7667 2 
  R.DQYEQMAEK.N 41.51 571.2452 2 
 Q3ZBU7|TBB4_BOVIN R.IMNTFSVVPSPK.V 75.69 660.3555 2 
  K.LAVNMVPFPR.L 69.06 572.3221 2 
  R.AVLVDLEPGTMDSVR.S 68.35 801.4139 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 108.84 854.3830 2 
  R.AETEC(+57.02)QNTEYQQLLDIK.
I 
107.89 1041.9778 2 
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  R.ALEESNYELEGK.I 94.20 691.3224 2 
  K.QSLEASLAETEGR.Y 92.61 695.8384 2 
  R.GSSGGGC(+57.02)FGGSSGGYG
GLGGFGGGSFR.G 
79.56 1171.9846 2 
  K.SKELTTEIDNNIEQISSYK.S 78.38 738.0303 3 
  K.ELTTEIDNNIEQISSYK.S 67.74 998.9795 2 
  R.VLDELTLTK.A 65.75 516.2979 2 
  L.GGGFSSGGFSGGSFSR.G 59.53 725.8135 2 
  K.DAEAWFNEK.S 51.31 555.2441 2 
  R.LKYENEVALR.Q 46.19 617.8383 2 
 P30883|TBB4_XENLA R.AVLVDLEPGTMDSVR.S 100.01 801.4074 2 
  R.IMNTFSVVPSPK.V 84.88 660.3494 2 
  K.NSSYFVEWIPNNVK.T 52.67 848.9125 2 
  K.LAVNMVPFPR.L 51.58 572.3154 2 
  R.ISEQFTAMFR.R 44.53 615.2976 2 
27 P08779|K1C16_HUMAN K.EVASNSELVQSSR.S 73.27 703.3500 2 
  R.NKIIAATIENAQPILQIDNAR.L 65.68 769.4349 3 
  R.ISSVLAGGSC(+57.02)R.A 62.96 553.7853 2 
  R.QTVEADVNGLRR.V 54.06 679.3635 2 
  R.LASYLDK.V 42.64 405.2244 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 108.64 854.3823 2 
  R.ALEESNYELEGK.I 78.30 691.3212 2 
  R.NVSTGDVNVEMN.A 66.01 639.7795 2 
  R.VLDELTLTK.A 53.97 516.2970 2 
  K.ELTTEIDNNIEQISSYK.S 51.89 998.9786 2 
  R.NVSTGDVNVEMNA.A 49.86 675.2971 2 
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  K.DAEAWFNEK.S 45.81 555.2438 2 
  L.GGGFSSGGFSGGSFSR.G 45.71 725.8158 2 
  G.SLGGGFSSGGFSGGSFSR.G 44.52 825.8727 2 
  R.QSVEADINGLR.R 41.71 601.3061 2 
 Q5R1X3|ACTB_PANTR K.SYELPDGQVITIGNER.F 98.73 895.9419 2 
  K.LC(+57.02)YVALDFEQEMATAA
SSSSLEK.S 
82.26 850.7227 3 
  R.VAPEEHPVLLTEAPLNPK.A 65.24 652.0214 3 
  F.NTPAMYVAIQAVLSLYASGR.T 64.06 709.0360 3 
  R.KYSVWIGGSILASLSTFQQMWIS
K.Q 
62.03 910.8092 3 
  K.DLYANTVLSGGTTMYPGIADR.M 59.42 1108.0305 2 
  R.GYSFTTTAER.E 52.31 566.7630 2 
  K.YSVWIGGSILASLSTFQQMWISK.
Q 
51.36 868.1229 3 
 P02769|ALBU_BOVIN K.DAFLGSFLYEYSR.R 83.26 784.3680 2 
  R.MPC(+57.02)TEDYLSLILNR.L 73.91 862.9183 2 
  K.LGEYGFQNALIVR.Y 70.01 740.3944 2 
  K.LVVSTQTALA 65.12 501.7909 2 
  K.GLVLIAFSQYLQQC(+57.02)PFD
EHVK.L 
58.47 831.4199 3 
  K.LVNELTEFAK.T 57.21 582.3134 2 
  R.RHPEYAVSVLLR.L 56.36 480.6046 3 
  K.SLHTLFGDELC(+57.02)K.V 54.07 473.8986 3 
  K.TVMENFVAFVDK.C 49.88 700.3425 2 
  K.HLVDEPQNLIK.Q 47.44 653.3564 2 
  Y.FYAPELLYYANK.Y 45.11 746.3723 2 
  K.LFTFHADIC(+57.02)TLPDTEK.Q 41.70 954.4558 2 
143 
 
28 Q2KJD0|TBB5_BOVIN K.GHYTEGAELVDSVLDVVR.K 92.21 979.9882 2 
  R.ALTVPELTQQVFDAK.N 77.42 830.4472 2 
  R.LHFFM(+15.99)PGFAPLTSR.G 77.42 546.2792 3 
  K.MAVTFIGNSTAIQELFK.R 76.48 935.4867 2 
  R.AILVDLEPGTM(+15.99)DSVR.S 70.19 816.4146 2 
  K.M(+15.99)AVTFIGNSTAIQELFK.
R 
70.12 943.4847 2 
  K.LAVNM(+15.99)VPFPR.L 62.61 580.3156 2 
29 P08418|HSP70_SCHMA K.NQVAMNPTNTVFDAKR.L 79.60 602.6379 3 
  R.IINEPTAAAIAYGLDKK.V 71.62 596.6688 3 
  R.IINEPTAAAIAYGLDK.K 65.49 830.4517 2 
  K.NQVAM(+15.99)NPTNTVFDAK.
R 
60.78 833.3989 2 
  K.VEIIANDQGNR.T 57.49 614.8181 2 
  R.TVSDAVITVPAYFNDSQR.Q 45.59 991.9963 2 
 P35527|K1C9_HUMAN R.HGVQELEIELQSQLSKK.A 87.57 656.0261 3 
  R.HGVQELEIELQSQLSK.K 56.31 919.4888 2 
  K.VQALEEANNDLENK.I 41.81 793.8872 2 
  R.LASYLDK.V 40.88 405.2239 2 
 Q9W6Y1|HSP7C_ORYLA K.NQVAMNPTNTVFDAK.R 97.87 825.3956 2 
  R.IINEPTAAAIAYGLDK.K 85.67 830.4452 2 
  K.SINPDEAVAYGAAVQAAILSGDK.
S 
66.79 1130.5618 2 
  K.DAGTISGLNVLR.I 66.48 608.3344 2 
  K.NQVAMNPTNTVFDAKR.L 46.99 602.6325 3 
  R.IINEPTAAAIAYGLDKK.V 46.76 894.4915 2 
  K.VEIIANDQGNR.T 45.50 614.8131 2 
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 A5A6M6|K2C1_PANTR R.FLEQQNQVLQTK.W 81.10 738.3911 2 
  R.TNAENEFVTIK.K 75.94 633.3168 2 
  K.YEELQITAGR.H 70.11 590.2988 2 
  K.SLNNQFASFIDK.V 64.16 692.3423 2 
  K.WELLQQVDTSTR.T 56.62 738.3724 2 
  K.QISNLQQSISDAEQR.G 53.50 858.9225 2 
  K.IEISELNR.V 47.00 487.2633 2 
  R.SGGGFSSGSAGIINYQR.R 45.30 829.3955 2 
30 P02538|K2C6A_HUMAN R.FLEQQNKVLETK.W 51.20 492.9408 3 
  R.GSGGLGGAC(+57.02)GGAGFGS
R.S 
41.04 712.8224 2 
 P13645|K1C10_HUMAN K.GSLGGGFSSGGFSGGSFSR.G 54.59 854.3817 2 
  K.QSLEASLAETEGR.Y 53.09 695.8366 2 
  R.ALEESNYELEGK.I 52.90 691.3212 2 
  R.SLLEGEGSSGGGGR.G 45.99 631.7961 2 
  K.SKELTTEIDNNIEQISSYK.S 45.71 1106.5424 2 
  R.LENEIQTYR.S 45.09 583.2901 2 
  R.VLDELTLTK.A 44.60 516.2971 2 
  L.GGGFSSGGFSGGSFSR.G 43.44 725.8125 2 
  K.ELTTEIDNNIEQISSYK.S 43.21 998.9813 2 
  R.QSVEADINGLR.R 41.35 601.3061 2 
  K.IRLENEIQTYR.S 40.75 717.8810 2 
  R.GSSGGGC(+57.02)FGGSSGGYG
GLGGFGGGSFR.G 
40.57 1171.9844 2 
  K.DAEAWFNEK.S 40.23 555.2428 2 
 
Table 4. Supporting peptides for the proteins identified by MS/MS analysis of SDS-I listed in 
Table 3. Spot numbers refer to Fig. 14 
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Table 6 
 
Spot n. Protein Accession Peptide -10lgP m/z z 
1 P46561|ATPB_CAEEL AHGGYSVFAGVGER 86.76 703.8434 2 
  DQEGQDVLLFIDNIFR 74.15 961.4874 2 
  VSLVYGQMNEPPGAR 70.77 809.4055 2 
  VVDLLAPYAK 69.59 544.8220 2 
  VSLVYGQM(+15.99)NEPPGAR 64.41 817.4019 2 
  IGLFGGAGVGK 49.51 488.2841 2 
 Q3MHM5|TBB2C_BOVIN IMNTFSVVPSPK 74.82 660.3542 2 
  LAVNM(+15.99)VPFPR 66.40 580.3181 2 
  LAVNMVPFPR 66.11 572.3214 2 
  AVLVDLEPGTM(+15.99)DSVR 60.88 809.4100 2 
  AVLVDLEPGTMDSVR 59.35 801.4162 2 
 Q6EIY9|K2C1_CANFA TNAENEFVTIKK 69.83 465.2471 3 
  FLEQQNQVLQTK 64.22 738.3936 2 
  SLNNQFASFIDK 51.56 692.3497 2 
  ALEESNYELEGK 62.98 691.3265 2 
2 Q3ZBU7|TBB4_BOVIN R.AVLVDLEPGTM(+15.99)DSVR.S 73.03 809.4104 2 
  R.AVLVDLEPGTMDSVR.S 71.75 801.4130 2 
  R.IMNTFSVVPSPK.V 60.65 660.3341 2 
3 A5A6M6|K2C1_PANTR R.TNAENEFVTIKK.D 78.17 465.2481 3 
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  R.FLEQQNQVLQTK.W 76.77 738.3968 2 
  K.AQYEDIAQK.S 63.68 533.2637 2 
4 P86700|ACT_CHIOP R.SYELPDGQVITIGNER.C 73.70 895.9501 2 
  R.AVFPSIVGRPR.D 69.15 400.2397 3 
  AGFAGDDAPR.A 63.59 488.7275 2 
5 P86700|ACT_CHIOP R.SYELPDGQVITIGNER.C 82.21 895.9490 2 
  R.AVFPSIVGRPR.D 69.67 400.2397 3 
  AGFAGDDAPR.A 62.49 488.7268 2 
6 P91754|ACT_LUMRU R.VAPEEHPVLLTEAPLNPK.A 80.22 977.5341 2 
  K.SYELPDGQVITIGNER.F 80.18 895.9476 2 
  R.AVFPSIVGRPR.H 72.87 400.2391 3 
  K.AGFAGDDAPR.A 70.78 488.7277 2 
  R.HQGVMVGMGQK.D 59.18 586.2876 2 
  R.GYSFTTTAER.E 45.26 566.7665 2 
7 A5DQP9|ACT_PICGU R.AVFPSIVGRPR.H 76.51 400.2400 3 
  K.SYELPDGQVITIGNER.F 74.36 895.9512 2 
8 P86700|ACT_CHIOP R.AVFPSIVGRPR.D 79.35 400.2404 3 
  AGFAGDDAPR.A 73.23 488.7280 2 
  K.IIAPPER.K 41.91 398.2402 2 
9 P13645|K1C10_HUMAN R.SLLEGEGSSGGGGR.G 59.13 631.8001 2 
  R.LAADDFR.L 40.71 404.2024 2 
  R.LASYLDK.V 40.30 405.2233 2 
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 P06604|TBA2_DROME K.VGINYQPPTVVPGGDLAK.V 51.83 912.9938 2 
  R.AVFVDLEPTVVDEVR.T 40.98 844.4468 2 
10 A5DQP9|ACT_PICGU K.SYELPDGQVITIGNER.F 72.44 895.9477 2 
  R.AVFPSIVGRPR.H 70.44 599.8553 2 
 
Table 6. Supporting peptides for the proteins identified by MS/MS analysis of SDS-I listed in 
Table 5. Spot numbers refer to Fig. 15 
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